Generated by All in One SEO v4.9.3, this is an llms.txt file, used by LLMs to index the site.

# Adocia

## Sitemaps

- [XML Sitemap](https://www.adocia.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Pages

- [Home](https://www.adocia.com/) - Adocia is a clinical-stage biotechnology company specialized in the development of innovative treatments for diabetes and obesity.
- [Événements et présentations](https://www.adocia.com/investors/events-and-presentations/) - Relation Investisseurs BIENVENUE DANS L’ESPACE DÉDIÉ AUX INVESTISSEURS Contactez-nous >Investisseurs>Événements et présentations Événements et présentations Past events 2026 16 JUN 2026 ADOCIA – BC Lispro Phase 3 Results KOL Webcast – June 16, 2026 2025 25 NOV 2025 ADOCIA – Investir Day – Nov. 2025 (FR) 2024 28 NOV 2024 ADOCIA – Investir Day –
- [Events and presentations](https://www.adocia.com/investors/events-and-presentations/) - Financials WELCOME TO THE INVESTORS SECTION OF ADOCIA Contact us >Investors>Events and presentations Events and presentations Past events 2026 16 JUN 2026 ADOCIA – BC Lispro Phase 3 Results KOL Webcast – June 16, 2026 2025 25 NOV 2025 ADOCIA – Investir Day – Nov. 2025 (FR) 2024 28 NOV 2024 ADOCIA – Investir Day
- [Investors](https://www.adocia.com/investors/) - Financials WELCOME TO THE INVESTORS SECTION OF ADOCIA Contact us Access to information Home >Investors Presentation Adocia is a biotechnology company specialized in the development of best-in-class medicines from already approved therapeutic proteins. Adocia is a French clinical-stage biotech company. The core activities of the company are to innovate, to discover and to develop new
- [Investisseurs](https://www.adocia.com/investors/) - Relation Investisseurs Bienvenue sur la page dédiée aux investisseurs Contact us Consulter les informations Home >Investisseurs Présentation Adocia est une société de biotechnologie au stade clinique spécialisée dans l’innovation et le développement de solutions thérapeutiques pour les maladies métaboliques Adocia est une société française de biotechnologie au stade clinique. Les principales activités de la société
- [Pipeline](https://www.adocia.com/products-and-platform/pipeline-2/) - Produits & plateformes La mission d’Adocia est de développer des formulations innovantes de peptides déjà approuvés et de nouvelles approches de thérapie cellulaire pour le traitement du diabète et de l’obésité. Nous contacter >Produits et plateformes>Pipeline Pipeline Au fil des années, Adocia a construit un portefeuille diversifié de produits de spécialité pour le traitement du
- [Pipeline](https://www.adocia.com/products-and-platform/pipeline-2/) - Produits & plateformes La mission d’Adocia est de développer des formulations innovantes de peptides déjà approuvés et de nouvelles approches de thérapie cellulaire pour le traitement du diabète et de l’obésité. Nous contacter >Produits et plateformes>Pipeline Pipeline Au fil des années, Adocia a construit un portefeuille diversifié de produits de spécialité pour le traitement du
- [Pipeline](https://www.adocia.com/products-and-platform/pipeline-2/) - Products & platforms Adocia mission is to develop innovative formulations of approved peptides and novel cell therapy approaches for the treatment of diabetes and obesity. Contact us >Products and platforms>Pipeline Pipeline Over the years, Adocia has built a diversified pipeline of specialty products for the treatment of diabetes and obesity. The products development stage ranges
- [Test page](https://www.adocia.com/test-page/)
- [Stock information](https://www.adocia.com/investors/stock-information/) - Financials WELCOME TO THE INVESTORS SECTION OF ADOCIA Contact us >Investors>Stock information Stock information Share information ADOCIAADOC.PA Euronext Paris – Compartment C First day of trading: February 20th, 2012, at €15.88 ISIN code: FR0011184241 Mnemo / Reuters / Bloomberg: ADOC, ADOC.PA, ADOC.FP US OTC market (ADR program): ADOCY Activity field: Pharmacy and biotechnology (classification ICB
- [Informations boursières](https://www.adocia.com/investors/stock-information/) - Relation Investisseurs BIENVENUE DANS L’ESPACE DÉDIÉ AUX INVESTISSEURS Nous contacter >Investisseurs>Informations boursières Informations boursières Cours de bourse ADOCIAADOC.PA Euronext Paris – Compartment C Premier jour de cotation : 20 Février 2012, à €15.88 Code ISIN : FR0011184241 Mnémonique / Reuters / Bloomberg : ADOC, ADOC.PA, ADOC.FP Marché américain OTC (programme ADR) : ADOCY Secteur d’activité
- [Assemblées générales](https://www.adocia.com/investors/general-meeting/) - Relation Investisseurs BIENVENUE DANS L’ESPACE DÉDIÉ AUX INVESTISSEURS Contact us >Investisseurs>Assemblées générales Assemblée générale 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Annual shareholders’ meeting 03/06/2026 General Shareholders' meeting – June 3, 2026 Replay - General Shareholders' meeting Notice of meeting and convocation to the General Shareholders' meeting
- [General meeting](https://www.adocia.com/investors/general-meeting/) - Financials WELCOME TO THE INVESTORS SECTION OF ADOCIA Contact us >Investors>General meeting General meeting 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Annual shareholders’ meeting 03/06/2026 General Shareholders' meeting – June 3, 2026 Replay - General Shareholders' meeting Notice of meeting and convocation to the General Shareholders' meeting
- [Privacy policy and cookies policy](https://www.adocia.com/personal-data/) - Privacy policy and cookies policy ADOCIA, a publicly held company with a Board of Directors, registered as a SA with the Trade and Companies Register (RCS) of Lyon under the number 487 647 737, whose head office is located at 115 avenue Lacassagne, 69003 Lyon (France), is concerned with the protection of personal data of visitors
- [Politique de confidentialité et politique de cookies](https://www.adocia.com/personal-data/) - Politique de confidentialité et politique des cookies ADOCIA, société anonyme à conseil d’administration, immatriculée au Registre du Commerce et des Sociétés de Lyon sous le numéro 487 647 737, dont le siège social est sis 115 avenue Lacassagne, 69003 Lyon (France), est soucieuse de la protection des données personnelles des visiteurs (ci-après « Vous »)
- [Board of directors](https://www.adocia.com/adocia/board-of-direction/) - Board of directors Contact us >Adocia>Board of directors Stéphane Boissel, MBA Chairman of the Board Stéphane Boissel is currently Chairman and CEO of SparingVision, a genomic medicine company in ophthalmology. He was previously Executive Vice President of Corporate Strategy at Sangamo Therapeutics, based in San Francisco (USA). He joined Sangamo Therapeutics on the back of
- [Conseil d'administration](https://www.adocia.com/adocia/board-of-direction/) - Conseil d’administration Nous contacter >Adocia>Conseil d’administration Stéphane boissel, MBA Président du conseil d'administration Stéphane Boissel est actuellement président-directeur général de SparingVision, une société de médecine génomique dans le domaine de l’ophtalmologie. Il était auparavant vice-président exécutif de la stratégie d’entreprise chez Sangamo Therapeutics, basée à San Francisco (États-Unis). Il a rejoint Sangamo Therapeutics à la
- [Politique RH](https://www.adocia.com/careers/hr-policy/) - Travailler chez Adocia Home >Carrière>Politique RH Politique des ressources humaines Le développement de carrière grâce à la formation professionnelle et à la mobilité interne La politique Ressources Humaines mise en œuvre à Adocia vise à bâtir et à développer une équipe d’excellence, pluridisciplinaire, internationale et hautement qualifiée, pour répondre à des objectifs scientifiques et technologiques
- [HR policy](https://www.adocia.com/careers/hr-policy/) - Working at Adocia The “Adocians” HR policy Work environment Join us Home >Careers>HR policy Human Resources Policy Career development through professional training and internal mobility The Adocia Human Resources policy aims to build and develop an excellent, international, highly qualified and multidisciplinary team, to meet complex scientific and technological objectives, in order to improve patients’
- [À propos](https://www.adocia.com/adocia/about/) - À propos Adocia est une société innovante de biotechnologie spécialisée dans l’innovation et le développement de solutions thérapeutiques pour les maladies métaboliques. Contact us >Adocia>À propos Adocia est une société française de biotechnologie au stade clinique Les principales activités de la société sont l’innovation, la recherche et le développement de nouvelles solutions thérapeutiques pour améliorer
- [À propos](https://www.adocia.com/adocia/about/) - À propos Adocia est une société innovante de biotechnologie spécialisée dans l’innovation et le développement de solutions thérapeutiques pour les maladies métaboliques. Contact us >Adocia>À propos Adocia est une société française de biotechnologie au stade clinique Les principales activités de la société sont l’innovation, la recherche et le développement de nouvelles solutions thérapeutiques pour améliorer
- [Les « Adociens »](https://www.adocia.com/careers/adocia-team/) - Les « Adociens » Home >Carrière>Les « Adociens » Travailler pour une société de biotechnologie innovante Adocia est une société de biotechnologie spécialisée dans la recherche et le développement de solutions thérapeutiques dans le domaine des maladies métaboliques, principalement le diabète et l’obésité. La majorité des salariés sont dédiés à la R&D, le cœur de l’activité d’Adocia. Adocia attache
- [The "Adocians"](https://www.adocia.com/careers/adocia-team/) - The “Adocians” The “Adocians” HR policy Work environment Join us Home >Careers>The “Adocians” Working for an innovative biotech company Adocia is an innovative biotech company specialized in the discovery and development of therapeutic solutions for metabolic diseases, such as diabetes and obesity. The majority of the employees are dedicated to Research and Development, the core
- [Partnering](https://www.adocia.com/partnering/) - Partnering Contact us Home >Partnering Business model: licensing-out innovative products and technology platforms Adocia business model is to develop innovative assets and establish proof-of-concept before licensing-out to pharmaceutical partners. Over the years, Adocia has built a diversified pipeline of specialty products in diabetes and obesity. The products development stage ranges from proof of concept in
- [Partenariat](https://www.adocia.com/partnering/) - Partenariat Nous contacter >Partenariat Modèle économique d’Adocia : licencier son portefeuille de produits innovants et ses plateformes technologiques Le modèle économique d’Adocia consiste à développer des produits innovants et à en établir la preuve de concept en vue de les licencier à des partenaires pharmaceutiques. Au fil des années, Adocia a construit un portefeuille diversifié
- [Plateformes technologiques](https://www.adocia.com/products-and-platform/technology-platforms/) - Produits & plateformes La mission d’Adocia est de développer des formulations innovantes de peptides approuvés et de nouvelles approches de thérapie cellulaire pour le traitement du diabète et de l’obésité Nous contacter >Produits et plateformes>Plateformes technologiques Plateformes technologiques Innovation en chimie, physico-chimie biologie, et biochimie est dans l’ADN d’Adocia depuis sa création. Les quatre plateformes
- [Technology Platforms](https://www.adocia.com/products-and-platform/technology-platforms/) - Products & platforms Adocia mission is to develop innovative formulations of approved peptides and novel cell therapy approaches for the treatment of diabetes and obesity. Contact us >Products and platforms>Technology Platforms Technology platforms Innovation in chemistry, physicochemistry and formulation is in Adocia DNA since its inception. All four technology platforms rely on disrupting innovations to
- [About](https://www.adocia.com/adocia/about/) - About Adocia is an innovative biotech company specialized in the discovery and development of therapeutic solutions for metabolic diseases. Contact us >Adocia>About Adocia, a French clinical-stage biotech company The core activities of the company are to innovate, to discover and to develop new therapeutic solutions to improve the lives of people suffering from chronic metabolic
- [Accueil](https://www.adocia.com/) - Adocia est une société française de biotechnologie au stade clinique spécialisée dans le développement de traitements innovants contre le diabète et l’obésité.
- [Contact](https://www.adocia.com/contact/) - Contact us Please fill out the form below to get in touch with us. We value your feedback and inquiries, and we will respond to you as soon as possible. Your input is important to us, and we are dedicated to providing you with accurate and timely information. Thank you for reaching out! Home >Contact
- [Contact](https://www.adocia.com/contact/) - Nous contacter Home >Contact Veuillez remplir le formulaire ci-dessous pour nous contacter. Nous accordons une grande importance à vos remarques et à vos demandes, nous y répondrons dans les plus brefs délais. Sujet*Demande généraleBusiness DevelopmentPresse et CommunicationRelations avec les investisseursRessources Humaines Nom* Email* Entreprise Votre message* En soumettant votre message, vous acceptez notre politique de
- [Adocia](https://www.adocia.com/adocia/) - Adocia Adocia has built a unique expertise in diabetes and obesity. Over the years, Adocia has consolidated a rich specialty product portfolio which is one of the broadest and most differentiated for the treatment of metabolic diseases. Contact us >Adocia About Adocia is a French clinical-stage biotech company The core activities of the company are
- [Adocia](https://www.adocia.com/adocia/) - Adocia Adocia a construit une expertise unique dans le diabète et l’obésité. Au fil des années, Adocia a consolidé un riche portefeuille de produits de spécialité qui est l’un des plus larges et des plus différenciés pour le traitement des maladies métaboliques. Nous contacter >Adocia À propos Adocia est une société française de biotechnologie au
- [Governance](https://www.adocia.com/investors/governance/) - Financials WELCOME TO THE INVESTORS SECTION OF ADOCIA Contact us >Investors>Governance Management Olivier Soula, PhD, MBA Chief Executive Officer, Co-founder Olivier Soula holds a PhD in Polymer Physico-Chemistry and an MBA. During the 8 years spent at Flamel Technologies, where he was Director of Research, he successfully led the development of Medusa, a sustained release
- [Accès et contact](https://www.adocia.com/access-contact/) - Venez nous rencontrer Adresse: 115 avenue Lacassagne 69003 Lyon France Tél: +33 (0)4 72 610 610 Fax: +33 (0)4 72 36 39 67 Nous contacter Tramway T3 : arrêt Dauphine – Lacassagne Bus C13 et 25 : arrêt Feuillat-Lacassagne Bus C9 : arrêt Cyrano Bus C11 : arrêt Maisons Neuves Bus C16 : arrêt Docteur
- [Access & contact](https://www.adocia.com/access-contact/) - Accessibility Address: 115 avenue Lacassagne 69003 Lyon France Phone : +33 (0)4 72 610 610 Fax: +33 (0)4 72 36 39 67 Contact us Metro D: stop Monplaisir Lumière Tramway T3: stop Dauphine – Lacassagne Bus C13 and 25: stop Feuillat-Lacassagne Bus C9: stop Cyrano Bus C11: stop Maisons Neuves Bus C16: stop Docteur Rebatel
- [Access & contact](https://www.adocia.com/access-contact/) - Accessibility Address: 115 avenue Lacassagne 69003 Lyon France Phone : +33 (0)4 72 610 610 Fax: +33 (0)4 72 36 39 67 Contact us Metro D: stop Monplaisir Lumière Tramway T3: stop Dauphine – Lacassagne Bus C13 and 25: stop Feuillat-Lacassagne Bus C9: stop Cyrano Bus C11: stop Maisons Neuves Bus C16: stop Docteur Rebatel
- [Management](https://www.adocia.com/adocia/management/) - Management Contact us >Adocia>Management Management Olivier Soula, PhD, MBA Directeur Général, Co-fondateur Olivier Soula est titulaire d’un doctorat en physico-chimie des polymères et d’un MBA. Pendant les 8 années passées chez Flamel Technologies, où il était directeur de la recherche, il a mené avec succès le développement de Medusa, une plateforme de libération prolongée de
- [Management](https://www.adocia.com/adocia/management/) - Management Contact us >Adocia>Management Management Olivier Soula, PhD, MBA Chief Executive Officer, Co-founder Olivier Soula holds a PhD in Polymer Physico-Chemistry and an MBA. During the 8 years spent at Flamel Technologies, where he was Director of Research, he successfully led the development of Medusa, a sustained release platform for therapeutic proteins which was partnered
- [Histoire](https://www.adocia.com/adocia/story/) - Histoire Adocia est une société française de biotechnologie fondée en 2005 par Gérard, Olivier et Rémi Soula avec l’objectif de développer des “médicaments innovants pour tous, partout”. Contact us >Adocia>Histoire Histoire L’histoire d’une famille d’entrepreneurs Adocia a été fondée en 2005 par Gérard Soula et ses deux fils, Olivier et Rémi. Ces trois scientifiques de
- [Histoire](https://www.adocia.com/adocia/story/) - Histoire Adocia est une société française de biotechnologie fondée en 2005 par Gérard, Olivier et Rémi Soula avec l’objectif de développer des “médicaments innovants pour tous, partout”. Contact us >Adocia>Histoire Histoire L’histoire d’une famille d’entrepreneurs Adocia a été fondée en 2005 par Gérard Soula et ses deux fils, Olivier et Rémi. Ces trois scientifiques de
- [History](https://www.adocia.com/adocia/story/) - History Adocia is a French biotech company founded in 2005 by Gérard, Olivier and Rémi Soula with the goal of developing “innovative medicines for everyone, everywhere”. Contact us >Adocia>History History A Story of Family Entrepreneurs Adocia was founded in 2005 by Gérard Soula and his two sons Olivier and Rémi. These three high-level scientists each
- [Advisory board](https://www.adocia.com/adocia/advisory-board/) - Advisory board Adocia breakthrough innovations are supported by a medical advisory board including some of the most distinguished key opinion leaders Contact us >Adocia>Advisory board Medical Advisory Board The Medical Advisory Board will serve as an ongoing key strategic resource to Adocia for the development of its expanding portfolio in diabetes. The members of Medical
- [Comité consultatif](https://www.adocia.com/adocia/advisory-board/) - Comité consultatif Les innovations d’Adocia sont soutenues par un comité médical réunissant des leaders d’opinion internationaux Nous contacter >Adocia>Comité consultatif Le Comité Médical Le comité médical est une ressource stratégique clé au service d’Adocia pour accompagner le développement de son portefeuille de produits dans le domaine des maladies métaboliques. Dr. Jay Skyler - MD Les
- [Environnement de travail](https://www.adocia.com/careers/work-environment/) - Environnement de travail Home >Carrière>Environnement de travail Dialogue, convivialité, bienveillance Les laboratoires et bureaux sont situés sur un unique site à Lyon, ce qui favorise la communication et les liens sociaux entre les équipes. Adocia y a aménagé un grand espace appelé “salle d’échanges” dans lequel les employés se retrouvent lors de pauses (boissons chaudes
- [Work environment](https://www.adocia.com/careers/work-environment/) - Work environment The “Adocians” HR policy Work environment Join us Home >Careers>Work environment Dialogue, conviviality, well-being Adocia laboratories and offices are located on a single site in Lyon, which encourages communication and social ties between the teams. To create a social link between employees, Adocia has set up a large space called “la salle d’échange”,
- [Nous rejoindre](https://www.adocia.com/careers/adocia-careers/) - Nous rejoindre Home >Carrière>Nous rejoindre Offres d’emploi Processus de recrutement 1ère étape : Vous effectuez un entretien de préselection, au téléphone ou en visioconférence, avec votre futur manager pour évaluer vos compétences techniques pour le poste. 2ème étape : Vous êtes invité dans nos locaux pour rencontrer divers membres de l’équipe, selon le poste auquel
- [Join us](https://www.adocia.com/careers/adocia-careers/) - Join us The “Adocians” HR policy Work environment Join us Home >Careers>Join us Job Offers Recruitment process 1st stage : You have a phone / video preselection interview with your future manager to assess your technical skills for the position. 2nd stage : You are invited to our headquarters to meet with various members of
- [Join Us](https://www.adocia.com/join-us/)
- [Management](https://www.adocia.com/investors/governance/) - Relation Investisseurs BIENVENUE DANS L’ESPACE DÉDIÉ AUX INVESTISSEURS Nous contacter >Investisseurs>Management Management Olivier Soula, PhD, MBA Chief Executive Officer, Co-founder Olivier Soula holds a PhD in Polymer Physico-Chemistry and an MBA. During the 8 years spent at Flamel Technologies, where he was Director of Research, he successfully led the development of Medusa, a sustained release
- [Liste de diffusion](https://www.adocia.com/mailing-list/) - Liste de diffusion Abonnez-vous à notre liste de diffusion pour recevoir des informations sur nos plateformes et produits. Home >Liste de diffusion Nom* Email* Pays* Entreprise* En soumettant votre message, vous acceptez notre politique de confidentialité.
- [Mailing List](https://www.adocia.com/mailing-list/) - Mailing list Subscribe to our mailing list to receive information about our platforms and products. Home >Mailing List Name* Email* Country* Company* By submitting this form, you agree to our privacy policy.
- [Mailing List](https://www.adocia.com/fr/mailing-list/) - Mailing list Subscribe to our mailing list to receive information about our platforms and products. Home >Mailing List Name* Email* Country* Company* By submitting this form, you agree to our privacy policy.
- [Mentions légales](https://www.adocia.com/legal-notice/) - Mentions légales Editeur: Le site www.adocia.com est édité par la société ADOCIA, société anonyme à conseil d’administration, immatriculée au Registre du Commerce et des Sociétés de Lyon sous le numéro 487 647 737. Adresse du siège social : 115 avenue Lacassagne, 69003 Lyon (France) Capital au 31 décembre 2022 : 872 631,7 euros Tel.: 04
- [Legal notice](https://www.adocia.com/legal-notice/) - Legal informations Editor: The website www.adocia.com is published by ADOCIA, a public limited company with a Board of Directors, registered in the Lyon Trade and Companies Register under number 487 647 737. Head office address: 115 avenue Lacassagne, 69003 Lyon (France) Capital on December 31, 2022: 872 631,7 euros. Tel.: 04 72 610 610 SIRET
- [Informations réglementées](https://www.adocia.com/investors/regulated-information/) - Relation Investisseurs Bienvenue sur la page dédiée aux investisseurs Contact us >Investisseurs>Informations réglementées Informations réglementées Adocia est une société de biotechnologie au stade clinique spécialisée dans l’innovation et le développement de solutions thérapeutiques pour les maladies métaboliques 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Financial Documents Universal
- [Gestion des cookies](https://www.adocia.com/managing-cookies/) - Gestion des cookies This Cookie Policy was last updated on 03/17/2026 and applies to citizens and legal permanent residents of the European Economic Area and Switzerland.1. IntroductionOur website, https://www.adocia.com (hereinafter: "the website") uses cookies and other related technologies (for convenience all technologies are referred to as "cookies"). Cookies are also placed by third parties we
- [Produits et plateformes](https://www.adocia.com/products-and-platform/) - Produits & plateformes La mission d’Adocia est de développer des formulations innovantes de peptides approuvés et de nouvelles approches de thérapie cellulaire pour le traitement du diabète et de l’obésité Nous contacter >Produits et plateformes Pipeline see more Plateformes technologiques see more
- [Regulated information](https://www.adocia.com/investors/regulated-information/) - Financials WELCOME TO THE INVESTORS SECTION OF ADOCIA Contact us >Investors>Regulated information Regulated information Adocia is a biotechnology company specialized in the development of best-in-class medicines from already approved therapeutic proteins. 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Financial Documents Universal Registration Document 2025
- [Carrière](https://www.adocia.com/careers/)
- [Careers](https://www.adocia.com/careers/)
- [Products and platforms](https://www.adocia.com/products-and-platform/) - Products & platforms Adocia mission is to develop innovative formulations of approved peptides and novel cell therapy approaches for the treatment of diabetes and obesity. Contact us >Products and platforms Pipeline see more Technology platforms see more
- [Managing cookies](https://www.adocia.com/managing-cookies/) - Managing cookies This Cookie Policy was last updated on 03/17/2026 and applies to citizens and legal permanent residents of the European Economic Area and Switzerland.1. IntroductionOur website, https://www.adocia.com (hereinafter: "the website") uses cookies and other related technologies (for convenience all technologies are referred to as "cookies"). Cookies are also placed by third parties we have

## Reusable Blocks

- [Médias et publications header](https://www.adocia.com/rcblocks/medias-and-publications-header/) - Actualités Les actualités rassemblent toutes les informations publiées sur les plateformes et les produits, ainsi que les actualités générales et financières. Pour vous inscrire à notre liste de diffusion, cliquez sur le bouton ci-dessous : S'abonner
- [Medias and publications header](https://www.adocia.com/rcblocks/medias-and-publications-header/) - News The news database brings together all published information on platforms and products, as well as financial and corporate news. Join our mailing list. Subscribe
- [Management](https://www.adocia.com/rcblocks/governance/) - Management Olivier Soula, PhD, MBA Directeur Général, Co-fondateur Olivier Soula est titulaire d’un doctorat en physico-chimie des polymères et d’un MBA. Pendant les 8 années passées chez Flamel Technologies, où il était directeur de la recherche, il a mené avec succès le développement de Medusa, une plateforme de libération prolongée de protéines thérapeutiques qui a
- [Management](https://www.adocia.com/rcblocks/governance/) - Management Olivier Soula, PhD, MBA Chief Executive Officer, Co-founder Olivier Soula holds a PhD in Polymer Physico-Chemistry and an MBA. During the 8 years spent at Flamel Technologies, where he was Director of Research, he successfully led the development of Medusa, a sustained release platform for therapeutic proteins which was partnered with Bristol Myers Squibb
- [Augmentation de capital](https://www.adocia.com/rcblocks/offering-section/) - Accès interdit aux États-Unis d’Amérique, au Canada, au Japon, à l’Afrique du Sud et à l’Australie. 04/12/2025 ADOCIA annonce la réalisation d’une levée de fonds de 10 millions d'euros[pdf-embedder url=”https://www.adocia.com/composants/uploads/2025/12/ADOCIA-CP-Realisation-dune-levee-de-fonds-de-10-millions-deuros.pdf” title=”ADOCIA CP – Réalisation d’une levée de fonds de 10 millions d’euros” width=”800″ toolbar=”both” toolbarfixed=”on”] 04/12/2025 Document d'Information[pdf-embedder url=”https://www.adocia.com/composants/uploads/2025/12/ADOCIA-Document-dInformation-4-decembre-2025-VF.pdf” title=”ADOCIA – Document d’Information – 4
- [Augmentation de capital](https://www.adocia.com/rcblocks/offering-section/) - Accès interdit aux États-Unis d’Amérique, au Canada, au Japon, à l’Afrique du Sud et à l’Australie. 04/12/2025 ADOCIA annonce la réalisation d’une levée de fonds de 10 millions d'euros[pdf-embedder url=”https://www.adocia.com/composants/uploads/2025/12/ADOCIA-CP-Realisation-dune-levee-de-fonds-de-10-millions-deuros.pdf” title=”ADOCIA CP – Réalisation d’une levée de fonds de 10 millions d’euros” width=”800″ toolbar=”both” toolbarfixed=”on”] 04/12/2025 Document d'Information[pdf-embedder url=”https://www.adocia.com/composants/uploads/2025/12/ADOCIA-Document-dInformation-4-decembre-2025-VF.pdf” title=”ADOCIA – Document d’Information – 4

## Technology platforms

- [AdoXLong<sup>TM</sup>](https://www.adocia.com/technology-platform/adoxlong/) - Drugs for long-term therapy typically need frequent administrations which can be a burden to patients and a barrier to effective therapy.
- [AdoXLong<sup>TM</sup>](https://www.adocia.com/technology-platform/adoxlong/) - Les médicaments destinés à un traitement chronique doivent généralement être administrés fréquemment, ce qui peut constituer un fardeau pour les patients et un obstacle à une thérapie efficace.
- [BioChaperone<sup>®</sup>](https://www.adocia.com/technology-platform/biochaperone/) - Technologie pour le développement de formulations innovantes de peptides et de protéines
- [BioChaperone<sup>®</sup>](https://www.adocia.com/technology-platform/biochaperone/) - Technology for the development of next-generation formulations of peptides and proteins
- [AdoShell<sup>®</sup>](https://www.adocia.com/technology-platform/adoshell/) - Encapsulating cells with an immunoprotective biomaterial, capable of maintaining their functionality while protecting them from degradation by the immune system
- [AdoShell<sup>®</sup>](https://www.adocia.com/technology-platform/adoshell/) - Encapsuler des cellules dans un biomatériau immunoprotecteur, capable de maintenir leur fonctionnalité, tout en les protégeant de la dégradation par le système immunitaire
- [AdOral<sup>®</sup>](https://www.adocia.com/technology-platform/adoral/) - Les formes orales améliorent l'adhésion et l'observance des patients, offrent un confort d'utilisation, simplifient l'administration des médicaments chez les enfants et, globalement, aident les patients à atteindre leurs objectifs thérapeutiques.
- [AdOral<sup>®</sup>](https://www.adocia.com/technology-platform/adoral/) - Oral forms improve patient adherence and compliance, provide comfort of use, simplify drug administration in children and overall, help patients to achieve their therapeutic goals.

## Products

- [M1Pram](https://www.adocia.com/products/m1pram/) - M1Pram, une formulation unique d’analogues d’amyline et d’insuline qui a déjà fait ses preuves Adocia a développé M1Pram pour permettre aux patients atteints à la fois de diabète et de surpoids ou d’obésité d’aborder la gestion du poids et le contrôle de la glycémie comme des objectifs de soins communs. Aujourd’hui, de plus en plus
- [M1Pram](https://www.adocia.com/products/m1pram/) - M1Pram, a unique formulation of amyline and insulin analogs with a proven track record Adocia has developed M1Pram to enable patients affected by both diabetes and overweight or obesity to address weight management and glycemic control as co-primary targets of care. Today, more and more people are affected by both diabetes and obesity, and “Diabesity”
- [BioChaperone<sup>®</sup> Lispro](https://www.adocia.com/products/biochaperone-lispro/) - BioChaperone® Lispro (BC Lispro) est une nouvelle formulation d’insuline prandiale ultra-rapide contenant de l’insuline lispro et la technologie brevetée BioChaperone®. L’excipient BioChaperone® garantit une absorption plus rapide de l’insuline et permet une gestion plus efficace de la glycémie. Les avantages concurrentiels de BC Lispro sont les suivants : Meilleur profil d’efficacité pour moins d’hyperglycémies et
- [BioChaperone<sup>®</sup> Lispro](https://www.adocia.com/products/biochaperone-lispro/) - BioChaperone® Lispro (BC Lispro) is a novel ultra-rapid prandial insulin formulation containing insulin lispro and Adocia proprietary technology BioChaperone®. The BioChaperone® excipient ensures a faster absorption of insulin and enables a more effective management of blood glucose levels. BC Lispro competitive advantages are: Better efficacy profile for less hyperglycemia and less hypoglycemia (“Faster-in” / “Faster-out”)
- [AdoShell<sup>®</sup>  Islets](https://www.adocia.com/products/adoshell-islets/) - AdoShell® Islets is a hydrogel-based implant designed to cure type 1 diabetes by cell therapy. In type 1 diabetes, the beta cells of islets of Langerhans are destroyed by an autoimmune mechanism. Transplantation of islets of Langerhans is the only curative treatment. This technique is practiced in various countries. However, it has a major pitfall:
- [AdoXLong<sup>TM</sup> Sema](https://www.adocia.com/products/adoxlong/)
- [AdoXLong<sup>TM</sup> Sema](https://www.adocia.com/products/adoxlong/)
- [AdOral<sup>®</sup> Sema](https://www.adocia.com/products/adoral-sema/) - AdOral Sema is an orally administered glucagon-like peptide 1 (GLP-1) receptor agonist: semaglutide. Semaglutide is approved as a treatment of type 2 diabetes to improve glycemic control. It is also approved for weight loss and weight maintenance. Adocia has applied its AdOral® technology to switch the administration route of semaglutide from injectable to oral. Preclinical
- [AdOral<sup>®</sup> Sema](https://www.adocia.com/products/adoral-sema/) - AdOral® Sema est une formulation orale d’un agoniste des récepteurs au glucagon-like peptide 1 (GLP-1) : le semaglutide. Le semaglutide est approuvé pour le traitement du diabète de type 2 pour l’amélioration du contrôle de la glycémie. Il est également approuvé pour la perte et le contrôle du poids. Adocia a appliqué sa technologie AdOral®
- [AdoShell<sup>®</sup>  Islets](https://www.adocia.com/products/adoshell-islets/) - AdoShell® Islets est un implant à base d’hydrogel conçu pour le traitement curatif du diabète de type 1 par thérapie cellulaire. En cas de diabète de type 1, les cellules bêta des îlots de Langerhans sont détruites par un mécanisme auto-immun. La transplantation d’îlots de Langerhans est le seul traitement curatif. Cette technique est pratiquée
- [BioChaperone<sup>®</sup> GLP-1 Amylin](https://www.adocia.com/products/biochaperone-glp-1-amyline/) - GLP-1 and amylin are two long-acting peptides with complementary mechanisms of action for the treatment of diabetes and obesity. Direct co-formulation of these two peptides can present major physicochemical compatibility challenges. Due to distinct solubility and stability profiles, there may be no single pH that can simultaneously ensure solubility, colloidal stability, resistance to amyloid fibrillation,
- [BioChaperone<sup>®</sup> GLP-1 Amyline](https://www.adocia.com/fr/products/biochaperone-glp-1-amyline/) - Les GLP-1 et l’amyline sont deux peptides à action prolongée et dotés de mécanismes d’action complémentaires pour le traitement du diabète et de l’obésité. La co-formulation directe de ces deux peptides peut présenter des défis majeurs de compatibilité physico-chimique. Il arrive qu’en raison de profils distincts de solubilité et de stabilité, aucun pH unique ne

## Medias and publications

- [ADOCIA annonce le bilan semestriel du contrat de liquidité conclu avec Kepler Capital Markets](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-bilan-semestriel-du-contrat-de-liquidite-conclu-avec-kepler-capital-markets-4/)
- [ADOCIA Announces Half-Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets](https://www.adocia.com/medias-publications/adocia-announces-half-year-report-on-adocias-liquidity-agreement-with-kepler-capital-markets-8/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 juin 2026](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-juin-2026/)
- [Number of Shares and Voting Rights of ADOCIA as of June 30, 2026](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-june-30-2026/)
- [ADOCIA annonce l’expiration du droit exclusif à négocier un partenariat pour M1Pram avec SANOFI](https://www.adocia.com/fr/medias-publications/adocia-annonce-lexpiration-du-droit-exclusif-a-negocier-un-partenariat-pour-m1pram-avec-sanofi/)
- [ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI](https://www.adocia.com/medias-publications/adocia-announces-the-expiration-of-exclusive-right-to-negotiate-partnership-for-m1pram-with-sanofi/)
- [ADOCIA - Investor Presentation - Biotech Showcase/JPM24 - January 2024](https://www.adocia.com/medias-publications/adocia-investor-presentation-biotech-showcase-jpm24-january-2024/)
- [ADOCIA - Investir Day - Nov. 2025 (FR)](https://www.adocia.com/medias-publications/adocia-investir-day-nov-2025-fr/)
- [Présentation d’AdoShell Islets 2022](https://www.adocia.com/fr/medias-publications/adoshell-islet-vimeo/)
- [Webinaire Investisseurs du 20 sept 2022](https://www.adocia.com/fr/medias-publications/webinar-investisseurs-sep-2022-fr/)
- [Résultats Annuels 2022](https://www.adocia.com/fr/medias-publications/resultats-annuels-2022-webinaire-investisseurs/)
- [Webconférence du 06 juillet 2023](https://www.adocia.com/fr/medias-publications/web-conference-du-6-juillet-2023/)
- [Jérémy Benattar - Investisseur.TV](https://www.adocia.com/fr/medias-publications/jeremy-benattar-investisseur-tv/)
- [Olivier Soula - Investival Showcase (English)](https://www.adocia.com/fr/medias-publications/olivier-soula-investival-showcase-english/)
- [Web conférence - Diabète : un laboratoire pour le futur de la santé - déc. 2023](https://www.adocia.com/fr/medias-publications/web-conference-diabete-un-laboratoire-pour-la-sante-14-decembre-2023/)
- [Olivier Soula - Le Revenu TV - Déc. 2023](https://www.adocia.com/medias-publications/olivier-soula-le-revenu-tv-dec-2023-fr/)
- [Olivier Soula - LSX World Congress - Avril 2024 (ENG)](https://www.adocia.com/fr/medias-publications/olivier-soula-lsx-world-congress-avril-2024-eng/)
- [Interview Olivier Soula – La France de Demain, Radio Classique - Mai 2024](https://www.adocia.com/fr/medias-publications/interview-olivier-soula-la-france-de-demain-radio-classique/)
- [Web Conférence - BioChaperone Combo - Juillet 2024](https://www.adocia.com/fr/medias-publications/web-conference-biochaperone-combo-juillet-2024/)
- [Olivier Soula – Bourse et Valeurs, Lyon Pole Bourse 2024](https://www.adocia.com/fr/medias-publications/olivier-soula-bourse-et-valeurs-lyon-pole-bourse-2024/)
- [Interview Olivier Soula – Bourse et Valeurs – Juillet 2025](https://www.adocia.com/fr/medias-publications/interview-olivier-soula-bourse-et-valeurs-juillet-2025/)
- [Olivier Soula et Mathieu-William Gilbert - Présentation Investir Day Novembre 2025](https://www.adocia.com/fr/medias-publications/adocia-olivier-soula-et-mathieu-william-gilbert-presentation-investir-day-novembre-2025/)
- [Interview Olivier Soula et Stéphane Boissel - La Bourse et la vie - Mai 2026](https://www.adocia.com/fr/medias-publications/24868/)
- [Assemblée Générale Mixte du 3 juin 2026](https://www.adocia.com/fr/medias-publications/assemblee-generale-mixte-du-3-juin-2026/)
- [2022 AdoShell Islets Presentation](https://www.adocia.com/medias-publications/test-vimeo/)
- [Investors Webinar of Sept 20th, 2022](https://www.adocia.com/medias-publications/6896/)
- [2022 Annual Results](https://www.adocia.com/medias-publications/6902/)
- [Webconference of July 6th, 2023](https://www.adocia.com/medias-publications/web-conference-du-july-6-2023/)
- [Olivier Soula - Bourse et Valeurs, Lyon Pole Bourse (FR)](https://www.adocia.com/medias-publications/olivier-soula-bourse-et-valeurs-lyon-pole-bourse-fr/)
- [Jérémy Benattar - Investisseur.TV (FR)](https://www.adocia.com/medias-publications/jeremy-benattar-investisseur-tv/)
- [Olivier Soula - Investival Showcase](https://www.adocia.com/medias-publications/olivier-soula-investival-showcase/)
- [Web conférence - Diabète : un laboratoire pour le futur de la santé - déc. 2023 (FR)](https://www.adocia.com/medias-publications/web-conference-diabete-un-laboratoire-pour-la-sante-decembre-2023-fr/)
- [Olivier Soula - Le Revenu TV - Dec. 2023 (FR)](https://www.adocia.com/medias-publications/olivier-soula-le-revenu-tv-dec-2023-fr/)
- [Web-conference - 4th Quarter 2023 Financial Results (FR)](https://www.adocia.com/medias-publications/web-conference-fourth-quarter-2023-financial-results-fr/)
- [BIO-Europe Spring 2024: Interview with Jérémy Benattar](https://www.adocia.com/medias-publications/bio-europe-spring-2024-interview-with-jeremy-benattar/)
- [Interview Olivier Soula - Le Journal des Biotechs - March 2024 (FR)](https://www.adocia.com/medias-publications/interview-olivier-soula-le-journal-des-biotechs-march-2024-fr/)
- [Olivier Soula - LSX World Congress - April 2024](https://www.adocia.com/medias-publications/olivier-soula-lsx-world-congress-april-2024/)
- [Interview Olivier Soula – La France de Demain, Radio Classique - May 2024 (FR)](https://www.adocia.com/medias-publications/interview-olivier-soula-la-france-de-demain-radio-classique-fr-2/)
- [Web Conference - BioChaperone Combo - July 2024 (FR)](https://www.adocia.com/medias-publications/web-conference-biochaperone-combo-july-2024-fr/)
- [Olivier Soula – Bourse et Valeurs, Lyon Pole Bourse 2024 (FR)](https://www.adocia.com/medias-publications/olivier-soula-bourse-et-valeurs-lyon-pole-bourse-2024-fr/)
- [General Shareholders Meeting - June 11, 2025 (FR)](https://www.adocia.com/medias-publications/general-shareholders-meeting-june-11-2025/)
- [Interview Olivier Soula – Bourse et Valeurs – July 2025 (FR)](https://www.adocia.com/medias-publications/interview-olivier-soula-bourse-et-valeurs-july-2025-fr/)
- [Olivier Soula and Mathieu-William Gilbert - Presentation Investir Day November 2025 (FR)](https://www.adocia.com/medias-publications/adocia-olivier-soula-and-mathieu-william-gilbert-presentation-investir-day-november-2025/)
- [Interview Stéphane Boissel - Chairman of the Board - March 2026](https://www.adocia.com/medias-publications/24310/)
- [Olivier Soula and Stéphane Boissel interview - La bourse et la vie - May 2026](https://www.adocia.com/medias-publications/olivier-soula-and-stephane-boissel-interview-la-bourse-et-la-vie-march-2026/)
- [General Shareholders Meeting – June 3, 2026 (FR)](https://www.adocia.com/medias-publications/general-shareholders-meeting-june-3-2026-fr/)
- [Web-conference - Financial Results - 2023 Fourth Quarter (French)](https://www.adocia.com/medias-publications/web-conference-financial-results-2023-fourth-quarter-french/)
- [Investor Presentation - LSX World Congress - April 2024](https://www.adocia.com/medias-publications/investor-presentation-lsx-world-congress-april-2024/)
- [ADOCIA - LSX Investival Presentation - Nov 2023 (ENG)](https://www.adocia.com/fr/medias-publications/adocia-lsx-investival-presentation-nov-2023-eng/)
- [ADOCIA - Investir Day - Nov 2023](https://www.adocia.com/fr/medias-publications/adocia-investir-day-nov-2023/)
- [ADOCIA - Investor Presentation - Biotech Showcase/JPM24 - January 2024 (ENG)](https://www.adocia.com/fr/medias-publications/adocia-investor-presentation-biotech-showcase-jpm24-january-2024-eng/)
- [Web-conférence - Résultats Financiers - Quatrième Trimestre 2023](https://www.adocia.com/medias-publications/web-conference-financial-results-2023-fourth-quarter-french/)
- [Web Conférence - Résultats financiers du 4ème trimestre 2023](https://www.adocia.com/medias-publications/web-conference-fourth-quarter-2023-financial-results-fr/)
- [Présentation Investisseur - LSX World Congress - Avril 2024 (ENG)](https://www.adocia.com/fr/medias-publications/presentation-investisseur-lsx-world-congress-avril-2024-eng/)
- [ADOCIA – Investir Day – Nov. 2024](https://www.adocia.com/fr/medias-publications/adocia-investir-day-nov-2024/)
- [ADOCIA – Webcast avec un leader d’opinion sur les résultats de phase 3 de BC Lispro – 16 juin 2026 (ENG)](https://www.adocia.com/medias-publications/adocia-bc-lispro-phase-3-results-kol-webcast-june-16-2026/)
- [ADOCIA - LSX Investival Presentation - Nov 2023](https://www.adocia.com/medias-publications/adocia-lsx-investival-presentation-nov-2023/)
- [ADOCIA - Investir Day - Nov 2023 (FR)](https://www.adocia.com/medias-publications/adocia-investir-day-nov-2023-fr/)
- [ADOCIA – Investir Day – Nov. 2024 (FR)](https://www.adocia.com/medias-publications/adocia-investir-day-nov-2024-fr/)
- [ADOCIA - BC Lispro Phase 3 Results KOL Webcast - June 16, 2026](https://www.adocia.com/medias-publications/adocia-bc-lispro-phase-3-results-kol-webcast-june-16-2026/)
- [ADOCIA - Investir Day - Nov. 2025](https://www.adocia.com/fr/medias-publications/adocia-investir-day-nov-2025-fr/)
- [Number of Shares and Voting Rights of ADOCIA as of May 31st, 2026](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-may-31st-2026/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mai 2026](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mai-2026/)
- [ADOCIA confirme son éligibilité au PEA-PME](https://www.adocia.com/fr/medias-publications/adocia-confirme-son-eligibilite-au-pea-pme-5/)
- [ADOCIA Confirms its Eligibility for the PEA PME Scheme](https://www.adocia.com/medias-publications/adocia-confirms-its-eligibility-for-the-pea-pme-scheme-2/)
- [Ultra-Rapid TDB0206 Injection (BioChaperone Lispro, BCLIS) Improves Postprandial And Daily Glucose Control Vs.  Lispro (LIS) In Chinese People With Type 2 Diabetes (T2D)](https://www.adocia.com/fr/medias-publications/ultra-rapid-tdb0206-injection-biochaperone-lispro-bclis-improves-postprandial-and-daily-glucose-control-vs-lispro-lis-in-chinese-people-with-type-2-diabetes-t2d/)
- [Ultra-Rapid TDB0206 Injection (BioChaperone Lispro, BCLIS) Improves Postprandial And Daily Glucose Control Vs.  Lispro (LIS) In Chinese People With Type 2 Diabetes (T2D)](https://www.adocia.com/medias-publications/ultra-rapid-tdb0206-injection-biochaperone-lispro-bclis-improves-postprandial-and-daily-glucose-control-vs-lispro-lis-in-chinese-people-with-type-2-diabetes-t2d/)
- [ADOCIA Announces THDB0206 (BioChaperone® Lispro) Phase 3 Data in Type 2 Diabetes Presented at ADA 86th Scientific Sessions, Confirming the Positive Results Previously Announced in July 2025](https://www.adocia.com/medias-publications/adocia-announces-thdb0206-biochaperone-lispro-phase-3-data-in-type-2-diabetes-presented-at-ada-86th-scientific-sessions-confirming-the-positive-results-previously-announced-in-july-2025/)
- [ADOCIA annonce la présentation des données de phase 3 de THDB0206 (BioChaperone® Lispro) dans le diabète de type 2 lors des 86e sessions scientifiques de l'ADA, confirmant les résultats positifs déjà annoncés en juillet 2025](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-presentation-des-donnees-de-phase-3-de-thdb0206-biochaperone-lispro-dans-le-diabete-de-type-2-lors-des-86e-sessions-scientifiques-de-lada-confirmant-les-resultats-positifs/)
- [Adocia annonce un évènement virtuel avec un leader d’opinion à l’occasion des résultats de phase 3 de l’insuline ultra-rapide BioChaperone® Lispro le 16 juin 2026](https://www.adocia.com/fr/medias-publications/adocia-annonce-un-evenement-virtuel-avec-un-leader-dopinion-a-loccasion-des-resultats-de-phase-3-de-linsuline-ultra-rapide-biochaperone-lispro-le-16-juin-2026/)
- [Adocia Announces a Virtual KOL Event to Review the Phase 3 Results of the Ultra-Rapid Insulin BioChaperone® Lispro on June 16, 2026](https://www.adocia.com/medias-publications/adocia-announces-a-virtual-kol-event-to-review-the-phase-3-results-of-the-ultra-rapid-insulin-biochaperone-lispro-on-june-16-2026/)
- [ADOCIA Reports First Quarter 2026 Financial Results and Provides a Business Update](https://www.adocia.com/medias-publications/adocia-reports-first-quarter-2026-financial-results-and-provides-a-business-update/)
- [ADOCIA publie ses résultats financiers du premier trimestre 2026 et fait le point sur ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-premier-trimestre-2026-et-fait-le-point-sur-ses-activites/)
- [ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 3rd, 2026 in Paris](https://www.adocia.com/medias-publications/adocia-announces-its-annual-shareholders-meeting-to-be-held-on-june-3rd-2026-in-paris/)
- [ADOCIA annonce la tenue de son assemblée générale annuelle le 3 juin 2026 à Paris](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-tenue-de-son-assemblee-generale-annuelle-le-3-juin-2026-a-paris/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 avril 2026](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-avril-2026/)
- [Number of Shares and Voting Rights of ADOCIA as of April 30, 2026](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-april-30-2026/)
- [ADOCIA Announces the Release of its Universal Registration Document for the Year 2025](https://www.adocia.com/medias-publications/adocia-announces-the-release-of-its-universal-registration-document-for-the-year-2025/)
- [ADOCIA annonce la mise à disposition de son Document d’Enregistrement Universel pour l’année 2025](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-mise-a-disposition-de-son-document-denregistrement-universel-pour-lannee-2025/)
- [ADOCIA Announces Full Year 2025 Financial Results and Provides a Corporate and Financial Update](https://www.adocia.com/medias-publications/adocia-announces-full-year-2025-financial-results-and-provides-a-corporate-and-financial-update/)
- [ADOCIA annonce ses résultats annuels 2025 et fait le point sur ses activités et sa situation financière](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-annuels-2025-et-fait-le-point-sur-ses-activites-et-sa-situation-financiere/)
- [ADOCIA et Vester Finance signent une convention d'avance en compte courant d’actionnaire permettant à ADOCIA d’étendre son horizon de trésorerie jusqu’au début du T2 2027](https://www.adocia.com/fr/medias-publications/adocia-et-vester-finance-signent-une-convention-davance-en-compte-courant-dactionnaire-permettant-a-adocia-detendre-son-horizon-de-tresorerie-jusquau-debut-du-t2-2027/)
- [ADOCIA and Vester Finance sign a shareholder loan agreement, enabling ADOCIA to extend its cash runway until beginning Q2 2027](https://www.adocia.com/medias-publications/adocia-and-vester-finance-sign-a-shareholder-loan-agreement-enabling-adocia-to-extend-its-cash-runway-until-beginning-q2-2027/)
- [Number of Shares and Voting Rights of ADOCIA as of March 31st, 2026](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-march-31st-2026/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mars 2026](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mars-2026/)
- [Interview Stéphane Boissel - Président du Conseil d'Administration - Mars 2026](https://www.adocia.com/medias-publications/24310/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 28 février 2026](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-28-fevrier-2026/)
- [Number of Shares and Voting Rights of ADOCIA as of February 28th, 2026](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-february-28th-2026/)
- [ADOCIA Reports Fourth Quarter 2025 Financial Results and Provides a Business Update](https://www.adocia.com/medias-publications/adocia-reports-fourth-quarter-2025-financial-results-and-provides-a-business-update/)
- [ADOCIA publie ses résultats financiers du quatrième trimestre 2025 et fait le point sur ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-quatrieme-trimestre-2025-et-fait-le-point-sur-ses-activites/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 janvier 2026](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-janvier-2026/)
- [Number of Shares and Voting Rights of ADOCIA as of January 31st, 2026](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-january-31st-2026/)
- [ADOCIA annonce le bilan semestriel du contrat de liquidité conclu avec Kepler Capital Markets](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-bilan-semestriel-du-contrat-de-liquidite-conclu-avec-kepler-capital-markets-3/)
- [ADOCIA Announces Half-Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets](https://www.adocia.com/medias-publications/adocia-announces-half-year-report-on-adocias-liquidity-agreement-with-kepler-capital-markets-7/)
- [ADOCIA Announces the Completion of a €10 Million Fundraising](https://www.adocia.com/medias-publications/adocia-announces-the-completion-of-a-e10-million-fundraising/)
- [ADOCIA annonce la réalisation d’une levée de fonds de 10 millions d’euros](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-realisation-dune-levee-de-fonds-de-10-millions-deuros/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 décembre 2025](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-decembre-2025/)
- [Number of Shares and Voting Rights of ADOCIA as of December 31st, 2025](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-december-31st-2025/)
- [ADOCIA annonce son calendrier financier pour l’année 2026](https://www.adocia.com/fr/medias-publications/adocia-annonce-son-calendrier-financier-pour-lannee-2026/)
- [ADOCIA Announces its Financial Calendar for 2026](https://www.adocia.com/medias-publications/adocia-announces-its-financial-calendar-for-2026/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 8 décembre 2025](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-8-decembre-2025/)
- [Number of Shares and Voting Rights of ADOCIA as of December 8th, 2025](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-december-8th-2025/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 octobre 2025](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-octobre-2025/)
- [Number of Shares and Voting Rights of ADOCIA as of October 31st, 2025](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-october-31st-2025/)
- [ADOCIA annonce le dépôt de brevet d’une nouvelle plateforme de peptides à action prolongée pour le diabète et l’obésité - AdoXLong - et fait le point sur sa plateforme BioChaperone®](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-depot-de-brevet-dune-nouvelle-plateforme-de-peptides-a-action-prolongee-pour-le-diabete-et-lobesite-adoxlong-et-fait-le-point-sur-sa-plateforme-biochaperone/)
- [ADOCIA Announces Filing of Patent for New Long-Acting Peptides Platform in Diabetes and Obesity - AdoXLong - and Provides an Update on its BioChaperone® Platform](https://www.adocia.com/medias-publications/adocia-announces-filing-of-patent-for-new-long-acting-peptides-platform-in-diabetes-and-obesity-adoxlong-and-provides-an-update-on-its-biochaperone-platform/)
- [ADOCIA Reports Third Quarter 2025 Financial Results and Provides a Business Update](https://www.adocia.com/medias-publications/adocia-reports-third-quarter-2025-financial-results-and-provides-a-business-update/)
- [ADOCIA publie ses résultats financiers du troisième trimestre 2025 et fait le point sur ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-troisieme-trimestre-2025-et-fait-le-point-sur-ses-activites/)
- [ADOCIA et Tonghua Dongbao annoncent les résultats positifs de l'essai clinique de Phase 3 sur l'insuline ultra-rapide BioChaperone® Lispro (THDB0206 injection) chez les personnes atteintes de Diabète de Type 1](https://www.adocia.com/fr/medias-publications/adocia-et-tonghua-dongbao-annoncent-les-resultats-positifs-de-lessai-clinique-de-phase-3-sur-linsuline-ultra-rapide-biochaperone-lispro-thdb0206-injection-chez-les-personnes-atteintes-de-d-2/)
- [ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in people with T1D](https://www.adocia.com/medias-publications/adocia-and-tonghua-dongbao-announce-positive-topline-results-of-phase-3-clinical-trial-on-ultra-rapid-insulin-biochaperone-lispro-thdb0206-injection-in-people-with-t1d/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 septembre 2025](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-septembre-2025/)
- [Number of Shares and Voting Rights of ADOCIA as of September 30th, 2025](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-september-30th-2025/)
- [ADOCIA publie ses résultats financiers du premier semestre 2025 et dresse un bilan de ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-premier-semestre-2025-et-dresse-un-bilan-de-ses-activites/)
- [ADOCIA Announces First Half 2025 Financial Results and Provides a Business Update](https://www.adocia.com/medias-publications/adocia-announces-first-half-2025-financial-results-and-provides-a-business-update/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 août 2025](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-aout-2025/)
- [Number of Shares and Voting Rights of ADOCIA as of August 31st, 2025](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-august-31st-2025/)
- [ADOCIA annonce la tenue de plusieurs présentations orales sur ses plateformes AdoShell® et BioChaperone® lors des congrès 2025 de l’EASD, ESB et PODD](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-tenue-de-plusieurs-presentations-orales-sur-ses-plateformes-adoshell-et-biochaperone-lors-des-congres-2025-de-leasd-esb-et-podd/)
- [ADOCIA Announces Oral Presentations on AdoShell® and BioChaperone® at EASD, ESB and PODD 2025 Annual Meetings](https://www.adocia.com/medias-publications/adocia-announces-oral-presentations-on-adoshell-and-biochaperone-at-easd-esb-and-podd-2025-annual-meetings/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 juillet 2025](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-juillet-2025/)
- [Number of Shares and Voting Rights of ADOCIA as of July 31st, 2025](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-july-31st-2025/)
- [ADOCIA et Tonghua Dongbao annoncent les résultats positifs de l'essai clinique de Phase 3 sur l'insuline ultra-rapide BioChaperone® Lispro (THDB0206 injection) chez les personnes atteintes de diabète de Type 2](https://www.adocia.com/fr/medias-publications/adocia-et-tonghua-dongbao-annoncent-les-resultats-positifs-de-lessai-clinique-de-phase-3-sur-linsuline-ultra-rapide-biochaperone-lispro-thdb0206-injection-chez-les-personnes-atteintes-de-d/)
- [ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in people with T2D](https://www.adocia.com/medias-publications/adocia-and-tonghua-dongbao-announce-positive-topline-results-of-phase-3-clinical-trial-on-ultra-rapid-insulin-biochaperone-lispro-thdb0206-injection-in-people-with-t2d/)
- [ADOCIA publie ses résultats financiers du deuxième trimestre 2025 et fait le point sur ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-deuxieme-trimestre-2025-et-fait-le-point-sur-ses-activites/)
- [ADOCIA Reports Second Quarter 2025 Financial Results and Provides a Business Update](https://www.adocia.com/medias-publications/adocia-reports-second-quarter-2025-financial-results-and-provides-a-business-update/)
- [ADOCIA annonce le bilan semestriel du contrat de liquidité conclu avec Kepler Capital Markets](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-bilan-semestriel-du-contrat-de-liquidite-conclu-avec-kepler-capital-markets-2/)
- [ADOCIA Announces Half-Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets](https://www.adocia.com/medias-publications/adocia-announces-half-year-report-on-adocias-liquidity-agreement-with-kepler-capital-markets-6/)
- [Number of Shares and Voting Rights of ADOCIA as of June 30th, 2025](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-june-30th-2025/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 juin 2025](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-juin-2025/)
- [ADOCIA présente lors des conférences ADA & IPITA la mise à l’échelle humaine et la bonne transposition d’AdoShell® des îlots pancréatiques humains aux îlots dérivés de cellules souches](https://www.adocia.com/fr/medias-publications/adocia-presente-lors-des-conferences-ada-ipita-la-mise-a-lechelle-humaine-et-la-bonne-transposition-dadoshell-des-ilots-pancreatiques-humains-aux-ilots-derives-de-cellules-so/)
- [ADOCIA Presentations at ADA & IPITA Scientific Conferences Highlight Scalability and Good Translation of AdoShell® from Human Islets to Stem Cell-Derived Islets](https://www.adocia.com/medias-publications/adocia-presentations-at-ada-ipita-scientific-conferences-highlight-scalability-and-good-translation-of-adoshell-from-human-islets-to-stem-cell-derived-islets/)
- [Assemblée Générale Mixte du 11 juin 2025](https://www.adocia.com/medias-publications/general-shareholders-meeting-june-11-2025/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mai 2025](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mai-2025/)
- [Number of Shares and Voting Rights of ADOCIA as of May 31st, 2025](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-may-31st-2025/)
- [ADOCIA confirme son éligibilité au PEA-PME](https://www.adocia.com/fr/medias-publications/adocia-confirme-son-eligibilite-au-pea-pme-4/)
- [ADOCIA Confirms its Eligibility for the PEA PME Scheme](https://www.adocia.com/medias-publications/adocia-confirms-its-eligibility-for-the-pea-pme-scheme/)
- [ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 11th, 2025 in Paris](https://www.adocia.com/medias-publications/adocia-announces-its-annual-shareholders-meeting-to-be-held-on-june-11th-2025-in-paris/)
- [ADOCIA annonce la tenue de son assemblée générale annuelle le 11 juin 2025 à Paris](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-tenue-de-son-assemblee-generale-annuelle-le-11-juin-2025-a-paris/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 avril 2025](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-avril-2025/)
- [Number of Shares and Voting Rights of ADOCIA as of April 30th, 2025](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-april-30th-2025/)
- [ADOCIA Reports First Quarter 2025 Financial Results and Provides a Business Update](https://www.adocia.com/medias-publications/21863/)
- [ADOCIA publie ses résultats financiers du premier trimestre 2025 et fait le point sur ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-premier-trimestre-2025-et-fait-le-point-sur-ses-activites/)
- [ADOCIA annonce la mise à disposition de son Document d’Enregistrement Universel pour l’année 2024](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-mise-a-disposition-de-son-document-denregistrement-universel-pour-lannee-2024/)
- [ADOCIA Announces the Release of its Universal Registration Document for the Year 2024](https://www.adocia.com/medias-publications/adocia-announces-the-release-of-its-universal-registration-document-for-the-year-2024/)
- [ADOCIA to Present New Data on AdoShell® at Upcoming Scientific Conferences – Showcasing Potential Curative Treatment for Type 1 Diabetes](https://www.adocia.com/medias-publications/adocia-to-present-new-data-on-adoshell-at-upcoming-scientific-conferences-showcasing-potential-curative-treatment-for-type-1-diabetes/)
- [ADOCIA présentera de nouvelles données sur AdoShell® lors de conférences scientifiques - mettant en lumière son potentiel en tant que traitement curatif du diabète de type 1](https://www.adocia.com/fr/medias-publications/adocia-presentera-de-nouvelles-donnees-sur-adoshell-lors-de-conferences-scientifiques-mettant-en-lumiere-son-potentiel-en-tant-que-traitement-curatif-du-diabete-de-type-1/)
- [ADOCIA annonce ses résultats annuels 2024 et fait le point sur ses activités et sa situation financière](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-annuels-2024-et-fait-le-point-sur-ses-activites-et-sa-situation-financiere/)
- [ADOCIA Announces Full Year 2024 Financial Results and Provides a Corporate and Financial Update](https://www.adocia.com/medias-publications/adocia-announces-full-year-2024-financial-results-and-provides-a-corporate-and-financial-update/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mars 2025](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mars-2025/)
- [Number of Shares and Voting Rights of ADOCIA as of March 31st, 2025](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-march-31st-2025/)
- [ADOCIA Announces the Successful Completion of a €9.7 Million Private Placement, Extending its Cash Runway to Q2 2026](https://www.adocia.com/medias-publications/adocia-announces-the-successful-completion-of-a-e9-7-million-private-placement-extending-its-cash-runway-to-q2-2026/)
- [ADOCIA Announces the Settlement-Delivery of its €9.7 Million Private Placement](https://www.adocia.com/medias-publications/adocia-announces-the-settlement-delivery-of-its-e9-7-million-private-placement/)
- [ADOCIA annonce la réalisation d’un placement privé de 9,7 millions d’euros, prolongeant sa trésorerie jusqu'au deuxième trimestre 2026](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-realisation-dun-placement-prive-de-97-millions-deuros-prolongeant-sa-tresorerie-jusquau-deuxieme-trimestre-2026/)
- [ADOCIA annonce le règlement-livraison de son placement privé de 9,7 millions d'euros](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-reglement-livraison-de-son-placement-prive-de-97-millions-deuros/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 28 février 2025](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-28-fevrier-2025/)
- [Number of Shares and Voting Rights of ADOCIA as of February 28th, 2025](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-february-28th-2025/)
- [ADOCIA publie ses résultats financiers du quatrième trimestre 2024 et fait le point sur ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-quatrieme-trimestre-2024-et-fait-le-point-sur-ses-activites/)
- [ADOCIA Reports Fourth Quarter 2024 Financial Results and Provides a Business Update](https://www.adocia.com/medias-publications/adocia-reports-fourth-quarter-2024-financial-results-and-provides-a-business-update/)
- [Number of Shares and Voting Rights of ADOCIA as of January 31st, 2025](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-january-31st-2025/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 janvier 2025](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-janvier-2025/)
- [ADOCIA Announces Half-Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets](https://www.adocia.com/medias-publications/adocia-announces-half-year-report-on-adocias-liquidity-agreement-with-kepler-capital-markets-5/)
- [ADOCIA annonce le bilan semestriel du contrat de liquidité conclu avec Kepler Capital Markets](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-bilan-semestriel-du-contrat-de-liquidite-conclu-avec-kepler-capital-markets/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 décembre 2024](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-decembre-2024/)
- [Number of Shares and Voting Rights of ADOCIA as of December 31st, 2024](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-december-31st-2024/)
- [ADOCIA annonce sa participation à des conférences investisseurs en 2025](https://www.adocia.com/fr/medias-publications/adocia-annonce-sa-participation-a-des-conferences-investisseurs-en-2025/)
- [ADOCIA Announces Its Participation at Upcoming Investor Conferences in 2025](https://www.adocia.com/medias-publications/adocia-announces-its-participation-at-upcoming-investor-conferences-in-2025/)
- [ADOCIA annonce son calendrier financier pour l’année 2025](https://www.adocia.com/fr/medias-publications/adocia-annonce-son-calendrier-financier-pour-lannee-2025/)
- [ADOCIA Announces its Financial Calendar for 2025](https://www.adocia.com/medias-publications/adocia-announces-its-financial-calendar-for-2025/)
- [ADOCIA et Tonghua Dongbao annoncent le dernier dosage dans une étude clinique de Phase 3 de BioChaperone® Lispro, étape associée à un paiement de 10 millions de dollars](https://www.adocia.com/fr/medias-publications/adocia-et-tonghua-dongbao-annoncent-le-dernier-dosage-dans-une-etude-clinique-de-phase-3-de-biochaperone-lispro-etape-associee-a-un-paiement-de-10-millions-de-dollars/)
- [ADOCIA and Tonghua Dongbao Announce the Final Dosing in a Phase 3 Clinical Study of BioChaperone® Lispro, Milestone Associated with a $10 Million Payment](https://www.adocia.com/medias-publications/adocia-and-tonghua-dongbao-announce-the-final-dosing-in-a-phase-3-clinical-study-of-biochaperone-lispro-milestone-associated-with-a-10-million-payment/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 novembre 2024](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-novembre-2024/)
- [Number of Shares and Voting Rights of ADOCIA as of November 30th, 2024](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-november-30th-2024/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 octobre 2024](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-octobre-2024/)
- [Number of Shares and Voting Rights of ADOCIA as of October 31st, 2024](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-october-31st-2024/)
- [ADOCIA publie ses résultats financiers du troisième trimestre 2024 et fait le point sur ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-troisieme-trimestre-2024-et-fait-le-point-sur-ses-activites/)
- [ADOCIA Reports Third Quarter 2024 Financial Results and Provides a Business Update](https://www.adocia.com/medias-publications/adocia-reports-third-quarter-2024-financial-results-and-provides-a-business-update/)
- [ADOCIA annonce breveter des combinaisons stables d’analogues de GLP-1 et d’amyline pour le traitement de l’obésité et du diabète grâce à sa plateforme BioChaperone®](https://www.adocia.com/fr/medias-publications/adocia-annonce-breveter-des-combinaisons-stables-danalogues-de-glp-1-et-damyline-pour-le-traitement-de-lobesite-et-du-diabete-grace-a-sa-plateforme-biochaperone/)
- [ADOCIA announces patenting stable combinations of GLP-1 and amylin analogs for the treatment of obesity and diabetes using its BioChaperone® platform](https://www.adocia.com/medias-publications/adocia-announces-patenting-stable-combinations-of-glp-1-and-amylin-analogs-for-the-treatment-of-obesity-and-diabetes-using-its-biochaperone-platform/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 septembre 2024](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-septembre-2024/)
- [Number of Shares and Voting Rights of ADOCIA as of September 30th, 2024](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-september-30th-2024/)
- [ADOCIA Announces Appointment of Mathieu William Gilbert as Chief Financial Officer](https://www.adocia.com/medias-publications/adocia-announces-appointment-of-mathieu-william-gilbert-as-chief-financial-officer/)
- [ADOCIA annonce la nomination de Mathieu William Gilbert au poste de Directeur Administratif et Financier](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-nomination-de-mathieu-william-gilbert-au-poste-de-directeur-administratif-et-financier/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 août 2024](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-aout-2024/)
- [Number of Shares and Voting Rights of ADOCIA as of August 31st, 2024](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-august-31st-2024/)
- [ADOCIA publie ses résultats financiers du premier semestre 2024 et dresse un bilan de ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-premier-semestre-2024-et-dresse-un-bilan-de-ses-activites/)
- [ADOCIA Announces First Half 2024 Financial Results and Provides a Business Update](https://www.adocia.com/medias-publications/adocia-announces-first-half-2024-financial-results-and-provides-a-business-update/)
- [ADOCIA to Deliver Oral Presentations on AdoShell® and AdoGel® at EASD Annual Meeting](https://www.adocia.com/medias-publications/adocia-to-deliver-oral-presentations-on-adoshell-and-adogel-at-easd-annual-meeting/)
- [ADOCIA annonce des présentations orales sur AdoShell® et AdoGel® au congrès annuel de l’EASD](https://www.adocia.com/fr/medias-publications/adocia-annonce-des-presentations-orales-sur-adoshell-et-adogel-au-congres-annuel-de-leasd/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 juillet 2024](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-juillet-2024/)
- [Number of Shares and Voting Rights of ADOCIA as of July 31st, 2024](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-july-31st-2024/)
- [ADOCIA publie ses résultats financiers du second trimestre 2024 et fait le point sur ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-second-trimestre-2024-et-fait-le-point-sur-ses-activites/)
- [ADOCIA Reports Second Quarter 2024 Financial Results and Provides a Business Update](https://www.adocia.com/medias-publications/adocia-reports-second-quarter-2024-financial-results-and-provides-a-business-update/)
- [ADOCIA annonce le bilan semestriel du contrat de liquidité conclu avec la société Kepler Capital Markets](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-bilan-semestriel-du-contrat-de-liquidite-conclu-avec-la-societe-kepler-capital-markets-4/)
- [ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets](https://www.adocia.com/medias-publications/adocia-announces-half-year-report-on-adocias-liquidity-agreement-with-kepler-capital-markets-4/)
- [ADOCIA : Information relative au nombre d’actions et de droits de vote en date du 30 juin 2024](https://www.adocia.com/fr/medias-publications/19236/)
- [Number of Shares and Voting Rights of ADOCIA as of June 30th, 2024](https://www.adocia.com/medias-publications/19231/)
- [ADOCIA annonce que Tonghua Dongbao met fin à un des deux programmes en partenariat : BioChaperone® Combo](https://www.adocia.com/fr/medias-publications/adocia-annonce-que-tonghua-dongbao-met-fin-a-un-des-deux-programmes-en-partenariat-biochaperone-combo/)
- [ADOCIA Announces that Tonghua Dongbao is Discontinuing one of the two Partnership Programs: BioChaperone® Combo](https://www.adocia.com/medias-publications/adocia-announces-that-tonghua-dongbao-is-discontinuing-one-of-the-two-partnership-programs-biochaperone-combo/)
- [ADOCIA annonce trois présentations lors des 84ème sessions scientifiques de l'American Diabetes Association](https://www.adocia.com/fr/medias-publications/adocia-annonce-trois-presentations-lors-des-84eme-sessions-scientifiques-de-lamerican-diabetes-association/)
- [ADOCIA Announces Three Presentations at the American Diabetes Association 84th Scientific Sessions](https://www.adocia.com/medias-publications/adocia-announces-three-presentations-at-the-american-diabetes-association-84th-scientific-sessions/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mai 2024](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mai-2024/)
- [Number of Shares and Voting Rights of ADOCIA as of May 31 st, 2024](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-may-31-st-2024/)
- [ADOCIA confirme son éligibilité au PEA-PME](https://www.adocia.com/fr/medias-publications/18772/)
- [ADOCIA confirms its eligibility for the PEA–PME](https://www.adocia.com/medias-publications/adocia-confirms-its-eligibility-for-the-pea-pme-4/)
- [ADOCIA annonce la nomination de Mathieu William Gilbert au poste de Directeur des Opérations](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-nomination-de-mathieu-william-gilbert-au-poste-de-directeur-des-operations/)
- [ADOCIA Announces Appointment of Mathieu William Gilbert as Chief Operating Officer](https://www.adocia.com/medias-publications/adocia-announces-appointment-of-mathieu-william-gilbert-as-chief-operating-officer/)
- [Number of shares and voting rights of ADOCIA as of February 29th, 2024](https://www.adocia.com/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-29-fevrier-2024/)
- [ADOCIA annonce la tenue de son assemblée générale annuelle le 13 juin 2024 à Paris](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-tenue-de-son-assemblee-generale-annuelle-le-13-juin-2024-a-paris/)
- [ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 13th, 2024 in Paris](https://www.adocia.com/medias-publications/adocia-announces-its-annual-shareholders-meeting-to-be-held-on-june-13th-2024-in-paris/)
- [Adocia announces revenues of EUR 4.7 M for Q3 of 2013 (with no cash impact) and maintained available cash at Eur 22.7 M](https://www.adocia.com/medias-publications/adocia-announces-revenues-of-eur-4-7-m-for-q3-of-2013-with-no-cash-impact-and-maintained-available-cash-at-eur-22-7-m/)
- [Half year report on Adocia’s liquidity agreement at December 2013](https://www.adocia.com/medias-publications/half-year-report-on-adocias-liquidity-agreement-at-december-2013/)
- [Adocia: Annual revenue of EUR 5.6 M in 2013](https://www.adocia.com/medias-publications/adocia-annual-revenue-of-eur-5-6-m-in-2013/)
- [Adocia presents financial results for the first half of 2015 highlighting strong growth](https://www.adocia.com/medias-publications/adocia-presents-financial-results-for-the-first-half-of-2015-highlighting-strong-growth/)
- [Adocia reinforces its focus on diabetes with the launch of a new project: BioChaperone Glucagon](https://www.adocia.com/medias-publications/adocia-reinforces-its-focus-on-diabetes-with-the-launch-of-a-new-project-biochaperone-glucagon/)
- [Adocia announces first quarter 2019 financial results:  cash position and revenue](https://www.adocia.com/medias-publications/adocia-announces-first-quarter-2019-financial-results-cash-position-and-revenue/)
- [ADOCIA’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial in China](https://www.adocia.com/medias-publications/adocias-partner-tonghua-dongbao-receives-clearance-to-start-ultra-rapid-insulin-biochaperone-lispro-phase-3-trial-in-china/)
- [Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes](https://www.adocia.com/medias-publications/adocia-initiates-phase-2-clinical-trial-for-m1pram-in-patients-with-type-1-diabetes/)
- [Adocia initie une étude clinique de Phase 2 sur le M1Pram chez les personnes atteintes de diabète de type 1](https://www.adocia.com/fr/medias-publications/adocia-initie-une-etude-clinique-de-phase-2-sur-le-m1pram-chez-les-personnes-atteintes-de-diabete-de-type-1/)
- [ADOCIA annonce les résultats positifs d’une étude de Phase 1 sur BioChaperone® Lispro avec son partenaire Tonghua Dongbao](https://www.adocia.com/fr/medias-publications/adocia-annonce-les-resultats-positifs-dune-etude-de-phase-1-sur-biochaperone-lispro-avec-son-partenaire-tonghua-dongbao/)
- [ADOCIA annonce une perte de poids exceptionnelle avec M1Pram chez des personnes obèses atteintes de diabète de type 1 dans une analyse post-hoc](https://www.adocia.com/fr/medias-publications/adocia-annonce-une-perte-de-poids-exceptionnelle-avec-m1pram-chez-des-personnes-obeses-atteintes-de-diabete-de-type-1-dans-une-analyse-post-hoc/)
- [Adocia et Tonghua Dongbao annoncent une alliance stratégique sur BioChaperone® Combo et BioChaperone® Lispro en Chine](https://www.adocia.com/fr/medias-publications/adocia-et-tonghua-dongbao-annoncent-une-alliance-strategique-sur-biochaperone-combo-et-biochaperone-lispro-en-chine/)
- [ADOCIA accorde à Sanofi un droit exclusif de négociation d’un partenariat sur M1Pram pour 10 millions d'euros et obtient l’engagement d’investisseurs pour une levée de fonds de 10 millions d’euros](https://www.adocia.com/fr/medias-publications/adocia-accorde-a-sanofi-un-droit-exclusif-de-negociation-dun-partenariat-sur-m1pram-pour-10-millions-deuros-et-obtient-lengagement-dinvestisseurs-pour-une-levee-de-fonds-d/)
- [ADOCIA annonce une première preuve de concept préclinique sur AdoShell® Islets pour le traitement du diabète de type 1 par thérapie cellulaire](https://www.adocia.com/fr/medias-publications/adocia-annonce-une-premiere-preuve-de-concept-preclinique-sur-adoshell-islets-pour-le-traitement-du-diabete-de-type-1-par-therapie-cellulaire/)
- [ADOCIA annonce le premier sujet traité dans les essais cliniques BioChaperone® Combo avec le partenaire Tonghua Dongbao](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-premier-sujet-traite-dans-les-essais-cliniques-biochaperone-combo-avec-le-partenaire-tonghua-dongbao/)
- [ADOCIA annonce que l'essai de phase 2 avec M1Pram a atteint son objectif principal de perte de poids des personnes en surpoids atteintes de diabète de type 1](https://www.adocia.com/fr/medias-publications/adocia-annonce-que-lessai-de-phase-2-avec-m1pram-a-atteint-son-objectif-principal-de-perte-de-poids-des-personnes-en-surpoids-atteintes-de-diabete-de-type-1/)
- [ADOCIA annonce le dosage du premier patient dans le programme de Phase 3 de BioChaperone® Lispro avec son partenaire Tonghua Dongbao](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-dosage-du-premier-patient-dans-le-programme-de-phase-3-de-biochaperone-lispro-avec-son-partenaire-tonghua-dongbao/)
- [ADOCIA annonce le lancement de 3 études cliniques sur BioChaperone® Combo avec son partenaire Tonghua Dongbao](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-lancement-de-3-etudes-cliniques-sur-biochaperone-combo-avec-son-partenaire-tonghua-dongbao/)
- [ADOCIA annonce que son partenaire Tonghua Dongbao a reçu l'autorisation de commencer le programme de Phase 3 de l'insuline ultra-rapide BioChaperone® Lispro  en Chine](https://www.adocia.com/fr/medias-publications/adocia-annonce-que-son-partenaire-tonghua-dongbao-a-recu-lautorisation-de-commencer-le-programme-de-phase-3-de-linsuline-ultra-rapide-biochaperone-lispro-en-chine/)
- [ADOCIA Announces the Successful Phase 1 Study for BioChaperone® Lispro with Partner Tonghua Dongbao](https://www.adocia.com/medias-publications/adocia-announces-the-successful-phase-1-study-for-biochaperone-lispro-with-partner-tonghua-dongbao/)
- [ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis](https://www.adocia.com/medias-publications/adocia-announces-exceptional-weight-loss-for-obese-people-with-type-1-diabetes-using-m1pram-in-a-post-hoc-analysis/)
- [Adocia and Tonghua Dongbao Announce a Strategic Alliance for BioChaperone®Combo and BioChaperone® Lispro in China.](https://www.adocia.com/medias-publications/adocia-and-tonghua-dongbao-announce-a-strategic-alliance-for-biochaperonecombo-and-biochaperone-lispro-in-china/)
- [ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes](https://www.adocia.com/medias-publications/adocia-announces-first-cell-therapy-preclinical-proof-of-concept-of-adoshell-islets-for-the-treatment-of-type-1-diabetes/)
- [ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes](https://www.adocia.com/medias-publications/adocia-announces-m1pram-phase-2-trial-meets-primary-objective-by-reducing-weight-in-overweight-people-with-type-1-diabetes/)
- [ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao](https://www.adocia.com/medias-publications/adocia-announces-the-first-subject-treated-in-biochaperone-combo-clinical-studies-with-partner-tonghua-dongbao/)
- [ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao](https://www.adocia.com/medias-publications/adocia-announces-the-first-patient-dosed-in-the-biochaperone-lispro-phase-3-program-with-partner-tonghua-dongbao/)
- [ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao](https://www.adocia.com/medias-publications/adocia-announces-start-of-3-clinical-studies-for-biochaperone-combo-with-partner-tonghua-dongbao/)
- [ADOCIA Grants Sanofi an Exclusive Right to Negotiate a Partnership on M1Pram for 10 Million Euros and Obtains Commitment from Investors to Provide 10 Million Euros in Financing](https://www.adocia.com/medias-publications/adocia-grants-sanofi-an-exclusive-right-to-negotiate-a-partnership-on-m1pram-for-10-million-euros-and-obtains-commitment-from-investors-to-provide-10-million-euros-in-financing/)
- [Number of shares and voting rights of ADOCIA as of April 30th, 2024](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-april-30th-2024/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 avril 2024](https://www.adocia.com/?post_type=customnews&p=18408)
- [ADOCIA publie ses résultats financiers du premier trimestre 2024 et fait le point sur ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-premier-trimestre-2024-et-fait-le-point-sur-ses-activites/)
- [ADOCIA Reports First Quarter 2024 Financial Results and Provides a Business Update](https://www.adocia.com/medias-publications/adocia-reports-first-quarter-2024-financial-results-and-provides-a-business-update/)
- [ADOCIA annonce la mise à disposition de son Document d’Enregistrement Universel pour l’année 2023](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-mise-a-disposition-de-son-document-denregistrement-universel-pour-lannee-2023/)
- [ADOCIA Announces the Release of its Universal Registration Document for the Year 2023](https://www.adocia.com/medias-publications/adocia-announces-the-release-of-its-universal-registration-document-for-the-year-2023/)
- [ADOCIA annonce ses résultats annuels 2023 et fait le point sur ses activités et sa situation financière à date](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-annuels-2023-et-fait-le-point-sur-ses-activites-et-sa-situation-financiere-a-date/)
- [ADOCIA Announces Full Year 2023 Financial Results and Provides a Corporate and Financial Update](https://www.adocia.com/medias-publications/adocia-announces-full-year-2023-financial-results-and-provides-a-corporate-and-financial-update/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mars 2024](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mars-2024/)
- [Number of shares and voting rights of ADOCIA as of March 31st, 2024](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-march-31st-2024/)
- [Interview Olivier Soula - Le Journal des Biotechs - Mars 2024](https://www.adocia.com/medias-publications/interview-olivier-soula-le-journal-des-biotechs-march-2024-fr/)
- [ADOCIA Announces a €2 Million Fundraising from its two Main Shareholders and a Member of its Management, and the Signature of an Equity Financing Line with Vester Finance](https://www.adocia.com/medias-publications/adocia-announces-a-e2-million-fundraising-from-its-two-main-shareholders-and-a-member-of-its-management-and-the-signature-of-an-equity-financing-line-with-vester-finance/)
- [ADOCIA annonce une levée de fonds de 2 millions d’euros auprès de ses deux actionnaires principaux et un membre de sa Direction, ainsi que la signature d’une ligne de financement en fonds propres avec Vester Finance](https://www.adocia.com/fr/medias-publications/adocia-annonce-une-levee-de-fonds-de-2-millions-deuros-aupres-de-ses-deux-actionnaires-principaux-et-un-membre-de-sa-direction-ainsi-que-la-signature-dune-ligne-de-financement-en-fo/)
- [BIO-Europe Spring 2024: Interview de Jérémy Benattar](https://www.adocia.com/medias-publications/bio-europe-spring-2024-interview-with-jeremy-benattar/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 29 février 2024](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-29-fevrier-2024/)
- [ADOCIA annonce sa participation à des évènements clés](https://www.adocia.com/fr/medias-publications/adocia-annonce-sa-participation-a-des-evenements-cles/)
- [ADOCIA Announces Its Participation at Key Events](https://www.adocia.com/medias-publications/adocia-announces-its-participation-at-key-events/)
- [ADOCIA publie ses résultats financiers du 4ème trimestre 2023 et fait le point sur ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-4eme-trimestre-2023-et-fait-le-point-sur-ses-activites/)
- [ADOCIA Reports Fourth Quarter 2023 Financial Results and Provides a Business Update](https://www.adocia.com/medias-publications/adocia-reports-fourth-quarter-2023-financial-results-and-provides-a-business-update/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 janvier 2024](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-janvier-2024/)
- [Number of shares and voting rights of ADOCIA as of January 31st, 2024](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-january-31st-2024/)
- [ADOCIA Announces the Release of its Universal Registration Document for the Year 2020](https://www.adocia.com/medias-publications/adocia-announces-the-release-of-its-universal-registration-document-for-the-year-2020/)
- [Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao](https://www.adocia.com/medias-publications/adocia-announces-positive-clinical-results-confirming-the-ultra-rapid-profile-of-a-biochaperone-lispro-formulation-containing-insulin-from-partner-tonghua-dongbao/)
- [ADOCIA annonce ses résultats annuels 2021 et présente un bilan de ses activités](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-annuels-2021-et-presente-un-bilan-de-ses-activites/)
- [Adocia annonce ses résultats annuels 2019](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-annuels-2019/)
- [Adocia initie une étude comparative BioChaperone® Lispro validant l’insuline lispro de THDB pour les Phases 3 de BC Lispro en Europe et aux Etats-Unis](https://www.adocia.com/fr/medias-publications/adocia-initie-une-etude-comparative-biochaperone-lispro-validant-linsuline-lispro-de-thdb-pour-les-phases-3-de-bc-lispro-en-europe-et-aux-etats-unis/)
- [ADOCIA publie sa position de trésorerie et son chiffre d’affaires pour le deuxième trimestre et dresse un bilan de ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-sa-position-de-tresorerie-et-son-chiffre-daffaires-pour-le-deuxieme-trimestre-et-dresse-un-bilan-de-ses-activites/)
- [Adocia annonce  des résultats cliniques positifs  confirmant le profil ultra-rapide  de BioChaperone®  Lispro comprenant l’insuline  de son partenaire Tonghua Dongbao](https://www.adocia.com/fr/medias-publications/adocia-announces-positive-clinical-results-confirming-the-ultra-rapid-profile-of-a-biochaperone-lispro-formulation-containing-insulin-from-partner-tonghua-dongbao/)
- [ADOCIA annonce son calendrier financier pour l’année 2022](https://www.adocia.com/fr/medias-publications/adocia-annonce-son-calendrier-financier-pour-lannee-2022/)
- [ADOCIA publie ses résultats financiers du premier trimestre 2023 et fait le point sur ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-premier-trimestre-2023-et-fait-le-point-sur-ses-activites/)
- [ADOCIA annonce son calendrier financier pour l’année 2024](https://www.adocia.com/fr/medias-publications/adocia-annonce-son-calendrier-financier-pour-lannee-2024/)
- [ADOCIA Announces its Financial Calendar for 2024](https://www.adocia.com/medias-publications/adocia-announces-its-financial-calendar-for-2024/)
- [ADOCIA annonce le bilan semestriel du contrat de liquidité conclu avec la société Kepler Capital Markets](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-bilan-semestriel-du-contrat-de-liquidite-conclu-avec-la-societe-kepler-capital-markets-3/)
- [ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets](https://www.adocia.com/medias-publications/adocia-announces-half-year-report-on-adocias-liquidity-agreement-with-kepler-capital-markets-3/)
- [Number of shares and voting rights of ADOCIA as of December 31st, 2023](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-december-31st-2023/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 décembre 2023](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-decembre-2023/)
- [ADOCIA annonce la mise à disposition de son Document d’Enregistrement Universel pour l’année 2022](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-nomination-dolivier-soula-au-poste-de-directeur-general/)
- [ADOCIA annonce la nomination d’Olivier Soula au poste de Directeur Général](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-nomination-dolivier-soula-au-poste-de-directeur-general-3/)
- [Number of shares and voting rights of ADOCIA as of November 30th, 2023](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-november-30th-2023/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 novembre 2023](https://www.adocia.com/?post_type=customnews&p=13023)
- [Number of shares and voting rights of ADOCIA as of October 31st, 2023](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-october-31st-2023/)
- [ADOCIA : Information relative au nombre d’actions et de droits de vote en date du 31 octobre 2023](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-octobre-2023/)
- [Lettre aux actionnaires - Novembre 2023](https://www.adocia.com/fr/medias-publications/lettre-aux-actionnaires-novembre-2023/)
- [Letter to Shareholders - November 2023](https://www.adocia.com/medias-publications/11458/)
- [ADOCIA dévoile des données précliniques prometteuses sur AdoShell® Islets pour la thérapie cellulaire du diabète](https://www.adocia.com/fr/medias-publications/adocia-devoile-des-donnees-precliniques-prometteuses-sur-adoshell-islets-pour-la-therapie-cellulaire-du-diabete/)
- [ADOCIA Revealed Promising Preclinical Data on AdoShell® Islets for Cell Therapy of Diabetes](https://www.adocia.com/medias-publications/adocia-revealed-promising-preclinical-data-on-adoshell-islets-for-cell-therapy-of-diabetes/)
- [ADOCIA publie ses résultats financiers du troisième trimestre 2023 et fait le point sur ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-troisieme-trimestre-2023-et-fait-le-point-sur-ses-activites/)
- [ADOCIA Reports Financial Results of Third Quarter 2023 and Provides an Update on its Activities](https://www.adocia.com/medias-publications/adocia-reports-financial-results-of-third-quarter-2023-and-provides-an-update-on-its-activities/)
- [ADOCIA et son partenaire Tonghua Dongbao annoncent les résultats positifs de trois essais cliniques sur BioChaperone® Combo](https://www.adocia.com/fr/medias-publications/adocia-et-son-partenaire-tonghua-dongbao-annoncent-les-resultats-positifs-de-trois-essais-cliniques-sur-biochaperone-combo/)
- [ADOCIA’s Partner Tonghua Dongbao Announces Positive Results of Three Clinical Trials on BioChaperone® Combo](https://www.adocia.com/medias-publications/adocias-partner-tonghua-dongbao-announces-positive-results-of-three-clinical-trials-on-biochaperone-combo/)
- [Number of shares and voting rights of ADOCIA as of September 30th, 2023](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-september-30th-2023/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 septembre 2023](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-septembre-2023/)
- [Olivier Soula - Bourse et Valeurs, Lyon Pole Bourse](https://www.adocia.com/medias-publications/olivier-soula-bourse-et-valeurs-lyon-pole-bourse-fr/)
- [BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in subjects with T2DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)](https://www.adocia.com/medias-publications/biochaperone-lispro-an-ultra-rapid-insulin-lispro-formulation-improves-post-prandial-blood-glucose-control-in-a-14-day-multiple-daily-insulin-injection-study-in-subjects-with-t2dm-dr-gregory-2/)
- [BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in subjects with T2DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)](https://www.adocia.com/medias-publications/biochaperone-lispro-an-ultra-rapid-insulin-lispro-formulation-improves-post-prandial-blood-glucose-control-in-a-14-day-multiple-daily-insulin-injection-study-in-subjects-with-t2dm-dr-gregory-2/)
- [BioChaperone® Glucagon, a stable ready-to-use liquid glucagon formulation, is well tolerated and quickly restores euglycemia after insulin-induced hypoglycemia, by Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/biochaperone-glucagon-a-stable-ready-to-use-liquid-glucagon-formulation-is-well-tolerated-and-quickly-restores-euglycemia-after-insulin-induced-hypoglycemia-by-dr-gregory-meiffren-78th-scie-2/)
- [BioChaperone® Glucagon, a stable ready-to-use liquid glucagon formulation, is well tolerated and quickly restores euglycemia after insulin-induced hypoglycemia, by Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/biochaperone-glucagon-a-stable-ready-to-use-liquid-glucagon-formulation-is-well-tolerated-and-quickly-restores-euglycemia-after-insulin-induced-hypoglycemia-by-dr-gregory-meiffren-78th-scie-2/)
- [BioChaperone® Technology Enables the Development of Pramlintide-Prandial Insulin Combinations, Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/biochaperone-technology-enables-the-development-of-pramlintide-prandial-insulin-combinations-dr-gregory-meiffren-78th-scientific-sessions-of-the-american-diabetes-association-22-26-june-2018-2/)
- [BioChaperone® Technology Enables the Development of Pramlintide-Prandial Insulin Combinations, Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/biochaperone-technology-enables-the-development-of-pramlintide-prandial-insulin-combinations-dr-gregory-meiffren-78th-scientific-sessions-of-the-american-diabetes-association-22-26-june-2018-2/)
- [The ultra-rapid insulin BioChaperone® Lispro shows favourable pharmacodynamics and pharmacokinetics compared to faster insulin aspart and insulin aspart in insulin pumps, Dr. Grégory Meiffren, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)](https://www.adocia.com/medias-publications/the-ultra-rapid-insulin-biochaperone-lispro-shows-favourable-pharmacodynamics-and-pharmacokinetics-compared-to-faster-insulin-aspart-and-insulin-aspart-in-insulin-pumps-dr-gregory-meiffren-54-2/)
- [The ultra-rapid insulin BioChaperone® Lispro shows favourable pharmacodynamics and pharmacokinetics compared to faster insulin aspart and insulin aspart in insulin pumps, Dr. Grégory Meiffren, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)](https://www.adocia.com/medias-publications/the-ultra-rapid-insulin-biochaperone-lispro-shows-favourable-pharmacodynamics-and-pharmacokinetics-compared-to-faster-insulin-aspart-and-insulin-aspart-in-insulin-pumps-dr-gregory-meiffren-54-2/)
- [BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in Subjects with T1DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)](https://www.adocia.com/medias-publications/biochaperone-lispro-an-ultra-rapid-insulin-lispro-formulation-improves-post-prandial-blood-glucose-control-in-a-14-day-multiple-daily-insulin-injection-study-in-subjects-with-t1dm-dr-gregory/)
- [BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in Subjects with T1DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)](https://www.adocia.com/medias-publications/biochaperone-lispro-an-ultra-rapid-insulin-lispro-formulation-improves-post-prandial-blood-glucose-control-in-a-14-day-multiple-daily-insulin-injection-study-in-subjects-with-t1dm-dr-gregory/)
- [“BioChaperone® 222, the new excipient enabling the ultra-rapid BioChaperone® Lispro formulation, is completely absorbed and rapidly excreted after subcutaneous injection” (Poster 816), presented by Dr. Olivier Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)](https://www.adocia.com/medias-publications/biochaperone-222-the-new-excipient-enabling-the-ultra-rapid-biochaperone-lispro-formulation-is-completely-absorbed-and-rapidly-excreted-after-subcutaneous-injection-po-2/)
- [“BioChaperone® 222, the new excipient enabling the ultra-rapid BioChaperone® Lispro formulation, is completely absorbed and rapidly excreted after subcutaneous injection” (Poster 816), presented by Dr. Olivier Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)](https://www.adocia.com/medias-publications/biochaperone-222-the-new-excipient-enabling-the-ultra-rapid-biochaperone-lispro-formulation-is-completely-absorbed-and-rapidly-excreted-after-subcutaneous-injection-po-2/)
- [Ultra-rapid BioChaperone® Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes. Diabetes Obes Metab., 2018;20(11):2627-2632.](https://www.adocia.com/medias-publications/ultra-rapid-biochaperone-lispro-improves-postprandial-blood-glucose-excursions-vs-insulin-lispro-in-a-14-day-crossover-treatment-study-in-people-with-type-1-diabetes-diabetes-obes-metab-2018/)
- [Ultra-rapid BioChaperone® Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes. Diabetes Obes Metab., 2018;20(11):2627-2632.](https://www.adocia.com/medias-publications/ultra-rapid-biochaperone-lispro-improves-postprandial-blood-glucose-excursions-vs-insulin-lispro-in-a-14-day-crossover-treatment-study-in-people-with-type-1-diabetes-diabetes-obes-metab-2018/)
- [Comparaison des profils pharmacocinétiques et de pharmacodynamie de l’insuline ultra rapide BioChaperone® Lispro avec les formulations Fiasp® et Novorapid® de l’insuline asparte administrées par pompes à insuline, Dr. Grégory Meiffren, March 27, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)](https://www.adocia.com/medias-publications/comparaison-des-profils-pharmacocinetiques-et-de-pharmacodynamie-de-linsuline-ultra-rapide-biochaperone-lispro-avec-les-formulations-fiasp-et-novorapid-de-linsuline-2/)
- [Comparaison des profils pharmacocinétiques et de pharmacodynamie de l’insuline ultra rapide BioChaperone® Lispro avec les formulations Fiasp® et Novorapid® de l’insuline asparte administrées par pompes à insuline, Dr. Grégory Meiffren, March 27, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)](https://www.adocia.com/medias-publications/comparaison-des-profils-pharmacocinetiques-et-de-pharmacodynamie-de-linsuline-ultra-rapide-biochaperone-lispro-avec-les-formulations-fiasp-et-novorapid-de-linsuline-2/)
- [The Ultra-Rapid Insulin BioChaperone® Lispro bolused by insulin pump shows favourable pharmacodynamics and pharmacokinetics vs. faster Aspart and insulin Aspart, Dr. Grégory Meiffren, February 23, 2019, ATTD, Berlin (Germany)](https://www.adocia.com/medias-publications/the-ultra-rapid-insulin-biochaperone-lispro-bolused-by-insulin-pump-shows-favourable-pharmacodynamics-and-pharmacokinetics-vs-faster-aspart-and-insulin-aspart-dr-gregory-meiffren-february-23-2/)
- [BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (pram) and human insulin (ins), improves post-prandial blood glucose versus both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D”, Dr. Grégory Meiffren, June 9th, 2019, ADA, San Francisco (USA)](https://www.adocia.com/medias-publications/biochaperone-pramlintide-insulin-bcpramins-a-new-co-formulation-of-pramlintide-pram-and-human-insulin-ins-improves-post-prandial-blood-glucose-versus-both-separate-injections-of-pramins-and-i-2/)
- [ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.](https://www.adocia.com/medias-publications/ado09-a-coformulation-of-pramlintide-pram-and-insulin-a21g-improves-postprandial-glucose-vs-novologr-in-type-1-diabetes-t1d-dr-gregory-meiffren-june-12-16-2020-ada-virtual-experience-2/)
- [AdoShell® Islets, a new biomaterial for allogenic islet encapsulation, shows 6 months insulin secretion in diabetic immunocompetent rats, Dr. Ouardane Jouannot, June 23, 2023, 83rd scientific Sessions, ADA 2023, San Diego, USA](https://www.adocia.com/medias-publications/adoshell-islets-a-new-biomaterial-for-allogenic-islet-encapsulation-shows-6-months-insulin-secretion-in-diabetic-immunocompetent-rats-dr-ouardane-jouannot-june-23-2023-83rd-scientific-ses/)
- [BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (pram) and human insulin (ins), improves post-prandial blood glucose versus both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D”, Dr. Grégory Meiffren, June 9th, 2019, ADA, San Francisco (USA)](https://www.adocia.com/medias-publications/biochaperone-pramlintide-insulin-bcpramins-a-new-co-formulation-of-pramlintide-pram-and-human-insulin-ins-improves-post-prandial-blood-glucose-versus-both-separate-injections-of-pramins-and-i-2/)
- [The Ultra-Rapid Insulin BioChaperone® Lispro bolused by insulin pump shows favourable pharmacodynamics and pharmacokinetics vs. faster Aspart and insulin Aspart, Dr. Grégory Meiffren, February 23, 2019, ATTD, Berlin (Germany)](https://www.adocia.com/medias-publications/the-ultra-rapid-insulin-biochaperone-lispro-bolused-by-insulin-pump-shows-favourable-pharmacodynamics-and-pharmacokinetics-vs-faster-aspart-and-insulin-aspart-dr-gregory-meiffren-february-23-2/)
- [ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.](https://www.adocia.com/medias-publications/ado09-a-coformulation-of-pramlintide-pram-and-insulin-a21g-improves-postprandial-glucose-vs-novologr-in-type-1-diabetes-t1d-dr-gregory-meiffren-june-12-16-2020-ada-virtual-experience-2/)
- [ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience.](https://www.adocia.com/medias-publications/ado09-a-co-formulation-of-the-amylin-analog-pramlintide-and-the-a21g-human-insulin-analog-lowers-postprandial-blood-glucose-versus-insulin-lispro-in-type-1-diabetes-t1d-presented-by-dr-gregory-me-2/)
- [ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D) (Poster # 2020-LB-7039-Diabetes), presented by Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.](https://www.adocia.com/medias-publications/ado09-a-coformulation-of-pramlintide-pram-and-insulin-a21g-improves-postprandial-glucose-vs-novolog-in-type-1-diabetes-t1d-poster-2020-lb-7039-diabetes-presented-by-dr-gregory-meiffren-j/)
- [ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D) (Poster # 2020-LB-7039-Diabetes), presented by Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.](https://www.adocia.com/medias-publications/ado09-a-coformulation-of-pramlintide-pram-and-insulin-a21g-improves-postprandial-glucose-vs-novolog-in-type-1-diabetes-t1d-poster-2020-lb-7039-diabetes-presented-by-dr-gregory-meiffren-j/)
- [ADO09, a co-formulation of amylin analog pramlintide and human insulin analog A21G, reduces postprandial blood sugar compared to insulin lispro in type 1 diabetes, Dr.  Grégory Meiffren, September 10, 2020, Société Francophone du Diabète, Virtual Event.](https://www.adocia.com/medias-publications/ado09-a-co-formulation-of-amylin-analog-pramlintide-and-human-insulin-analog-a21g-reduces-postprandial-blood-sugar-compared-to-insulin-lispro-in-type-1-diabetes-dr-gregory-meiffren-septembe/)
- [ADO09, a co-formulation of amylin analog pramlintide and human insulin analog A21G, reduces postprandial blood sugar compared to insulin lispro in type 1 diabetes, Dr.  Grégory Meiffren, September 10, 2020, Société Francophone du Diabète, Virtual Event.](https://www.adocia.com/medias-publications/ado09-a-co-formulation-of-amylin-analog-pramlintide-and-human-insulin-analog-a21g-reduces-postprandial-blood-sugar-compared-to-insulin-lispro-in-type-1-diabetes-dr-gregory-meiffren-septembe/)
- [AdoShell® Islets, a new biomaterial for allogenic islet encapsulation, shows 6 months insulin secretion in diabetic immunocompetent rats, Dr. Ouardane Jouannot, June 23, 2023, 83rd scientific Sessions, ADA 2023](https://www.adocia.com/medias-publications/adoshell-islets-a-new-biomaterial-for-allogenic-islet-encapsulation-shows-6-months-insulin-secretion-in-diabetic-immunocompetent-rats-dr-ouardane-jouannot-june-23-2023-83rd-scientific-ses/)
- [ADO09, a co-formulation of pramlintide and insulin A21G improves postprandial glucose (PPG) versus insulin Aspart  in type 1 diabetes, Dr.  Grégory Meiffren, June 2, 2021, ATTD, Virtual event.](https://www.adocia.com/medias-publications/ado09-a-co-formulation-of-pramlintide-and-insulin-a21g-improves-postprandial-glucose-ppg-versus-insulin-aspart-in-type-1-diabetes-dr-gregory-meiffren-june-2-2021-attd-virtual-even/)
- [ADO09, a co-formulation of pramlintide and insulin A21G improves postprandial glucose (PPG) versus insulin Aspart  in type 1 diabetes, Dr.  Grégory Meiffren, June 2, 2021, ATTD, Virtual event.](https://www.adocia.com/medias-publications/ado09-a-co-formulation-of-pramlintide-and-insulin-a21g-improves-postprandial-glucose-ppg-versus-insulin-aspart-in-type-1-diabetes-dr-gregory-meiffren-june-2-2021-attd-virtual-even/)
- [ADO09, a coformulation of insulin A21G and pramlintide (Pram), improves blood glucose control and reduces body weight in subjects with T1D, Dr. Grégory Meiffren, June 27, 2021, ADA virtual event.](https://www.adocia.com/medias-publications/ado09-a-coformulation-of-insulin-a21g-and-pramlintide-pram-improves-blood-glucose-control-and-reduces-body-weight-in-subjects-with-t1d-dr-gregory-meiffren-june-27-2021-ada-virtual-event/)
- [ADO09, a coformulation of insulin A21G and pramlintide (Pram), improves blood glucose control and reduces body weight in subjects with T1D, Dr. Grégory Meiffren, June 27, 2021, ADA virtual event.](https://www.adocia.com/medias-publications/ado09-a-coformulation-of-insulin-a21g-and-pramlintide-pram-improves-blood-glucose-control-and-reduces-body-weight-in-subjects-with-t1d-dr-gregory-meiffren-june-27-2021-ada-virtual-event/)
- [ADOCIA annonce des présentations orales sur AdoShell® Islets à l’occasion des congrès de l’EASD et de l’IPITA-IXA-CTRMS](https://www.adocia.com/fr/medias-publications/adocia-annonce-des-presentations-orales-sur-adoshell-islets-a-loccasion-des-congres-de-leasd-et-de-lipita-ixa-ctrms/)
- [ADOCIA Announces Oral Presentations on AdoShell® Islets at EASD and IPITA-IXA-CTRMS Congresses](https://www.adocia.com/medias-publications/adocia-announces-oral-presentations-on-adoshell-islets-at-easd-and-ipita-ixa-ctrms-congresses/)
- [ADOCIA Announces First Half 2023 Financial Results and Provides a Business Update](https://www.adocia.com/medias-publications/adocia-announces-first-half-2023-financial-results-and-provides-a-business-update/)
- [Number of shares and voting rights of ADOCIA as of August 31st, 2023](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-august-31st-2023/)
- [ADOCIA Announces the Availability of a Prospectus for the Admission to Trading of Shares Issued or likely to be Issued to IPF Partners on Exercise of its Warrants](https://www.adocia.com/medias-publications/adocia-announces-the-availability-of-a-prospectus-for-the-admission-to-trading-of-shares-issued-or-likely-to-be-issued-to-ipf-partners-on-exercise-of-its-warrants/)
- [ADOCIA Announces that it has Received €500.000 in Proceeds from a Partial Exercise of Warrants Held by IPF Partners](https://www.adocia.com/medias-publications/adocia-announces-that-it-has-received-e500-000-in-proceeds-from-a-partial-exercise-of-warrants-held-by-ipf-partners/)
- [Number of shares and voting rights of ADOCIA as of July 31st, 2023](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-july-31st-2023/)
- [ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets](https://www.adocia.com/medias-publications/adocia-announces-half-year-report-on-adocias-liquidity-agreement-with-kepler-capital-markets-2/)
- [ADOCIA Announces the Availability of a Prospectus for its Capital Increase and Convertible Bond Issue](https://www.adocia.com/medias-publications/adocia-announces-the-availability-of-a-prospectus-for-its-capital-increase-and-convertible-bond-issue/)
- [ADOCIA announces Q2 2023 financial results and a €10 million financing operation](https://www.adocia.com/medias-publications/adocia-announces-q2-2023-financial-results-and-a-e10-million-financing-operation/)
- [ADOCIA confirms its eligibility for the PEA–PME](https://www.adocia.com/medias-publications/adocia-confirms-its-eligibility-for-the-pea-pme-3/)
- [Number of shares and voting rights of ADOCIA as of June 30th, 2023](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-june-30th-2023/)
- [ADOCIA publie ses résultats financiers du premier semestre 2023 et dresse un bilan de ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-premier-semestre-2023-et-dresse-un-bilan-de-ses-activites/)
- [ADOCIA : Information relative au nombre d’actions et de droits de vote en date du 31 août 2023](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-aout-2023/)
- [ADOCIA annonce la mise à disposition d’un prospectus à l’occasion de l’admission aux négociations d’actions émises et susceptibles d’être émises au profit d’IPF Partners sur exercice de ses BSA](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-mise-a-disposition-dun-prospectus-a-loccasion-de-ladmission-aux-negociations-dactions-emises-et-susceptibles-detre-emises-au-profit-d/)
- [ADOCIA annonce l’encaissement de 500 000 euros au titre de l’exercice par IPF Partners d’une partie de ses Bons de Souscription d’Actions](https://www.adocia.com/fr/medias-publications/adocia-annonce-lencaissement-de-500-000-euros-au-titre-de-lexercice-par-ipf-partners-dune-partie-de-ses-bons-de-souscription-dactions/)
- [ADOCIA : Information relative au nombre d’actions et de droits de vote en date du 31 juillet 2023](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-juillet-2023/)
- [ADOCIA annonce le bilan semestriel du contrat de liquidité conclu avec la société Kepler Capital Markets](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-bilan-semestriel-du-contrat-de-liquidite-conclu-avec-la-societe-kepler-capital-markets-2/)
- [ADOCIA annonce ses résultats financiers du 2ème trimestre 2023 et un financement de 10 millions d’euros](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-du-2eme-trimestre-2023-et-un-financement-de-10-millions-deuros/)
- [ADOCIA annonce la mise à disposition d’un prospectus dans le cadre de son augmentation de capital et émission d’obligations convertibles](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-mise-a-disposition-dun-prospectus-dans-le-cadre-de-son-augmentation-de-capital-et-emission-dobligations-convertibles/)
- [ADOCIA confirme son éligibilité au PEA-PME](https://www.adocia.com/fr/medias-publications/adocia-confirme-son-eligibilite-au-pea-pme-3/)
- [ADOCIA : Information relative au nombre d’actions et de droits de vote en date du 30 juin 2023](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-juin-2023/)
- [ADOCIA publishes its Letter to Shareholders](https://www.adocia.com/medias-publications/adocia-news-2023/)
- [ADOCIA : résultats annuels 2022 et bilan des activités et de la situation financière à date](https://www.adocia.com/fr/medias-publications/adocia-resultats-annuels-2022-et-bilan-des-activites-et-de-la-situation-financiere-a-date/)
- [BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. Diabetes Obes Metab., 2019;21(4):1066-1070.](https://www.adocia.com/medias-publications/biochaperone-lispro-versus-faster-aspart-and-insulin-aspart-in-patients-with-type-1-diabetes-using-continuous-subcutaneous-insulin-infusion-a-randomized-euglycemic-clamp-study-diabetes-obes-metab/)
- [BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. Diabetes Obes Metab., 2019;21(4):1066-1070.](https://www.adocia.com/medias-publications/biochaperone-lispro-versus-faster-aspart-and-insulin-aspart-in-patients-with-type-1-diabetes-using-continuous-subcutaneous-insulin-infusion-a-randomized-euglycemic-clamp-study-diabetes-obes-metab/)
- [ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes Obes Metab., 2021;23(4):961-970.](https://www.adocia.com/medias-publications/ado09-a-co‐formulation-of-the-amylin-analogue-pramlintide-and-the-insulin-analogue-a21g-lowers-postprandial-blood-glucose-versus-insulin-lispro-in-type-1-diabetes-diabetes-obes-metab-2021/)
- [ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes Obes Metab., 2021;23(4):961-970.](https://www.adocia.com/medias-publications/ado09-a-co‐formulation-of-the-amylin-analogue-pramlintide-and-the-insulin-analogue-a21g-lowers-postprandial-blood-glucose-versus-insulin-lispro-in-type-1-diabetes-diabetes-obes-metab-2021/)
- [Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes. Diabetes Obes Metab., 2019;21(7):15701575.](https://www.adocia.com/medias-publications/better-glycemic-control-with-biochaperone-combo-bc-combo-than-with-insulin-lispro-mix25-lmix-or-separate-glargine-lispro-gl-administrations-after-a-test-meal-in-subjects-with-type-2-dia/)
- [Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes. Diabetes Obes Metab., 2019;21(7):15701575.](https://www.adocia.com/medias-publications/better-glycemic-control-with-biochaperone-combo-bc-combo-than-with-insulin-lispro-mix25-lmix-or-separate-glargine-lispro-gl-administrations-after-a-test-meal-in-subjects-with-type-2-dia/)
- [EndoC-bH5 cells are storable and ready-to-use human pancreatic beta cells with physiological insulin secretion. Mol Metab. 2023 Jul 11;76:101772](https://www.adocia.com/medias-publications/endoc-bh5-cells-are-storable-and-ready-to-use-human-pancreatic-beta-cells-with-physiological-insulin-secretion/)
- [EndoC-bH5 cells are storable and ready-to-use human pancreatic beta cells with physiological insulin secretion. Mol Metab. 2023 Jul 11;76:101772](https://www.adocia.com/medias-publications/endoc-bh5-cells-are-storable-and-ready-to-use-human-pancreatic-beta-cells-with-physiological-insulin-secretion/)
- [A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes Obes Metab., 2023;25(5):1241-1248.](https://www.adocia.com/medias-publications/grit-andersen-md-rosy-eloy-md-susanne-famulla-phd-tim-heise-md-gregory-meiffren-phd-cyril-seroussi-msc-martin-gaudier-phd-claire-megret-phd-you-ping-chan-phd-olivier-soula-phd-matthew-riddle/)
- [A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes Obes Metab., 2023;25(5):1241-1248.](https://www.adocia.com/medias-publications/grit-andersen-md-rosy-eloy-md-susanne-famulla-phd-tim-heise-md-gregory-meiffren-phd-cyril-seroussi-msc-martin-gaudier-phd-claire-megret-phd-you-ping-chan-phd-olivier-soula-phd-matthew-riddle/)
- [“Proportional Dose-Exposure Relationship of Ultra-rapid BioChaperone® Lispro (BCLIS) in Healthy Japanese Subjects” (Poster 996), presented by Dr. Grégory Meiffren, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)](https://www.adocia.com/medias-publications/profil-pharmacodynamique-de-biochaperone-combo-une-co-formulation-liquide-des-insulines-lispro-et-glargine-chez-des-sujets-diabetiques-de-type-2-abstract-cad-19-presented/)
- [“L’insuline ultra-rapide BioChaperone® Lispro améliore le contrôle glycémique postprandial par rapport à Humalog® chez des sujets diabétiques de type 1” (Abstract CAD-19), presented by Dr. Grégory Meiffren, 2017, Société Francophone du Diabète (France)](https://www.adocia.com/medias-publications/ultra-rapid-biochaperone-lispro-bclis-improves-postprandial-blood-glucose-ppg-control-vs-insulin-lispro-lis-in-a14-day-treatment-study-in-subjects-with-type-2-diabetes-t2dm/)
- [“BioChaperone® Combo (BC Combo) reduces post-prandial glucose in type 1 diabetes compared to conventional lispro mix 75/25 (LMx)” (Poster 836), presented by Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)](https://www.adocia.com/medias-publications/biochaperone-combo-bc-combo-reduces-post-prandial-glucose-in-type-1-diabetes-compared-to-conventional-lispro-mix-75-25-lmx-poster-836-presented-by-dr-s-bruce-52nd-eur/)
- [“BioChaperone® technology enables the development of pramlintide-prandial insulin combinations” (Poster 811), presented by Dr. Remi Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)](https://www.adocia.com/medias-publications/biochaperone-combo-une-combinaison-fixe-dinsuline-lispro-et-dinsuline-glargine-ameliore-les-profils-de-glycemie-postprandiale-par-rapport-a-un-premix-dinsuline-li/)
- [“BioChaperone Combo, une combinaison fixe d’insuline lispro et d’insuline glargine, améliore les profils de glycémie postprandiale par rapport à un premix d’insuline lispro et les administrations séparées d’insuline lispro et d’insuline glargine dans une étude de phase 1 chez des sujets diabétiques de type 2” (Poster), Author Dr. Claire Mégret, March 26, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)](https://www.adocia.com/medias-publications/biochaperone-combo-une-combinaison-fixe-dinsuline-lispro-et-dinsuline-glargine-ameliore-les-profils-de-glycemie-postprandiale-par-rapport-a-un-premix-dinsuline-li-2/)
- [“BioChaperone® Glucagon, A Stable Ready-To-Use Liquid Glucagon Formulation Enabled By Biochaperone Technology, Is Well Tolerated And Quickly Restores Euglycemia After Insulin-Induced Hypoglycemia” (E-Poster Discussion 05), presented by Mr. Aymeric Ranson, February 22, 2019, ATTD, Berlin (Germany)](https://www.adocia.com/medias-publications/biochaperone-glucagon-a-stable-ready-to-use-liquid-glucagon-formulation-enabled-by-biochaperone-technology-is-well-tolerated-and-quickly-restores-euglycemia-after-insulin-induced-hypo/)
- [“BioChaperone® Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects” (EPO2 E-Poster Viewing), presented by Dr. Grégory Meiffren, February 21, 2019, ATTD, Berlin (Germany)](https://www.adocia.com/medias-publications/biochaperone-combo-a-co-formulation-of-lispro-and-glargine-improves-postprandial-glucose-control-compared-to-lispromix25-or-lispro-and-glargine-injections-in-type-2-diabetes-subjects-2/)
- [“BioChaperone Glucagon, une formulation de glucagon liquide, stable, prête à l’emploi, est bien tolérée et rétablit rapidement la normoglycemie après une hypoglycémie provoquée par infusion d’insuline” (Poster), Author Mr. Aymeric Ranson, March 26, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)](https://www.adocia.com/medias-publications/biochaperone-glucagon-exenatide-bc-glu-exe-a-stable-combination-of-glucagon-glu-and-exenatide-exe-achieved-larger-body-weight-bw-loss-than-exe-alone-in-dio-mice-poster-au/)
- [“BioChaperone Glucagon Exenatide (BC Glu Exe), a Stable Combination of Glucagon (Glu) and Exenatide (Exe) Achieved Larger Body Weight (BW) Loss than Exe Alone in DIO Mice” (Poster), Author Dr. Martin Gaudier, June 10, 2019, ADA, San Francisco (USA)](https://www.adocia.com/medias-publications/biochaperone-glucagon-une-formulation-de-glucagon-liquide-stable-prete-a-lemploi-est-bien-toleree-et-retablit-rapidement-la-normoglycemie-apres-une-hypoglycemie-provoquee-par-inf/)
- [“Better Postprandial Glucose (PPG) Control with BioChaperone® Combo (BC Combo) than with Lispro Mix25 (LMx) or separate Glargine & Lispro (G+L) Administration in Subjects with Type 2 Diabetes (T2DM)” (Poster 1001), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/biochaperone-technology-enables-the-development-of-pramlintide-prandial-insulin-combinations-poster-811-presented-by-dr-remi-soula-54th-annual-meeting-of-the-european-asso/)
- [“Pooled Analysis of Clinical Trials Investigating the Pharmacokinetics (PK) of Ultra-Rapid Insulin BioChaperone® Lispro (BCLIS) versus Lispro (LIS) in Subjects with Type 1 (T1D) and Type 2 (T2D) Diabetes” (Poster 998), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/biochaperone-lispro-une-formulation-ultra-rapide-dinsuline-lispro-ameliore-le-controle-glycemique-post-prandial-de-sujets-diabetiques-de-type-1-traites-par-de-multiples-injec/)
- [“The Ultra-Rapid Insulin (URI) BioChaperone® Lispro (BCLIS) shows Favorable Pharmacodynamics (PD) and Pharmacokinetics (PK) vs Faster Aspart (FIA) and Insulin Aspart (ASP) in Insulin Pumps (CSII)” (Poster 1035), presented by Dr. Bruce W. Bode, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/the-ultra-rapid-insulin-uri-biochaperone-lispro-bclis-shows-favorable-pharmacodynamics-pd-and-pharmacokinetics-pk-vs-faster-aspart-fia-and-insulin-aspart-asp-in-insulin-pump/)
- [“BioChaperone® Lispro, une formulation ultra-rapide d’insuline lispro, améliore le contrôle glycémique post-prandial de sujets diabétiques de type 1 traités par de multiples injections quotidiennes d’insuline pendant 14 jours.” (Abstract CAD-19), presented by Dr. Grégory Meiffren, 2018, Société Francophone du Diabète (France)](https://www.adocia.com/medias-publications/pooled-analysis-of-clinical-trials-investigating-the-pharmacokinetics-pk-of-ultra-rapid-insulin-biochaperone-lispro-bclis-versus-lispro-lis-in-subjects-with-type-1-t1d-and-type-2/)
- [“Ultra-rapid BioChaperone® Lispro ameliorates postprandial blood glucose (PPG) control compared to Humalog in subjects with type 1 diabetes mellitus” (Poster PI005), presented by Dr G. Anderson, American Society for Clinical Pharmacology & Therapeutics (ASCPT)](https://www.adocia.com/medias-publications/better-postprandial-glucose-ppg-control-with-biochaperone-combo-bc-combo-than-with-lispro-mix25-lmx-or-separate-glargine-lispro-gl-administration-in-subjects-with-type-2-diab-2/)
- [“Ultra-rapid BioChaperone® Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Excursions vs. Insulin Lispro (LIS) in a 14-Day Treatment Study in Subjects with Type 1 Diabetes (T1DM)” (Poster 964) presented by Dr. Tim Heise, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)](https://www.adocia.com/medias-publications/biochaperone-combo-une-co-formulation-liquide-des-insulines-lispro-et-glargine-presente-un-controle-glycemique-ameliore-par-rapport-a-un-premix-dinsuline-abstract/)
- [“Ultra-rapid BioChaperone® Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Control vs. Insulin Lispro (LIS) in a14-Day Treatment Study in Subjects with Type 2 Diabetes (T2DM)” (Poster 994) presented by Dr. Tim Heise, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)](https://www.adocia.com/medias-publications/linsuline-ultra-rapide-biochaperone-lispro-ameliore-le-controle-glycemique-postprandial-par-rapport-a-humalog-chez-des-sujets-diabetiques-de-type-1-abstract-cad/)
- [“Proportional Dose-Exposure Relationship of Ultra-rapid BioChaperone® Lispro (BCLIS) in Healthy Japanese Subjects” (Poster 996), presented by Dr. Grégory Meiffren, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)](https://www.adocia.com/medias-publications/profil-pharmacodynamique-de-biochaperone-combo-une-co-formulation-liquide-des-insulines-lispro-et-glargine-chez-des-sujets-diabetiques-de-type-2-abstract-cad-19-presented/)
- [“Preclinical Efficacy of a Stable Aqueous Formulation of Human Glucagon with BioChaperone® Technology (BC GLU)” (Poster 1150), presented by Dr Grégory Meiffren, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)](https://www.adocia.com/medias-publications/preclinical-efficacy-of-a-stable-aqueous-formulation-of-human-glucagon-with-biochaperone-technology-bc-glu-poster-1150-presented-by-dr-gregory-meiffren-77th-scientific-se/)
- [“Profil pharmacodynamique de BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, chez des sujets diabétiques de type 2” (Abstract CAD-19), presented by Dr. Martin Gaudier, 2017, Société Francophone du Diabète (France)](https://www.adocia.com/medias-publications/proportional-dose-exposure-relationship-of-ultra-rapid-biochaperone-lispro-bclis-in-healthy-japanese-subjects-poster-996-presented-by-dr-gregory-meiffren-77th-scientific/)
- [“L’insuline ultra-rapide BioChaperone® Lispro améliore le contrôle glycémique postprandial par rapport à Humalog® chez des sujets diabétiques de type 1” (Abstract CAD-19), presented by Dr. Grégory Meiffren, 2017, Société Francophone du Diabète (France)](https://www.adocia.com/medias-publications/ultra-rapid-biochaperone-lispro-bclis-improves-postprandial-blood-glucose-ppg-control-vs-insulin-lispro-lis-in-a14-day-treatment-study-in-subjects-with-type-2-diabetes-t2dm/)
- [“BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, présente un contrôle glycémique amélioré par rapport à un premix d’insuline.” (Abstract CAD-19), presented by Dr. Claire Megret, 2017, Société Francophone du Diabète (France)](https://www.adocia.com/medias-publications/ultra-rapid-biochaperone-lispro-ameliorates-postprandial-blood-glucose-ppg-control-compared-to-humalog-in-subjects-with-type-1-diabetes-mellitus-poster-pi005-presented-by-2/)
- [“BioChaperone® Combo (BC Combo) reduces post-prandial glucose in type 1 diabetes compared to conventional lispro mix 75/25 (LMx)” (Poster 836), presented by Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)](https://www.adocia.com/medias-publications/biochaperone-combo-bc-combo-reduces-post-prandial-glucose-in-type-1-diabetes-compared-to-conventional-lispro-mix-75-25-lmx-poster-836-presented-by-dr-s-bruce-52nd-eur/)
- [“A Pilot Bioequivalence (BE) Study of Ultra-Rapid Concentrated BioChaperone® Lispro (BCLIS) U200 to BCLIS U100”, (Abstract 2242-PUB), presented by Dr. Grit Anderson, 76th Scientific Sessions of the American Diabetes Association, 10-14 June 2016, New Orleans, LO (USA)](https://www.adocia.com/medias-publications/pharmacodynamic-pd-profile-of-biochaperone-combo-bc-combo-a-new-combination-of-rapid-acting-and-long-acting-insulin-in-subjects-with-type-2-diabetes-mellitus-t2dm-post/)
- [“Pharmacodynamic (PD) Profile of BioChaperone® Combo (BC Combo), a New Combination of Rapid-Acting and Long-Acting Insulin, in Subjects with Type 2 Diabetes Mellitus (T2DM)” (Poster 942), presented by Dr. Simon Bruce, 76th Scientific Sessions American Diabetes Association 11-13 June 2016, New Orleans, LO (USA)](https://www.adocia.com/medias-publications/a-pilot-bioequivalence-be-study-of-ultra-rapid-concentrated-biochaperone-lispro-bclis-u200-to-bclis-u100-abstract-2242-pub-presented-by-dr-grit-anderson-76th-scientif/)
- [“Ultra-Rapid BioChaperone® Insulin Lispro (BC LIS): Linear Dose-Response and Faster Absorption than Insulin Lispro (LIS)” (Poster 979), presented by Dr. Grit Anderson, 75th Scientific Sessions of the American Diabetes Association, 5-9 June 2015, Boston, MA (USA)](https://www.adocia.com/medias-publications/ultra-rapid-biochaperone-insulin-lispro-bc-lis-linear-dose-response-and-faster-absorption-than-insulin-lispro-lis-poster-979-presented-by-dr-grit-anderson-75th-scient/)
- [“Pharmacokinetic (PK) and Pharmacodynamic (PD) Characteristics of BioChaperone Combo (BC Combo), the First Fixed Combination of Glargine and Lispro, in Type 1 Diabetes”, (Poster 83-LB), presented by Dr. Ulrike Hövelmann, 74th Scientific Sessions American Diabetes Association 13-17 June 2014, San Francisco, CA, (USA)](https://www.adocia.com/medias-publications/pharmacokinetic-pk-and-pharmacodynamic-pd-characteristics-of-biochaperone-combo-bc-combo-the-first-fixed-combination-of-glargine-and-lispro-in-type-1-diabetes-poster-83-lb/)
- [“The Ultra-Rapid BioChaperone® Insulin Lispro shows a Faster Onset of Action and Stronger Early Metabolic Effect than Native Insulin Lispro” (Poster 78-LB), presented by Dr. Grit Anderson, 74th Scientific Sessions of the American Diabetes Association, 13-17 June 2014, San Francisco, CA (USA)](https://www.adocia.com/medias-publications/the-ultra-rapid-biochaperone-insulin-lispro-shows-a-faster-onset-of-action-and-stronger-early-metabolic-effect-than-native-insulin-lispro-poster-78-lb-presented-by-dr-grit/)
- [Mise à disposition de la Lettre aux actionnaires](https://www.adocia.com/fr/medias-publications/mise-a-disposition-de-la-lettre-aux-actionnaires/)
- [Number of shares and voting rights of ADOCIA as of April 30th, 2023](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-april-30th-2023/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 avril 2023](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-avril-2023/)
- [Résiliation du contrat de liquidité avec DSF Markets](https://www.adocia.com/fr/medias-publications/resiliation-du-contrat-de-liquidite-avec-dsf-markets/)
- [Suspension de la cotation de l’action Adocia](https://www.adocia.com/fr/medias-publications/6416/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 janvier 2019  Lyon, le 8 février 2019 - 18h CET – Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers (« AMF »).  ADOCIA SA,](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-janvier-2019-lyon-le-8-fevrier-2019-18h-cet-conformement-aux-dispositions-de-larticle-l-233/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 janvier 2020  Lyon, le 6 février 2020 - 18h CET – Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers (« AMF »).  ADOCIA SA, 115, avenue Lacassagne, 69003 Lyon (Euronext Paris : FR0011184241 – ADOC – la « Société »), société biopharmaceutique spécialisée dans le traitement du diabète par des formulations innovante](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-janvier-2020-lyon-le-6-fevrier-2020-18h-cet-conformement-aux-dispositions-de-larticle-l-233/)
- [Article : Grégory Meiffren PhD, Theresa Herbrand MD, Ernestos Anastassiadis MD, Oliver Klein MD, J. Hans DeVries MD, Tim Heise MD, Bertrand Alluis PhD, Claire Mégret PhD, Martin Gaudier PhD, Olivier Soula PhD, Leona Plum‐Mörschel MD. <br>“Better glycemic control with BioChaperone® Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM)”<br>Diabetes Obes Metab., 2019;21(7):15701575.](https://www.adocia.com/medias-publications/gregory-meiffren-phd-theresa-herbrand-md-ernestos-anastassiadis-md-oliver-klein-md-j-hans-devries-md-tim-heise-md-bertrand-alluis-phd-claire-megret-phd-martin-gaudier-phd-olivier-soula-phd/)
- [BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in subjects with T2DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)](https://www.adocia.com/medias-publications/biochaperone-lispro-an-ultra-rapid-insulin-lispro-formulation-improves-post-prandial-blood-glucose-control-in-a-14-day-multiple-daily-insulin-injection-study-in-subjects-with-t2dm-dr-gregory/)
- [Listing of ADOCIA shares suspended](https://www.adocia.com/medias-publications/listing-of-adocia-shares-suspended/)
- [Bilan Semestriel du contrat de liquidité Adocia conclu avec la société Kepler Capital Markets](https://www.adocia.com/medias-publications/bilan-semestriel-du-contrat-de-liquidite-adocia-conclu-avec-la-societe-kepler-capital-markets-2/)
- [Résiliation du contrat de liquidité avec DSF Markets](https://www.adocia.com/medias-publications/resiliation-du-contrat-de-liquidite-avec-dsf-markets-2/)
- [Adocia announces financial results for the third quarter 2017](https://www.adocia.com/medias-publications/adocia-announces-financial-results-for-the-third-quarter-2017-2/)
- [“Pooled Analysis of Clinical Trials Investigating the Pharmacokinetics (PK) of Ultra-Rapid Insulin BioChaperone® Lispro (BCLIS) versus Lispro (LIS) in Subjects with Type 1 (T1D) and Type 2 (T2D) Diabetes” (Poster 998), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/pooled-analysis-of-clinical-trials-investigating-the-pharmacokinetics-pk-of-ultra-rapid-insulin-biochaperone-lispro-bclis-versus-lispro-lis-in-subjects-with-type-1-t1d-and-type/)
- [“Better Postprandial Glucose (PPG) Control with BioChaperone® Combo (BC Combo) than with Lispro Mix25 (LMx) or separate Glargine & Lispro (G+L) Administration in Subjects with Type 2 Diabetes (T2DM)” (Poster 1001), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/better-postprandial-glucose-ppg-control-with-biochaperone-combo-bc-combo-than-with-lispro-mix25-lmx-or-separate-glargine-lispro-gl-administration-in-subjects-with-type-2-diab/)
- [“BioChaperone® 222, the new excipient enabling the ultra-rapid BioChaperone® Lispro formulation, is completely absorbed and rapidly excreted after subcutaneous injection” (Poster 816), presented by Dr. Olivier Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)](https://www.adocia.com/medias-publications/biochaperone-222-the-new-excipient-enabling-the-ultra-rapid-biochaperone-lispro-formulation-is-completely-absorbed-and-rapidly-excreted-after-subcutaneous-injection-po/)
- [“BioChaperone® Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects” (EPO2 E-Poster Viewing), presented by Dr. Grégory Meiffren, February 21, 2019, ATTD, Berlin (Germany)](https://www.adocia.com/medias-publications/biochaperone-combo-a-co-formulation-of-lispro-and-glargine-improves-postprandial-glucose-control-compared-to-lispromix25-or-lispro-and-glargine-injections-in-type-2-diabetes-subjects/)
- [ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience.](https://www.adocia.com/medias-publications/ado09-a-co-formulation-of-the-amylin-analog-pramlintide-and-the-a21g-human-insulin-analog-lowers-postprandial-blood-glucose-versus-insulin-lispro-in-type-1-diabetes-t1d-presented-by-dr-gregory-me/)
- [Ultra-Rapid BioChaperone® Lispro ameliorates postprandial blood glucose control compared with Humalog(R) in subjects with type 1 diabetes mellitus, Dr. Grit Anderen, 76th Scientific Sessions American Diabetes Association 10-14 June 2016, New Orleans, LO (USA)](https://www.adocia.com/medias-publications/ultra-rapid-biochaperone-lispro-ameliorates-postprandial-blood-glucose-control-compared-with-humalogr-in-subjects-with-type-1-diabetes-mellitus-dr-grit-anderen-76th-scientific-sessions-amer/)
- [BioChaperone® Combo (BC Combo) improves postprandial glycemia vs. Humalog® Mix 75/25™ (HMx) in people with type 1 diabetes mellitus (T1DM, Dr. Steven V. Edelman, 76th Scientific Sessions American Diabetes Association 11-13 June 2016, New Orleans, LO (USA)](https://www.adocia.com/medias-publications/biochaperone-combo-bc-combo-improves-postprandial-glycemia-vs-humalog-mix-75-25-hmx-in-people-with-type-1-diabetes-mellitus-t1dm-dr-steven-v-edelman-76th-scientific-sess/)
- [BioChaperone® Combo, a co-formulation of lispro and glargine, demonstrates both prandial and basal insulin time-action profiles in a single injection in type 2 diabetes, Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)](https://www.adocia.com/medias-publications/biochaperone-combo-a-co-formulation-of-lispro-and-glargine-demonstrates-both-prandial-and-basal-insulin-time-action-profiles-in-a-single-injection-in-type-2-diabetes-dr-s-bruce-52nd-europe/)
- [BioChaperone® Glucagon, a stable ready-to-use liquid glucagon formulation, is well tolerated and quickly restores euglycemia after insulin-induced hypoglycemia, by Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/biochaperone-glucagon-a-stable-ready-to-use-liquid-glucagon-formulation-is-well-tolerated-and-quickly-restores-euglycemia-after-insulin-induced-hypoglycemia-by-dr-gregory-meiffren-78th-scie/)
- [BioChaperone® Technology Enables the Development of Pramlintide-Prandial Insulin Combinations, Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/biochaperone-technology-enables-the-development-of-pramlintide-prandial-insulin-combinations-dr-gregory-meiffren-78th-scientific-sessions-of-the-american-diabetes-association-22-26-june-2018/)
- [The ultra-rapid insulin BioChaperone® Lispro shows favourable pharmacodynamics and pharmacokinetics compared to faster insulin aspart and insulin aspart in insulin pumps, Dr. Grégory Meiffren, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)](https://www.adocia.com/medias-publications/the-ultra-rapid-insulin-biochaperone-lispro-shows-favourable-pharmacodynamics-and-pharmacokinetics-compared-to-faster-insulin-aspart-and-insulin-aspart-in-insulin-pumps-dr-gregory-meiffren-54/)
- [BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (pram) and human insulin (ins), improves post-prandial blood glucose versus both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D”, Dr. Grégory Meiffren, June 9th, 2019, ADA, San Francisco (USA)](https://www.adocia.com/medias-publications/biochaperone-pramlintide-insulin-bcpramins-a-new-co-formulation-of-pramlintide-pram-and-human-insulin-ins-improves-post-prandial-blood-glucose-versus-both-separate-injections-of-pramins-and-i/)
- [Comparaison des profils pharmacocinétiques et de pharmacodynamie de l’insuline ultra rapide BioChaperone® Lispro avec les formulations Fiasp® et Novorapid® de l’insuline asparte administrées par pompes à insuline, Dr. Grégory Meiffren, March 27, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)](https://www.adocia.com/medias-publications/comparaison-des-profils-pharmacocinetiques-et-de-pharmacodynamie-de-linsuline-ultra-rapide-biochaperone-lispro-avec-les-formulations-fiasp-et-novorapid-de-linsuline/)
- [The Ultra-Rapid Insulin BioChaperone® Lispro bolused by insulin pump shows favourable pharmacodynamics and pharmacokinetics vs. faster Aspart and insulin Aspart, Dr. Grégory Meiffren, February 23, 2019, ATTD, Berlin (Germany)](https://www.adocia.com/medias-publications/the-ultra-rapid-insulin-biochaperone-lispro-bolused-by-insulin-pump-shows-favourable-pharmacodynamics-and-pharmacokinetics-vs-faster-aspart-and-insulin-aspart-dr-gregory-meiffren-february-23/)
- [ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.](https://www.adocia.com/medias-publications/ado09-a-coformulation-of-pramlintide-pram-and-insulin-a21g-improves-postprandial-glucose-vs-novologr-in-type-1-diabetes-t1d-dr-gregory-meiffren-june-12-16-2020-ada-virtual-experience/)
- [Andersen G, Meiffren G, Lamers D, DeVries JH, Ranson A, Seroussi C, Alluis B, Gaudier M, Soula O, Heise T. <br>“Ultra-rapid BioChaperone® Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.”<br>Diabetes Obes Metab., 2018;20(11):2627-2632.](https://www.adocia.com/medias-publications/andersen-g-meiffren-g-lamers-d-devries-jh-ranson-a-seroussi-c-alluis-b-gaudier-m-soula-o-heise-t-ultra-rapid-biochaperone-lispro-improves-postprandial-blood-glucose-excursions/)
- [Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode BW.<br>  “BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.”<br>  Diabetes Obes Metab., 2019;21(4):1066-1070.](https://www.adocia.com/medias-publications/heise-t-meiffren-g-alluis-b-seroussi-c-ranson-a-arrubla-j-correia-j-gaudier-m-soula-o-soula-r-devries-jh-klein-o-bode-bw-biochaperone-lispro-versus-faster-aspart-and-insulin-asp/)
- [ADOCIA Announces the Appointment of Olivier Soula as Chief Executive Officer](https://www.adocia.com/medias-publications/adocia-announces-the-appointment-of-olivier-soula-as-chief-executive-officer/)
- [ADOCIA Announces the Release of its Universal Registration Document for the Year 2022](https://www.adocia.com/medias-publications/adocia-announces-the-release-of-its-universal-registration-document-for-the-year-2022/)
- [ADOCIA Reports Financial Results of First Quarter 2023 and Provides an Update on its Activities](https://www.adocia.com/medias-publications/adocia-reports-financial-results-of-first-quarter-2023-and-provides-an-update-on-its-activities/)
- [ADOCIA annonce la tenue de son assemblée générale annuelle le 11 mai 2023 à Paris](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-tenue-de-son-assemblee-generale-annuelle-le-11-mai-2023-a-paris/)
- [ADOCIA announces its annual Shareholders’ meeting to be held on May 11, 2023 in Paris](https://www.adocia.com/medias-publications/adocia-announces-its-annual-shareholders-meeting-to-be-held-on-may-11-2023-in-paris/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mars 2023](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mars-2023/)
- [Number of shares and voting rights of ADOCIA as of March 31st, 2023](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-march-31st-2023/)
- [Number of shares and voting rights of ADOCIA as of February 28th, 2023](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-february-28th-2023/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 28 février 2023](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-28-fevrier-2023/)
- [ADOCIA announces its annual results for 2022 and provides corporate and financial update](https://www.adocia.com/medias-publications/adocia-announces-its-annual-results-for-2022-and-provides-corporate-and-financial-update/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 janvier 2023](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-janvier-2023/)
- [Number of shares and voting rights of ADOCIA as of January 31st, 2023](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-january-31st-2023/)
- [ADOCIA annonce le bilan semestriel du contrat de liquidité conclu avec la société Kepler Capital Markets](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-bilan-semestriel-du-contrat-de-liquidite-conclu-avec-la-societe-kepler-capital-markets/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 décembre 2022](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-decembre-2022/)
- [Number of shares and voting rights of ADOCIA as of December 31st, 2022](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-december-31st-2022/)
- [ADOCIA annonce son calendrier financier pour l’année 2023](https://www.adocia.com/fr/medias-publications/adocia-annonce-son-calendrier-financier-pour-lannee-2023/)
- [ADOCIA Announces its financial calendar for 2023](https://www.adocia.com/medias-publications/adocia-announces-its-financial-calendar-for-2023/)
- [ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023](https://www.adocia.com/medias-publications/adocia-announces-its-participation-at-upcoming-investor-conferences-in-january-2023/)
- [ADOCIA annonce sa participation à des conférences investisseurs en janvier 2023](https://www.adocia.com/fr/medias-publications/adocia-annonce-sa-participation-a-des-conferences-investisseurs-en-janvier-2023/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 novembre 2022](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-novembre-2022/)
- [Number of shares and voting rights of ADOCIA as of November 30th, 2022](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-november-30th-2022/)
- [Adocia strengthens its cash position with EUR 6 million through the issuance of convertible bonds subscribed by European investors in order to accelerate the development of key products](https://www.adocia.com/medias-publications/adocia-strengthens-its-cash-position-with-eur-6-million-through-the-issuance-of-convertible-bonds-subscribed-by-european-investors-in-order-to-accelerate-the-development-of-key-products/)
- [Adocia renforce sa position de trésorerie de 6 millions d’euros par émission d’obligations convertibles auprès d’investisseurs européens afin d’accélérer le développement de ses produits phares](https://www.adocia.com/fr/medias-publications/adocia-renforce-sa-position-de-tresorerie-de-6-millions-deuros-par-emission-dobligations-convertibles-aupres-dinvestisseurs-europeens-afin-daccelerer-le-developpeme/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 octobre 2022](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-octobre-2022/)
- [Number of shares and voting rights of ADOCIA as of October 31st, 2022](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-october-31st-2022/)
- [ADOCIA publie sa position de trésorerie et son chiffre d’affaires pour le troisième trimestre 2022 et dresse un bilan de ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-sa-position-de-tresorerie-et-son-chiffre-daffaires-pour-le-troisieme-trimestre-2022-et-dresse-un-bilan-de-ses-activites/)
- [ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates](https://www.adocia.com/medias-publications/adocia-reports-its-cash-position-and-revenue-for-the-third-quarter-of-2022-and-provides-business-updates/)
- [Number of shares and voting rights of ADOCIA as of September 30th, 2022](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-september-30th-2022/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 septembre 2022](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-septembre-2022/)
- [ADOCIA: Upcoming investor meetings](https://www.adocia.com/medias-publications/adocia-upcoming-investor-meetings/)
- [ADOCIA : Prochains rendez-vous investisseurs](https://www.adocia.com/fr/medias-publications/adocia-prochains-rendez-vous-investisseurs/)
- [ADOCIA publie ses résultats financiers du premier semestre 2022 et dresse un bilan de ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-premier-semestre-2022-et-dresse-un-bilan-de-ses-activites/)
- [ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update](https://www.adocia.com/medias-publications/adocia-announces-first-half-2022-financial-results-and-provides-a-business-update/)
- [Adocia publiera ses résultats semestriels 2022 le 19 septembre et tiendra un webinaire le 20 septembre](https://www.adocia.com/fr/medias-publications/adocia-publiera-ses-resultats-semestriels-2022-le-19-septembre-et-tiendra-un-webinaire-le-20-septembre/)
- [ADOCIA Will Release its 2022 Half-Year Results on September 19th and Hold a Webinar on September 20th](https://www.adocia.com/medias-publications/adocia-will-release-its-2022-half-year-results-on-september-19th-and-hold-a-webinar-on-september-20th/)
- [Number of shares and voting rights of ADOCIA as of August 31st, 2022](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-august-31st-2022/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 août 2022](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-aout-2022/)
- [Number of shares and voting rights of ADOCIA as of July 31st, 2022](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-july-31st-2022/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 juillet 2022](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-juillet-2022/)
- [ADOCIA Reports Cash and Revenue for the Second Quarter and Provides Corporate Update](https://www.adocia.com/medias-publications/adocia-reports-cash-and-revenue-for-the-second-quarter-and-provides-corporate-update/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 juin 2022](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-juin-2022/)
- [Number of shares and voting rights of ADOCIA as of June 30th, 2022](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-june-30th-2022/)
- [Adocia publishes its Letter to Shareholders](https://www.adocia.com/medias-publications/adocia-publishes-its-letter-to-shareholders/)
- [Number of shares and voting rights of ADOCIA as of May 31st, 2022](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-may-31st-2022/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mai 2022](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mai-2022/)
- [ADOCIA Announces its annual Shareholders’ meeting to be held on June 28, 2022 in Paris](https://www.adocia.com/medias-publications/adocia-announces-its-annual-shareholders-meeting-to-be-held-on-june-28-2022-in-paris/)
- [ADOCIA annonce la tenue de son assemblée générale annuelle le 28 juin 2022 à Paris](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-tenue-de-son-assemblee-generale-annuelle-le-28-juin-2022-a-paris/)
- [ADOCIA publie ses résultats financiers du premier trimestre 2022 et dresse un bilan de ses activités](https://www.adocia.com/fr/medias-publications/adocia-publie-ses-resultats-financiers-du-premier-trimestre-2022-et-dresse-un-bilan-de-ses-activites/)
- [ADOCIA Reports Financial Results of First Quarter 2022 and Provides Corporate Update](https://www.adocia.com/medias-publications/adocia-reports-financial-results-of-first-quarter-2022-and-provides-corporate-update/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 avril 2022](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-avril-2022/)
- [Number of shares and voting rights of ADOCIA as of April 30th, 2022](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-april-30th-2022/)
- [ADOCIA annonce la mise à disposition de son Document d’Enregistrement Universel pour l’année 2021](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-mise-a-disposition-de-son-document-denregistrement-universel-pour-lannee-2021/)
- [ADOCIA Announces the Release of its Universal Registration Document for the Year 2021](https://www.adocia.com/medias-publications/adocia-announces-the-release-of-its-universal-registration-document-for-the-year-2021/)
- [ADOCIA announces its annual results for 2021 and presents an update on activities](https://www.adocia.com/medias-publications/adocia-announces-its-annual-results-for-2021-and-presents-an-update-on-activities/)
- [Number of shares and voting rights of ADOCIA as of March 31st, 2022](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-march-31st-2022/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mars 2022](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mars-2022/)
- [Adocia renforce sa trésorerie de 19 millions d’euros à la suite d’une opération immobilière](https://www.adocia.com/fr/medias-publications/adocia-renforce-sa-tresorerie-de-19-millions-deuros-a-la-suite-dune-operation-immobiliere/)
- [Adocia strengthens its cash position by 19 million euros following a real estate transaction](https://www.adocia.com/medias-publications/adocia-strengthens-its-cash-position-by-19-million-euros-following-a-real-estate-transaction/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 28 février 2022](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-28-fevrier-2022/)
- [Number of shares and voting rights of ADOCIA as of February 28th, 2022](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-february-28th-2022/)
- [ADOCIA announces 2021 fourth quarter financial results](https://www.adocia.com/medias-publications/adocia-announces-2021-fourth-quarter-financial-results/)
- [ADOCIA communique ses résultats financiers du 4ème trimestre 2021](https://www.adocia.com/fr/medias-publications/adocia-communique-ses-resultats-financiers-du-4eme-trimestre-2021/)
- [Number of shares and voting rights of ADOCIA as of January 31st, 2021](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-january-31st-2021/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 janvier 2022](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-janvier-2022/)
- [Number of shares and voting rights of ADOCIA as of December 31st, 2021](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-december-31st-2021/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 décembre 2021](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-decembre-2021/)
- [ADOCIA announces its financial calendar for 2022](https://www.adocia.com/medias-publications/adocia-announces-its-financial-calendar-for-2022/)
- [ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2022](https://www.adocia.com/medias-publications/adocia-announces-its-participation-at-upcoming-investor-conferences-in-january-2022/)
- [ADOCIA annonce sa participation à des conférences investisseurs en janvier 2022](https://www.adocia.com/fr/medias-publications/adocia-annonce-sa-participation-a-des-conferences-investisseurs-en-janvier-2022/)
- [Number of shares and voting rights of ADOCIA as of November 30th, 2021](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-november-30th-2021/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 novembre 2021](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-novembre-2021/)
- [Adocia Files Patent for Technology to Enable Oral Drug Delivery of Peptides](https://www.adocia.com/medias-publications/adocia-files-patent-for-technology-to-enable-oral-drug-delivery-of-peptides/)
- [Adocia annonce le dépôt d’un brevet sur une technologie de délivrance orale de peptides](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-depot-dun-brevet-sur-une-technologie-de-delivrance-orale-de-peptides/)
- [Number of shares and voting rights of ADOCIA as of October 31st, 2021](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-october-31st-2021/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 octobre 2021](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-octobre-2021/)
- [Adocia annonce ses résultats financiers du 3ème trimestre et un financement de 7 millions d’euros](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-du-3eme-trimestre-et-un-financement-de-7-millions-deuros/)
- [Adocia announces 2021 third quarter financial results and a financing of €7 million](https://www.adocia.com/medias-publications/adocia-announces-2021-third-quarter-financial-results-and-a-financing-of-e7-million/)
- [Number of shares and voting rights of ADOCIA as of September 30th, 2021](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-september-30th-2021/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 septembre 2021](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-septembre-2021/)
- [ADOCIA announces Oral Presentation Reviewing M1Pram (ADO09) at the occasion of the 57th Annual Meeting of EASD](https://www.adocia.com/medias-publications/adocia-announces-oral-presentation-reviewing-m1pram-ado09-at-the-occasion-of-the-57th-annual-meeting-of-easd/)
- [ADOCIA annonce une présentation orale de M1Pram (ADO09) à l'occasion du 57ème Congrès Annuel de l'EASD](https://www.adocia.com/fr/medias-publications/adocia-annonce-une-presentation-orale-de-m1pram-ado09-a-loccasion-du-57eme-congres-annuel-de-leasd/)
- [Number of shares and voting rights of ADOCIA as of August 31st, 2021](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-august-31st-2021/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 Août 2021](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-aout-2021/)
- [Adocia fera une présentation  lors de l’évènement H.C. Wainwright Global Investment Conference](https://www.adocia.com/fr/medias-publications/adocia-fera-une-presentation-lors-de-levenement-h-c-wainwright-global-investment-conference/)
- [Adocia To Participate  in the H.C. Wainwright 23rd Annual Global  Investment Conference](https://www.adocia.com/medias-publications/adocia-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference/)
- [ADOCIA Announces First Half 2021 Financial Results and Provides an Update on Activities](https://www.adocia.com/medias-publications/adocia-announces-first-half-2021-financial-results-and-provides-an-update-on-activities/)
- [ADOCIA annonce ses résultats financiers pour le premier semestre 2021 et fait le point sur ses activités](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-pour-le-premier-semestre-2021-et-fait-le-point-sur-ses-activites/)
- [Number of shares and voting rights of ADOCIA as of July 31st, 2021](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-july-31st-2021/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 Juillet 2021](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-juillet-2021/)
- [ADOCIA annonce ses résultats financiers du 2ème trimestre 2021](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-du-2eme-trimestre-2021/)
- [ADOCIA Announces Second Quarter 2021 Financial Results](https://www.adocia.com/medias-publications/adocia-announces-second-quarter-2021-financial-results/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 Juin 2021](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-juin-2021/)
- [Number of shares and voting rights of ADOCIA as of June 30th, 2021](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-june-30th-2021/)
- [ADOCIA Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes](https://www.adocia.com/medias-publications/adocia-initiates-bc-lispram-phase-1-clinical-trial-in-pump-for-people-with-type-1-diabetes/)
- [ADOCIA initie une étude de Phase 1 chez le patient diabétique de type 1 avec BC LisPram administré en pompe](https://www.adocia.com/fr/medias-publications/adocia-initie-une-etude-de-phase-1-chez-le-patient-diabetique-de-type-1-avec-bc-lispram-administre-en-pompe/)
- [ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions](https://www.adocia.com/medias-publications/adocia-announces-m1pram-clinical-data-presentation-at-the-american-diabetes-association-81st-scientific-sessions/)
- [ADOCIA annonce une présentation des résultats cliniques de M1Pram à l’occasion des 81èmes Sessions Scientifiques de l’American Diabetes Association®](https://www.adocia.com/fr/medias-publications/adocia-annonce-une-presentation-des-resultats-cliniques-de-m1pram-a-loccasion-des-81emes-sessions-scientifiques-de-lamerican-diabetes-association/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 Mai 2021](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mai-2021/)
- [Number of shares and voting rights of ADOCIA as of May 31st, 2021](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-may-31st-2021/)
- [ADOCIA confirms its eligibility for the PEA–PME](https://www.adocia.com/medias-publications/adocia-confirms-its-eligibility-for-the-pea-pme-2/)
- [ADOCIA confirme son éligibilité au PEA-PME](https://www.adocia.com/fr/medias-publications/adocia-confirme-son-eligibilite-au-pea-pme-2/)
- [ADOCIA présente des résultats cliniques sur M1Pram lors de la 14ème conférence internationale ATTD 2021](https://www.adocia.com/fr/medias-publications/adocia-presente-des-resultats-cliniques-sur-m1pram-lors-de-la-14eme-conference-internationale-attd-2021/)
- [ADOCIA Presents Clinical Results on M1Pram at the 14th International Conference on ATTD 2021](https://www.adocia.com/medias-publications/adocia-presents-clinical-results-on-m1pram-at-the-14th-international-conference-on-attd-2021/)
- [ADOCIA reinforces its board of directors with the appointment of three new independent members.](https://www.adocia.com/medias-publications/adocia-reinforces-its-board-of-directors-with-the-appointment-of-three-new-independent-members/)
- [ADOCIA renforce son conseil d'administration avec la nomination de trois nouveaux membres indépendants.](https://www.adocia.com/fr/medias-publications/adocia-renforce-son-conseil-dadministration-avec-la-nomination-de-trois-nouveaux-membres-independants/)
- [ADOCIA Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps](https://www.adocia.com/medias-publications/adocia-expands-clinical-development-to-obesity-with-patent-applications-on-short-acting-multihormonal-combinations-administered-by-pumps/)
- [ADOCIA étend ses développements cliniques à l'obésité avec des demandes de brevets sur des combinaisons d’hormones à courte durée d'action administrées par des pompes](https://www.adocia.com/fr/medias-publications/adocia-etend-ses-developpements-cliniques-a-lobesite-avec-des-demandes-de-brevets-sur-des-combinaisons-dhormones-a-courte-duree-daction-administrees-par-des-pompes/)
- [Number of shares and voting rights of ADOCIA as of April 30, 2021](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-april-30-2021/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 avril 2021](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-avril-2021/)
- [ADOCIA annonce la diffusion en direct de son assemblée générale annuelle le 20 mai 2021](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-diffusion-en-direct-de-son-assemblee-generale-annuelle-le-20-mai-2021/)
- [ADOCIA Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021](https://www.adocia.com/medias-publications/adocia-announces-the-live-broadcast-of-its-annual-general-meeting-on-may-20th-2021/)
- [ADOCIA Announces First Quarter 2021 Financial Results](https://www.adocia.com/medias-publications/adocia-announces-first-quarter-2021-financial-results/)
- [ADOCIA annonce la mise à disposition de son Document d’Enregistrement Universel 2020](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-mise-a-disposition-de-son-document-denregistrement-universel-2020/)
- [ADOCIA annonce ses résultats financiers du 1er trimestre 2021](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-du-1er-trimestre-2021/)
- [ADOCIA: Number of shares and voting rights of ADOCIA as of March 31st, 2021](https://www.adocia.com/medias-publications/adocia-number-of-shares-and-voting-rights-of-adocia-as-of-march-31st-2021/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 Mars 2021](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mars-2021/)
- [ADOCIA annonce ses résultats annuels 2020 et fait un bilan de ses activités.](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-annuels-2020-et-fait-un-bilan-de-ses-activites/)
- [ADOCIA Announces Financial Results 2020 And Provides Corporate Update.](https://www.adocia.com/medias-publications/adocia-announces-financial-results-2020-and-provides-corporate-update/)
- [ADOCIA : Information relative  au nombre d'actions et  de droits de vote  en date du 28 Février 2021](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-28-fevrier-2021/)
- [Number of shares  and voting rights  of ADOCIA  as of February 28th, 2021](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-february-28th-2021/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 janvier 2021](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-janvier-2021/)
- [Number of shares and voting rights of ADOCIA as of January 31, 2021](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-january-31-2021/)
- [Number of shares and voting rights of ADOCIA as of December 31, 2020](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-december-31-2020/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 décembre 2020](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-decembre-2020/)
- [Adocia Announces half year report on Adocia’s liquidity agreement with Kepler Capital Markets](https://www.adocia.com/medias-publications/adocia-announces-half-year-report-on-adocias-liquidity-agreement-with-kepler-capital-markets/)
- [Adocia annonce le bilan semestriel du contrat de liquidité Adocia conclu avec la société Kepler Capital Markets](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-bilan-semestriel-du-contrat-de-liquidite-adocia-conclu-avec-la-societe-kepler-capital-markets/)
- [Adocia annonce le dépôt d’un brevet sur une matrice hydrogel pour la thérapie cellulaire du diabète de type 1](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-depot-dun-brevet-sur-une-matrice-hydrogel-pour-la-therapie-cellulaire-du-diabete-de-type-1/)
- [Adocia Files Patent on a Hydrogel Scaffold for Cell Therapy in the Treatment of Type 1 Diabetes](https://www.adocia.com/medias-publications/adocia-files-patent-on-a-hydrogel-scaffold-for-cell-therapy-in-the-treatment-of-type-1-diabetes/)
- [Adocia annonce son calendrier financier pour l’année 2021](https://www.adocia.com/fr/medias-publications/adocia-annonce-son-calendrier-financier-pour-lannee-2021/)
- [Adocia announces its financial calendar for 2021](https://www.adocia.com/medias-publications/adocia-announces-its-financial-calendar-for-2021/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 novembre 2020](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-novembre-2020/)
- [Number of shares and voting rights of ADOCIA as of November 30, 2020](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-november-30-2020/)
- [Number of shares  and voting rights  of ADOCIA  as of October 31, 2020](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-october-31-2020/)
- [ADOCIA : Information relative  au nombre d'actions et  de droits de vote  en date du 31 octobre 2020](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-octobre-2020/)
- [Adocia annonce ses résultats financiers pour le troisième trimestre 2020](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-pour-le-troisieme-trimestre-2020/)
- [Adocia Announces Third Quarter 2020 Financial Results](https://www.adocia.com/medias-publications/adocia-announces-third-quarter-2020-financial-results/)
- [Number of shares  and voting rights  of ADOCIA  as of September 30, 2020](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-september-30-2020/)
- [ADOCIA : Information relative  au nombre d'actions et  de droits de vote  en date du 30 septembre 2020](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-septembre-2020/)
- [Adocia annonce la tenue d’une vidéo conférence pour présenter le bilan de ses activités mercredi 23 septembre 2020](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-tenue-dune-video-conference-pour-presenter-le-bilan-de-ses-activites-mercredi-23-septembre-2020/)
- [Adocia announces a Video Conference to Present a Corporate Update Wednesday, September 23rd, 2020](https://www.adocia.com/medias-publications/adocia-announces-a-video-conference-to-present-a-corporate-update-wednesday-september-23rd-2020/)
- [Adocia announces Positive Topline Results of Phase 1b Study for M1Pram in People with type 1 Diabetes.](https://www.adocia.com/medias-publications/adocia-announces-positive-topline-results-of-phase-1b-study-for-m1pram-in-people-with-type-1-diabetes/)
- [Adocia annonce les résultats préliminaires positifs de l'étude de Phase 1b de M1Pram chez des patients diabétiques de type 1.](https://www.adocia.com/fr/medias-publications/adocia-annonce-les-resultats-preliminaires-positifs-de-letude-de-phase-1b-de-m1pram-chez-des-patients-diabetiques-de-type-1/)
- [Number of shares and voting rights of ADOCIA as of August 31, 2020](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-august-31-2020/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 aout 2020](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-aout-2020/)
- [Ce 15 septembre, Adocia fera une présentation lors de la conférence H.C. Wainwright Global Investment Conference (Evenement virtuel)](https://www.adocia.com/fr/medias-publications/ce-15-septembre-adocia-fera-une-presentation-lors-de-la-conference-h-c-wainwright-global-investment-conference-evenement-virtuel/)
- [September 15th: Adocia to Present at H.C. Wainwright Global Investment Conference (Virtual Event)](https://www.adocia.com/medias-publications/september-15th-adocia-to-present-at-h-c-wainwright-global-investment-conference-virtual-event/)
- [ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience.](https://www.adocia.com/medias-publications/ado09-a-co-formulation-of-the-amylin-analog-pramlintide-and-the-a21g-human-insulin-analog-lowers-postprandial-blood-glucose-versus-insulin-lispro-in-type-1-diabetes-t1d-presented-by-dr-gregory-me-2/)
- [September 10th: Adocia Oral Presentation at the Annual Congress of the Société Francophone du Diabète (SFD).](https://www.adocia.com/medias-publications/september-10th-adocia-oral-presentation-at-the-annual-congress-of-the-societe-francophone-du-diabete-sfd/)
- [10 septembre prochain : Communication Orale d'Adocia lors du Congrès Annuel de la Société Francophone du Diabète (SFD)](https://www.adocia.com/fr/medias-publications/10-septembre-prochain-communication-orale-dadocia-lors-du-congres-annuel-de-la-societe-francophone-du-diabete-sfd/)
- [Number of shares and voting rights of ADOCIA as of July 31, 2020](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-july-31-2020/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 juillet 2020](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-juillet-2020/)
- [Adocia was granted a State-guaranteed loan (PGE) for EUR 7 million associated with a rescheduling of the loan terms contracted in 2019.](https://www.adocia.com/medias-publications/adocia-was-granted-a-state-guaranteed-loan-pge-for-eur-7-million-associated-with-a-rescheduling-of-the-loan-terms-contracted-in-2019/)
- [Adocia obtient un Prêt Garanti par l’Etat (PGE) de 7 millions d’euros associé à un réaménagement de la dette contractée en 2019.](https://www.adocia.com/fr/medias-publications/adocia-obtient-un-pret-garanti-par-letat-pge-de-7-millions-deuros-associe-a-un-reamenagement-de-la-dette-contractee-en-2019/)
- [Adocia initiates BioChaperone® Lispro comparative study to validate THDB insulin lispro for Phase 3 BC Lispro trials in Europe and U.S](https://www.adocia.com/medias-publications/adocia-initiates-biochaperone-lispro-comparative-study-to-validate-thdb-insulin-lispro-for-phase-3-bc-lispro-trials-in-europe-and-u-s/)
- [Adocia Announces First Half 2020 Financial Results](https://www.adocia.com/medias-publications/adocia-announces-first-half-2020-financial-results/)
- [Adocia annonce ses résultats financiers pour le premier semestre 2020](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-pour-le-premier-semestre-2020/)
- [Number of shares and voting rights of ADOCIA as of June 30, 2020](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-june-30-2020/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 juin 2020](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-juin-2020/)
- [ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.](https://www.adocia.com/medias-publications/ado09-a-coformulation-of-pramlintide-pram-and-insulin-a21g-improves-postprandial-glucose-vs-novologr-in-type-1-diabetes-t1d-dr-gregory-meiffren-june-12-16-2020-ada-virtual-experience/)
- [ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D) (Poster # 2020-LB-7039-Diabetes), presented by Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.](https://www.adocia.com/fr/medias-publications/ado09-a-coformulation-of-pramlintide-pram-and-insulin-a21g-improves-postprandial-glucose-vs-novolog-in-type-1-diabetes-t1d-poster-2020-lb-7039-diabetes-presented-by-dr-gregory-meiffren-j-2/)
- [Adocia annonce une présentation des résultats cliniques de M1Pram à l’occasion des 80èmes Sessions Scientifiques de l’American Diabetes Association® – Expérience virtuelle](https://www.adocia.com/fr/medias-publications/adocia-annonce-une-presentation-des-resultats-cliniques-de-m1pram-a-loccasion-des-80emes-sessions-scientifiques-de-lamerican-diabetes-association-experience-virtuelle/)
- [Adocia Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 80th Scientific Sessions – Virtual experience](https://www.adocia.com/medias-publications/adocia-announces-m1pram-clinical-data-presentation-at-the-american-diabetes-association-80th-scientific-sessions-virtual-experience/)
- [Number of shares and voting rights of ADOCIA as of May 31, 2020](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-may-31-2020/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mai 2020](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mai-2020/)
- [ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience.](https://www.adocia.com/medias-publications/ado09-a-co-formulation-of-the-amylin-analog-pramlintide-and-the-a21g-human-insulin-analog-lowers-postprandial-blood-glucose-versus-insulin-lispro-in-type-1-diabetes-t1d-presented-by-dr-gregory-me/)
- [Number of shares and voting rights of ADOCIA as of April 30, 2020](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-april-30-2020/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 avril 2020](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-avril-2020/)
- [Adocia announces positive topline results of the exploratory Phase 1b study of ADO09 (M1Pram) in people with type 1 diabetes](https://www.adocia.com/medias-publications/adocia-announces-positive-topline-results-of-the-exploratory-phase-1b-study-of-ado09-m1pram-in-people-with-type-1-diabetes/)
- [Adocia annonce les résultats préliminaires positifs de l’étude exploratoire de Phase 1b de ADO09 (M1Pram) chez des diabétiques de type 1](https://www.adocia.com/fr/medias-publications/adocia-annonce-les-resultats-preliminaires-positifs-de-letude-exploratoire-de-phase-1b-de-ado09-m1pram-chez-des-diabetiques-de-type-1/)
- [Adocia annonce la mise à disposition de son document d’enregistrement universel pour l’année 2019](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-mise-a-disposition-de-son-document-denregistrement-universel-pour-lannee-2019/)
- [Adocia announces the release of its Universal Reference Document for the year 2019](https://www.adocia.com/medias-publications/adocia-announces-the-release-of-its-universal-reference-document-for-the-year-2019/)
- [Adocia to hold its annual shareholders’ meeting on May 28th, 2020 in Lyon](https://www.adocia.com/medias-publications/adocia-to-hold-its-annual-shareholders-meeting-on-may-28th-2020-in-lyon/)
- [Adocia annonce la tenue de son assemblée générale annuelle le 28 mai 2020](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-tenue-de-son-assemblee-generale-annuelle-le-28-mai-2020/)
- [Adocia annonce ses résultats financiers du 1er trimestre 2020 et fait le point sur l’impact du COVID-19](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-du-1er-trimestre-2020-et-fait-le-point-sur-limpact-du-covid-19/)
- [Adocia announces first quarter 2020 financial results  and update on the impact of COVID-19](https://www.adocia.com/medias-publications/adocia-announces-first-quarter-2020-financial-results-and-update-on-the-impact-of-covid-19/)
- [Number of shares and voting rights of ADOCIA as of March 31, 2020](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-march-31-2020/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mars 2020](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mars-2020/)
- [Adocia Announces Full Year 2019 Financial Results](https://www.adocia.com/medias-publications/adocia-announces-full-year-2019-financial-results/)
- [Number of shares and voting rights of ADOCIA as of February 28, 2020](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-february-28-2020/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 28 Février 2020](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-28-fevrier-2020/)
- [“BioChaperone® Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects” (EPO2 E-Poster Viewing), presented by Dr. Grégory Meiffren, February 21, 2019, ATTD, Berlin (Germany)](https://www.adocia.com/medias-publications/biochaperone-combo-a-co-formulation-of-lispro-and-glargine-improves-postprandial-glucose-control-compared-to-lispromix25-or-lispro-and-glargine-injections-in-type-2-diabetes-subjects/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 janvier 2020](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-janvier-2020/)
- [Number of shares and voting rights of ADOCIA as of December 31, 2019](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-december-31-2019/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 décembre 2019](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-decembre-2019/)
- [Adocia annonce son calendrier financier pour l’année 2020](https://www.adocia.com/fr/medias-publications/adocia-annonce-son-calendrier-financier-pour-lannee-2020/)
- [Adocia announces its financial calendar for 2020](https://www.adocia.com/medias-publications/adocia-announces-its-financial-calendar-for-2020/)
- [Adocia Announces the Subscription of the Second Tranche of the Financing Line obtained from IPF Partners](https://www.adocia.com/medias-publications/adocia-announces-the-subscription-of-the-second-tranche-of-the-financing-line-obtained-from-ipf-partners/)
- [Adocia annonce la souscription de la seconde tranche de la ligne de financement obtenue auprès d’IPF Partners](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-souscription-de-la-seconde-tranche-de-la-ligne-de-financement-obtenue-aupres-dipf-partners/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 novembre 2019](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-novembre-2019/)
- [Number of shares and voting rights of ADOCIA as of November 30, 2019](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-november-30-2019/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 octobre 2019](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-octobre-2019/)
- [Number of shares and voting rights of ADOCIA as of October 31st, 2019](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-october-31st-2019/)
- [Adocia Announces Third Quarter 2019 Financial Results](https://www.adocia.com/medias-publications/adocia-announces-third-quarter-2019-financial-results/)
- [Adocia annonce ses résultats financiers pour le troisième trimestre 2019](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-pour-le-troisieme-trimestre-2019/)
- [Adocia obtains additional financial resources to accelerate its growth](https://www.adocia.com/medias-publications/adocia-obtains-additional-financial-resources-to-accelerate-its-growth/)
- [Adocia se dote de moyens financiers supplémentaires pour accélérer sa croissance](https://www.adocia.com/fr/medias-publications/adocia-se-dote-de-moyens-financiers-supplementaires-pour-accelerer-sa-croissance/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 septembre 2019](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-septembre-2019/)
- [Number of shares and voting rights of ADOCIA as of September 30, 2019](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-september-30-2019/)
- [Adocia annonce, d’une part, l’encaissement de 14,3 millions de dollars de la part de Eli Lilly suite à la conclusion de l’arbitrage et, d’autre part, la décision d’un commun accord avec Eli Lilly de clore la procédure civile](https://www.adocia.com/fr/medias-publications/adocia-annonce-dune-part-lencaissement-de-143-millions-de-dollars-de-la-part-de-eli-lilly-suite-a-la-conclusion-de-larbitrage-et-dautre-part-la-decision-d/)
- [Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case](https://www.adocia.com/medias-publications/adocia-announces-receipt-of-usd-14-3-million-payment-from-eli-lilly-following-arbitration-conclusion-and-the-decision-by-mutual-consent-with-eli-lilly-to-conclude-the-civil-case/)
- [Adocia Announces Oral Presentation Covering ADO09, its pramlintide insulin coformulation, at EASD](https://www.adocia.com/medias-publications/adocia-announces-oral-presentation-covering-ado09-its-pramlintide-insulin-coformulation-at-easd/)
- [Adocia annonce une présentation orale portant sur ADO09, sa coformulation de pramlintide et d’insuline à l’occasion de l’EASD](https://www.adocia.com/fr/medias-publications/adocia-annonce-une-presentation-orale-portant-sur-ado09-sa-coformulation-de-pramlintide-et-dinsuline-a-loccasion-de-leasd/)
- [Number of shares and voting rights of ADOCIA as of August 31, 2019](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-august-31-2019/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 aout 2019](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-aout-2019/)
- [Adocia annonce la décision du tribunal arbitral de l’Association Américaine d’Arbitrage](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-decision-du-tribunal-arbitral-de-lassociation-americaine-darbitrage/)
- [Adocia announces the decision of the American Arbitration Association Tribunal](https://www.adocia.com/medias-publications/adocia-announces-the-decision-of-the-american-arbitration-association-tribunal/)
- [Number of shares and voting rights of ADOCIA as of July 31st 2019](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-july-31st-2019/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 juillet 2019](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-juillet-2019/)
- [Adocia Presents First Half 2019 Financial Results](https://www.adocia.com/medias-publications/adocia-presents-first-half-2019-financial-results/)
- [Adocia annonce ses résultats financiers pour le premier semestre 2019](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-pour-le-premier-semestre-2019/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 juin 2019](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-juin-2019/)
- [Number of shares and voting rights of ADOCIA as of June 30, 2019](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-june-30-2019/)
- [Number of shares and voting rights of ADOCIA as of May 31, 2019](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-may-31-2019/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mai 2019](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mai-2019/)
- [“BioChaperone Glucagon Exenatide (BC Glu Exe), a Stable Combination of Glucagon (Glu) and Exenatide (Exe) Achieved Larger Body Weight (BW) Loss than Exe Alone in DIO Mice” (Poster), Author Dr. Martin Gaudier, June 10, 2019, ADA, San Francisco (USA)](https://www.adocia.com/medias-publications/biochaperone-glucagon-une-formulation-de-glucagon-liquide-stable-prete-a-lemploi-est-bien-toleree-et-retablit-rapidement-la-normoglycemie-apres-une-hypoglycemie-provoquee-par-inf/)
- [BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (pram) and human insulin (ins), improves post-prandial blood glucose versus both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D”, Dr. Grégory Meiffren, June 9th, 2019, ADA, San Francisco (USA)](https://www.adocia.com/medias-publications/biochaperone-pramlintide-insulin-bcpramins-a-new-co-formulation-of-pramlintide-pram-and-human-insulin-ins-improves-post-prandial-blood-glucose-versus-both-separate-injections-of-pramins-and-i/)
- [Adocia lance une étude clinique de Phase 1b de trois semaines avec ADO09, une coformulation de pramlintide et d’une insuline prandiale, chez des sujets diabétiques de type 1](https://www.adocia.com/fr/medias-publications/adocia-lance-une-etude-clinique-de-phase-1b-de-trois-semaines-avec-ado09-une-coformulation-de-pramlintide-et-dune-insuline-prandiale-chez-des-sujets-diabetiques-de-type-1/)
- [Adocia initiates a 3-week Phase 1b study of ADO09,  a co-formulation of pramlintide and mealtime insulin, in people with type 1 diabetes](https://www.adocia.com/medias-publications/adocia-initiates-a-3-week-phase-1b-study-of-ado09-a-co-formulation-of-pramlintide-and-mealtime-insulin-in-people-with-type-1-diabetes/)
- [Adocia présentera deux abstracts à l’occasion des  79èmes Sessions Scientifiques de l’American Diabetes Association®](https://www.adocia.com/fr/medias-publications/adocia-presentera-deux-abstracts-a-loccasion-des-79emes-sessions-scientifiques-de-lamerican-diabetes-association/)
- [Adocia Announces Scientific Data Presentations at the American Diabetes Association® 79th Scientific Sessions](https://www.adocia.com/medias-publications/adocia-announces-scientific-data-presentations-at-the-american-diabetes-association-79th-scientific-sessions/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 avril 2019](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-avril-2019/)
- [Number of shares and voting rights of ADOCIA as of April 30, 2019](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-april-30-2019/)
- [Article : Grégory Meiffren PhD, Theresa Herbrand MD, Ernestos Anastassiadis MD, Oliver Klein MD, J. Hans DeVries MD, Tim Heise MD, Bertrand Alluis PhD, Claire Mégret PhD, Martin Gaudier PhD, Olivier Soula PhD, Leona Plum‐Mörschel MD. <br>“Better glycemic control with BioChaperone® Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM)”<br>Diabetes Obes Metab., 2019;21(7):15701575.](https://www.adocia.com/medias-publications/gregory-meiffren-phd-theresa-herbrand-md-ernestos-anastassiadis-md-oliver-klein-md-j-hans-devries-md-tim-heise-md-bertrand-alluis-phd-claire-megret-phd-martin-gaudier-phd-olivier-soula-phd/)
- [Adocia annonce la mise à disposition de son document de référence pour l’année 2018](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-mise-a-disposition-de-son-document-de-reference-pour-lannee-2018/)
- [Adocia announces the release of its Reference Document for the year 2018](https://www.adocia.com/medias-publications/adocia-announces-the-release-of-its-reference-document-for-the-year-2018/)
- [Adocia annonce ses résultats financiers du 1er trimestre 2019 :  Position de trésorerie et Chiffre d’Affaires](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-du-1er-trimestre-2019-position-de-tresorerie-et-chiffre-daffaires/)
- [Adocia annonce les résultats préliminaires de la première étude ADO09, nouvelle coformulation de pramlintide et d’insuline](https://www.adocia.com/fr/medias-publications/adocia-annonce-les-resultats-preliminaires-de-la-premiere-etude-ado09-nouvelle-coformulation-de-pramlintide-et-dinsuline/)
- [Adocia announces topline results for the first clinical study of ADO09, a new co-formulation of pramlintide and a prandial insulin](https://www.adocia.com/medias-publications/adocia-announces-topline-results-for-the-first-clinical-study-of-ado09-a-new-co-formulation-of-pramlintide-and-a-prandial-insulin/)
- [Adocia annonce la tenue de son assemblée générale annuelle le 16 mai 2019 à Paris](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-tenue-de-son-assemblee-generale-annuelle-le-16-mai-2019-a-paris/)
- [Adocia to hold its annual shareholders’ meeting on May 16, 2019 in Paris](https://www.adocia.com/medias-publications/adocia-to-hold-its-annual-shareholders-meeting-on-may-16-2019-in-paris/)
- [Number of shares and voting rights of ADOCIA as of March 31, 2019](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-march-31-2019/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mars 2019](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mars-2019/)
- [Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode BW.<br>  “BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.”<br>  Diabetes Obes Metab., 2019;21(4):1066-1070.](https://www.adocia.com/medias-publications/heise-t-meiffren-g-alluis-b-seroussi-c-ranson-a-arrubla-j-correia-j-gaudier-m-soula-o-soula-r-devries-jh-klein-o-bode-bw-biochaperone-lispro-versus-faster-aspart-and-insulin-asp/)
- [Comparaison des profils pharmacocinétiques et de pharmacodynamie de l’insuline ultra rapide BioChaperone® Lispro avec les formulations Fiasp® et Novorapid® de l’insuline asparte administrées par pompes à insuline, Dr. Grégory Meiffren, March 27, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)](https://www.adocia.com/medias-publications/comparaison-des-profils-pharmacocinetiques-et-de-pharmacodynamie-de-linsuline-ultra-rapide-biochaperone-lispro-avec-les-formulations-fiasp-et-novorapid-de-linsuline/)
- [“BioChaperone Combo, une combinaison fixe d’insuline lispro et d’insuline glargine, améliore les profils de glycémie postprandiale par rapport à un premix d’insuline lispro et les administrations séparées d’insuline lispro et d’insuline glargine dans une étude de phase 1 chez des sujets diabétiques de type 2” (Poster), Author Dr. Claire Mégret, March 26, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)](https://www.adocia.com/medias-publications/biochaperone-combo-une-combinaison-fixe-dinsuline-lispro-et-dinsuline-glargine-ameliore-les-profils-de-glycemie-postprandiale-par-rapport-a-un-premix-dinsuline-li-2/)
- [“BioChaperone Glucagon, une formulation de glucagon liquide, stable, prête à l’emploi, est bien tolérée et rétablit rapidement la normoglycemie après une hypoglycémie provoquée par infusion d’insuline” (Poster), Author Mr. Aymeric Ranson, March 26, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)](https://www.adocia.com/medias-publications/biochaperone-glucagon-exenatide-bc-glu-exe-a-stable-combination-of-glucagon-glu-and-exenatide-exe-achieved-larger-body-weight-bw-loss-than-exe-alone-in-dio-mice-poster-au/)
- [Adocia annonce ses résultats annuels 2018 :  un chiffre d’affaires en augmentation et une trésorerie renforcée](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-annuels-2018-un-chiffre-daffaires-en-augmentation-et-une-tresorerie-renforcee/)
- [Adocia Announces its Financial Results for 2018: Higher Revenue and Reinforced Cash Position](https://www.adocia.com/medias-publications/adocia-announces-its-financial-results-for-2018-higher-revenue-and-reinforced-cash-position/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 28 février 2019](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-28-fevrier-2019/)
- [Number of shares and voting rights of ADOCIA as of February 28, 2019](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-february-28-2019/)
- [The Ultra-Rapid Insulin BioChaperone® Lispro bolused by insulin pump shows favourable pharmacodynamics and pharmacokinetics vs. faster Aspart and insulin Aspart, Dr. Grégory Meiffren, February 23, 2019, ATTD, Berlin (Germany)](https://www.adocia.com/medias-publications/the-ultra-rapid-insulin-biochaperone-lispro-bolused-by-insulin-pump-shows-favourable-pharmacodynamics-and-pharmacokinetics-vs-faster-aspart-and-insulin-aspart-dr-gregory-meiffren-february-23/)
- [“BioChaperone® Glucagon, A Stable Ready-To-Use Liquid Glucagon Formulation Enabled By Biochaperone Technology, Is Well Tolerated And Quickly Restores Euglycemia After Insulin-Induced Hypoglycemia” (E-Poster Discussion 05), presented by Mr. Aymeric Ranson, February 22, 2019, ATTD, Berlin (Germany)](https://www.adocia.com/medias-publications/biochaperone-glucagon-a-stable-ready-to-use-liquid-glucagon-formulation-enabled-by-biochaperone-technology-is-well-tolerated-and-quickly-restores-euglycemia-after-insulin-induced-hypo/)
- [“BioChaperone® Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects” (EPO2 E-Poster Viewing), presented by Dr. Grégory Meiffren, February 21, 2019, ATTD, Berlin (Germany)](https://www.adocia.com/medias-publications/biochaperone-combo-a-co-formulation-of-lispro-and-glargine-improves-postprandial-glucose-control-compared-to-lispromix25-or-lispro-and-glargine-injections-in-type-2-diabetes-subjects-2/)
- [Adocia to Present New Clinical Data on BioChaperone® Technology at ATTD 2019](https://www.adocia.com/medias-publications/adocia-to-present-new-clinical-data-on-biochaperone-technology-at-attd-2019/)
- [Adocia présente les derniers résultats cliniques de la technologie BioChaperone® lors de l'événement ATTD 2019](https://www.adocia.com/fr/medias-publications/adocia-presente-les-derniers-resultats-cliniques-de-la-technologie-biochaperone-lors-de-levenement-attd-2019/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 janvier 2019](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-janvier-2019/)
- [Number of shares and voting rights of ADOCIA as of January 31, 2019](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-january-31-2019/)
- [Adocia confirms its financial calendar for 2019](https://www.adocia.com/medias-publications/adocia-confirms-its-financial-calendar-for-2019/)
- [Adocia confirme son calendrier financier pour l’année 2019](https://www.adocia.com/fr/medias-publications/adocia-confirme-son-calendrier-financier-pour-lannee-2019/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 décembre 2018](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-decembre-2018/)
- [Number of shares and voting rights of ADOCIA as of December 31, 2018](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-december-31-2018/)
- [CP : Adocia annonce un essai clinique évaluant BioChaperone® Lispro et d’autres analogues prandiaux d’insuline dans le Pancréas Bionique iLetTM](https://www.adocia.com/fr/medias-publications/cp-adocia-annonce-un-essai-clinique-evaluant-biochaperone-lispro-et-dautres-analogues-prandiaux-dinsuline-dans-le-pancreas-bionique-ilettm/)
- [PR: Adocia Announces a Clinical Trial Evaluating BioChaperone® Lispro and Other Rapid-Acting Insulin Analogs Using iLetTM Bionic Pancreas](https://www.adocia.com/medias-publications/pr-adocia-announces-a-clinical-trial-evaluating-biochaperone-lispro-and-other-rapid-acting-insulin-analogs-using-ilettm-bionic-pancreas/)
- [Adocia annonce son calendrier financier pour l’année 2019](https://www.adocia.com/fr/medias-publications/adocia-annonce-son-calendrier-financier-pour-lannee-2019/)
- [Adocia announces its financial calendar for 2019](https://www.adocia.com/medias-publications/adocia-announces-its-financial-calendar-for-2019/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 novembre 2018](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-novembre-2018/)
- [Number of shares and voting rights of ADOCIA as of November 30, 2018](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-november-30-2018/)
- [Andersen G, Meiffren G, Lamers D, DeVries JH, Ranson A, Seroussi C, Alluis B, Gaudier M, Soula O, Heise T. <br>“Ultra-rapid BioChaperone® Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.”<br>Diabetes Obes Metab., 2018;20(11):2627-2632.](https://www.adocia.com/medias-publications/andersen-g-meiffren-g-lamers-d-devries-jh-ranson-a-seroussi-c-alluis-b-gaudier-m-soula-o-heise-t-ultra-rapid-biochaperone-lispro-improves-postprandial-blood-glucose-excursions/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 octobre 2018](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-octobre-2018/)
- [Number of shares and voting rights of ADOCIA as of October 31, 2018](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-october-31-2018/)
- [Adocia annonce ses résultats financiers pour le troisième trimestre 2018](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-pour-le-troisieme-trimestre-2018/)
- [Adocia Announces Third Quarter 2018 Financial Results](https://www.adocia.com/medias-publications/adocia-announces-third-quarter-2018-financial-results/)
- [Adocia informs about a civil action filed by Eli Lilly](https://www.adocia.com/medias-publications/adocia-informs-about-a-civil-action-filed-by-eli-lilly/)
- [Adocia informe que Eli Lilly a engagé une action civile](https://www.adocia.com/fr/medias-publications/adocia-informe-que-eli-lilly-a-engage-une-action-civile/)
- [Adocia to hold an ordinary shareholders’ meeting on November 9, 2018 in Lyon](https://www.adocia.com/medias-publications/adocia-to-hold-an-ordinary-shareholders-meeting-on-november-9-2018-in-lyon/)
- [Adocia annonce la tenue d’une assemblée générale ordinaire le 9 novembre 2018 à Lyon](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-tenue-dune-assemblee-generale-ordinaire-le-9-novembre-2018-a-lyon/)
- [“BioChaperone® technology enables the development of pramlintide-prandial insulin combinations” (Poster 811), presented by Dr. Remi Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)](https://www.adocia.com/medias-publications/biochaperone-combo-une-combinaison-fixe-dinsuline-lispro-et-dinsuline-glargine-ameliore-les-profils-de-glycemie-postprandiale-par-rapport-a-un-premix-dinsuline-li/)
- [Number of shares and voting rights of ADOCIA as of September 30, 2018](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-september-30-2018/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 septembre 2018](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-septembre-2018/)
- [“BioChaperone® 222, the new excipient enabling the ultra-rapid BioChaperone® Lispro formulation, is completely absorbed and rapidly excreted after subcutaneous injection” (Poster 816), presented by Dr. Olivier Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)](https://www.adocia.com/medias-publications/biochaperone-222-the-new-excipient-enabling-the-ultra-rapid-biochaperone-lispro-formulation-is-completely-absorbed-and-rapidly-excreted-after-subcutaneous-injection-po/)
- [The ultra-rapid insulin BioChaperone® Lispro shows favourable pharmacodynamics and pharmacokinetics compared to faster insulin aspart and insulin aspart in insulin pumps, Dr. Grégory Meiffren, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)](https://www.adocia.com/medias-publications/the-ultra-rapid-insulin-biochaperone-lispro-shows-favourable-pharmacodynamics-and-pharmacokinetics-compared-to-faster-insulin-aspart-and-insulin-aspart-in-insulin-pumps-dr-gregory-meiffren-54/)
- [“Better Postprandial Glucose (PPG) Control with BioChaperone® Combo (BC Combo) than with Lispro Mix25 (LMx) or separate Glargine & Lispro (G+L) Administration in Subjects with Type 2 Diabetes (T2DM)” (Poster 1001), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/biochaperone-technology-enables-the-development-of-pramlintide-prandial-insulin-combinations-poster-811-presented-by-dr-remi-soula-54th-annual-meeting-of-the-european-asso/)
- [Adocia to Present Five Abstracts at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD)](https://www.adocia.com/medias-publications/adocia-to-present-five-abstracts-at-the-54th-annual-meeting-of-the-european-association-for-the-study-of-diabetes-easd/)
- [Adocia annonce cinq présentations à l’occasion du 54ème Congrès Annuel de l’Association Européenne pour l’Etude du Diabète (EASD)](https://www.adocia.com/fr/medias-publications/adocia-annonce-cinq-presentations-a-loccasion-du-54eme-congres-annuel-de-lassociation-europeenne-pour-letude-du-diabete-easd/)
- [“Pooled Analysis of Clinical Trials Investigating the Pharmacokinetics (PK) of Ultra-Rapid Insulin BioChaperone® Lispro (BCLIS) versus Lispro (LIS) in Subjects with Type 1 (T1D) and Type 2 (T2D) Diabetes” (Poster 998), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/biochaperone-lispro-une-formulation-ultra-rapide-dinsuline-lispro-ameliore-le-controle-glycemique-post-prandial-de-sujets-diabetiques-de-type-1-traites-par-de-multiples-injec/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 août 2018](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-aout-2018/)
- [Number of shares and voting rights of ADOCIA as of August 31, 2018](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-august-31-2018/)
- [Adocia annonce les résultats préliminaires positifs de la première étude clinique de BioChaperone® Pramlintide Insulin chez des personnes avec un diabète de type 1](https://www.adocia.com/fr/medias-publications/adocia-annonce-les-resultats-preliminaires-positifs-de-la-premiere-etude-clinique-de-biochaperone-pramlintide-insulin-chez-des-personnes-avec-un-diabete-de-type-1/)
- [Adocia announces positive topline results for the first clinical study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes](https://www.adocia.com/medias-publications/adocia-announces-positive-topline-results-for-the-first-clinical-study-of-biochaperone-pramlintide-insulin-in-people-with-type-1-diabetes/)
- [Adocia annonce deux développements dans le cadre de la deuxième phase de la procédure d’arbitrage à l’encontre d’Eli Lilly](https://www.adocia.com/fr/medias-publications/adocia-annonce-deux-developpements-dans-le-cadre-de-la-deuxieme-phase-de-la-procedure-darbitrage-a-lencontre-deli-lilly/)
- [Adocia Announces Update to Second Arbitration Against Eli Lilly & Company](https://www.adocia.com/medias-publications/adocia-announces-update-to-second-arbitration-against-eli-lilly-company/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 juillet 2018](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-juillet-2018/)
- [Number of shares and voting rights of ADOCIA as of July 31, 2018](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-july-31-2018/)
- [Le tribunal arbitral de l’Association Américaine d’Arbitrage statue en faveur d’Adocia dans la première phase de la procédure d’arbitrage à l’encontre d’Eli Lilly](https://www.adocia.com/fr/medias-publications/le-tribunal-arbitral-de-lassociation-americaine-darbitrage-statue-en-faveur-dadocia-dans-la-premiere-phase-de-la-procedure-darbitrage-a-lencontre-d/)
- [American Arbitration Association Panel Finds In Favor Of Adocia In First Phase Of Arbitration Against Eli Lilly](https://www.adocia.com/medias-publications/american-arbitration-association-panel-finds-in-favor-of-adocia-in-first-phase-of-arbitration-against-eli-lilly/)
- [Adocia Presents First Half 2018 Financial Results](https://www.adocia.com/medias-publications/adocia-presents-first-half-2018-financial-results/)
- [Adocia annonce ses résultats financiers  pour le premier semestre 2018](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-pour-le-premier-semestre-2018/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 juin 2018](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-juin-2018/)
- [Number of shares and voting rights of ADOCIA as of June 30, 2018](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-june-30-2018/)
- [BioChaperone® Technology Enables the Development of Pramlintide-Prandial Insulin Combinations, Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/biochaperone-technology-enables-the-development-of-pramlintide-prandial-insulin-combinations-dr-gregory-meiffren-78th-scientific-sessions-of-the-american-diabetes-association-22-26-june-2018/)
- [“Pooled Analysis of Clinical Trials Investigating the Pharmacokinetics (PK) of Ultra-Rapid Insulin BioChaperone® Lispro (BCLIS) versus Lispro (LIS) in Subjects with Type 1 (T1D) and Type 2 (T2D) Diabetes” (Poster 998), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/pooled-analysis-of-clinical-trials-investigating-the-pharmacokinetics-pk-of-ultra-rapid-insulin-biochaperone-lispro-bclis-versus-lispro-lis-in-subjects-with-type-1-t1d-and-type/)
- [“Better Postprandial Glucose (PPG) Control with BioChaperone® Combo (BC Combo) than with Lispro Mix25 (LMx) or separate Glargine & Lispro (G+L) Administration in Subjects with Type 2 Diabetes (T2DM)” (Poster 1001), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/better-postprandial-glucose-ppg-control-with-biochaperone-combo-bc-combo-than-with-lispro-mix25-lmx-or-separate-glargine-lispro-gl-administration-in-subjects-with-type-2-diab/)
- [BioChaperone® Glucagon, a stable ready-to-use liquid glucagon formulation, is well tolerated and quickly restores euglycemia after insulin-induced hypoglycemia, by Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/biochaperone-glucagon-a-stable-ready-to-use-liquid-glucagon-formulation-is-well-tolerated-and-quickly-restores-euglycemia-after-insulin-induced-hypoglycemia-by-dr-gregory-meiffren-78th-scie/)
- [“The Ultra-Rapid Insulin (URI) BioChaperone® Lispro (BCLIS) shows Favorable Pharmacodynamics (PD) and Pharmacokinetics (PK) vs Faster Aspart (FIA) and Insulin Aspart (ASP) in Insulin Pumps (CSII)” (Poster 1035), presented by Dr. Bruce W. Bode, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)](https://www.adocia.com/medias-publications/the-ultra-rapid-insulin-uri-biochaperone-lispro-bclis-shows-favorable-pharmacodynamics-pd-and-pharmacokinetics-pk-vs-faster-aspart-fia-and-insulin-aspart-asp-in-insulin-pump/)
- [“BioChaperone® Lispro, une formulation ultra-rapide d’insuline lispro, améliore le contrôle glycémique post-prandial de sujets diabétiques de type 1 traités par de multiples injections quotidiennes d’insuline pendant 14 jours.” (Abstract CAD-19), presented by Dr. Grégory Meiffren, 2018, Société Francophone du Diabète (France)](https://www.adocia.com/medias-publications/pooled-analysis-of-clinical-trials-investigating-the-pharmacokinetics-pk-of-ultra-rapid-insulin-biochaperone-lispro-bclis-versus-lispro-lis-in-subjects-with-type-1-t1d-and-type-2/)
- [“Ultra-rapid BioChaperone® Lispro ameliorates postprandial blood glucose (PPG) control compared to Humalog in subjects with type 1 diabetes mellitus” (Poster PI005), presented by Dr G. Anderson, American Society for Clinical Pharmacology & Therapeutics (ASCPT)](https://www.adocia.com/medias-publications/better-postprandial-glucose-ppg-control-with-biochaperone-combo-bc-combo-than-with-lispro-mix25-lmx-or-separate-glargine-lispro-gl-administration-in-subjects-with-type-2-diab-2/)
- [Ultra-Rapid BioChaperone® Lispro ameliorates postprandial blood glucose control compared with Humalog(R) in subjects with type 1 diabetes mellitus, Dr. Grit Anderen, 76th Scientific Sessions American Diabetes Association 10-14 June 2016, New Orleans, LO (USA)](https://www.adocia.com/medias-publications/ultra-rapid-biochaperone-lispro-ameliorates-postprandial-blood-glucose-control-compared-with-humalogr-in-subjects-with-type-1-diabetes-mellitus-dr-grit-anderen-76th-scientific-sessions-amer/)
- [Adocia présentera six abstracts à l’occasion des 78èmes Sessions Scientifiques de l’American Diabetes Association®](https://www.adocia.com/fr/medias-publications/adocia-presentera-six-abstracts-a-loccasion-des-78emes-sessions-scientifiques-de-lamerican-diabetes-association/)
- [Adocia to Present Six Abstracts at the American Diabetes Association® 78th Scientific Sessions](https://www.adocia.com/medias-publications/adocia-to-present-six-abstracts-at-the-american-diabetes-association-78th-scientific-sessions/)
- [BioChaperone® Combo (BC Combo) improves postprandial glycemia vs. Humalog® Mix 75/25™ (HMx) in people with type 1 diabetes mellitus (T1DM, Dr. Steven V. Edelman, 76th Scientific Sessions American Diabetes Association 11-13 June 2016, New Orleans, LO (USA)](https://www.adocia.com/medias-publications/biochaperone-combo-bc-combo-improves-postprandial-glycemia-vs-humalog-mix-75-25-hmx-in-people-with-type-1-diabetes-mellitus-t1dm-dr-steven-v-edelman-76th-scientific-sess/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mai 2018](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mai-2018/)
- [Number of shares and voting rights of ADOCIA as of May, 31 2018](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-may-31-2018/)
- [Adocia to Participate in the Jefferies 2018 Global Healthcare Conference](https://www.adocia.com/medias-publications/adocia-to-participate-in-the-jefferies-2018-global-healthcare-conference/)
- [Adocia participera à la Jefferies 2018 Global Healthcare Conference](https://www.adocia.com/fr/medias-publications/adocia-participera-a-la-jefferies-2018-global-healthcare-conference/)
- [Adocia et Tonghua Dongbao annoncent des accords globaux d’approvisionnement en insuline lispro et en insuline glargine](https://www.adocia.com/fr/medias-publications/adocia-et-tonghua-dongbao-annoncent-des-accords-globaux-dapprovisionnement-en-insuline-lispro-et-en-insuline-glargine/)
- [Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin Glargine](https://www.adocia.com/medias-publications/adocia-and-tonghua-dongbao-announce-global-supply-agreements-for-insulin-lispro-and-insulin-glargine/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 avril 2018](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-avril-2018/)
- [Number of shares and voting rights of ADOCIA as of April, 30 2018](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-april-30-2018/)
- [Adocia organise une conférence téléphonique suite à l’annonce de l’alliance stratégique conclue avec la société chinoise Tonghua Dongbao](https://www.adocia.com/fr/medias-publications/adocia-organise-une-conference-telephonique-suite-a-lannonce-de-lalliance-strategique-conclue-avec-la-societe-chinoise-tonghua-dongbao/)
- [Adocia to hold conference call in regard to the Strategic Alliance for BioChaperone® Combo and BioChaperone® Lispro in China with Tonghua Dongbao](https://www.adocia.com/medias-publications/adocia-to-hold-conference-call-in-regard-to-the-strategic-alliance-for-biochaperone-combo-and-biochaperone-lispro-in-china-with-tonghua-dongbao/)
- [Adocia announces the release  of its Reference Document for the year 2017](https://www.adocia.com/medias-publications/adocia-announces-the-release-of-its-reference-document-for-the-year-2017/)
- [Adocia annonce la mise à disposition de son document de référence pour l’année 2017](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-mise-a-disposition-de-son-document-de-reference-pour-lannee-2017/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mars 2018](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mars-2018/)
- [Number of shares and voting rights of ADOCIA as of March, 31 2018](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-march-31-2018/)
- [Adocia initie la première étude clinique de BioChaperone Pramlintide Insuline, chez des personnes avec un diabète de type 1](https://www.adocia.com/fr/medias-publications/adocia-initie-la-premiere-etude-clinique-de-biochaperone-pramlintide-insuline-chez-des-personnes-avec-un-diabete-de-type-1/)
- [Adocia initiates First-in-Human Clinical Study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes](https://www.adocia.com/medias-publications/adocia-initiates-first-in-human-clinical-study-of-biochaperone-pramlintide-insulin-in-people-with-type-1-diabetes/)
- [Adocia annonce ses résultats financiers du 1er trimestre 2018 :  Position de trésorerie et Chiffre d’Affaires](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-du-1er-trimestre-2018-position-de-tresorerie-et-chiffre-daffaires/)
- [Adocia announces first quarter 2018  financial results: Cash position and revenue](https://www.adocia.com/medias-publications/adocia-announces-first-quarter-2018-financial-results-cash-position-and-revenue/)
- [Adocia to hold its annual shareholders’ meeting on May 17, 2018 in Lyon](https://www.adocia.com/medias-publications/adocia-to-hold-its-annual-shareholders-meeting-on-may-17-2018-in-lyon/)
- [Adocia annonce la tenue de son assemblée générale annuelle le 17 mai 2018 à Lyon](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-tenue-de-son-assemblee-generale-annuelle-le-17-mai-2018-a-lyon/)
- [ADOCIA annonce ses résultats annuels 2017 et ses perspectives pour 2018](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-annuels-2017-et-ses-perspectives-pour-2018/)
- [ADOCIA announced its financial results for 2017  and its perspectives for 2018](https://www.adocia.com/medias-publications/adocia-announced-its-financial-results-for-2017-and-its-perspectives-for-2018/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 28 février 2018](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-28-fevrier-2018/)
- [Number of shares and voting rights of ADOCIA as of February 28, 2018](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-february-28-2018/)
- [BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in subjects with T2DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)](https://www.adocia.com/medias-publications/biochaperone-lispro-an-ultra-rapid-insulin-lispro-formulation-improves-post-prandial-blood-glucose-control-in-a-14-day-multiple-daily-insulin-injection-study-in-subjects-with-t2dm-dr-gregory/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 janvier 2018](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-janvier-2018/)
- [Number of shares and voting rights of ADOCIA as of January 31, 2018](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-january-31-2018/)
- [Adocia: additional resources allocated to the liquidity agreement](https://www.adocia.com/medias-publications/adocia-additional-resources-allocated-to-the-liquidity-agreement/)
- [Adocia donnera une présentation à la conférence BIO CEO & Investor à New York](https://www.adocia.com/fr/medias-publications/adocia-donnera-une-presentation-a-la-conference-bio-ceo-investor-a-new-york/)
- [Adocia to Present at the 2018 BIO CEO & Investor Conference in New York](https://www.adocia.com/medias-publications/adocia-to-present-at-the-2018-bio-ceo-investor-conference-in-new-york/)
- [Adocia dépose des demandes d'arbitrage supplémentaires à l’encontre de Eli Lilly & Company](https://www.adocia.com/fr/medias-publications/adocia-depose-des-demandes-darbitrage-supplementaires-a-lencontre-de-eli-lilly-company/)
- [Adocia Files Additional Arbitration Claims Against Eli Lilly & Company](https://www.adocia.com/medias-publications/adocia-files-additional-arbitration-claims-against-eli-lilly-company/)
- [Adocia Announces Positive Topline Data From a  Dose-Proportionality Study of  BioChaperone® Combo in People with Type 2 Diabetes](https://www.adocia.com/medias-publications/adocia-announces-positive-topline-data-from-a-dose-proportionality-study-of-biochaperone-combo-in-people-with-type-2-diabetes/)
- [Adocia annonce les résultats principaux positifs d’une étude de dose-proportionnalité de BioChaperone® Combo chez des personnes diabétiques de type 2](https://www.adocia.com/fr/medias-publications/adocia-annonce-les-resultats-principaux-positifs-dune-etude-de-dose-proportionnalite-de-biochaperone-combo-chez-des-personnes-diabetiques-de-type-2/)
- [Number of shares and voting rights of ADOCIA as of December 31, 2017](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-december-31-2017/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 décembre 2017](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-decembre-2017/)
- [Adocia announces its financial calendar for 2018](https://www.adocia.com/medias-publications/adocia-announces-its-financial-calendar-for-2018/)
- [Adocia annonce son calendrier financier  pour l’année 2018](https://www.adocia.com/fr/medias-publications/adocia-annonce-son-calendrier-financier-pour-lannee-2018/)
- [Adocia announces expanded use of BioChaperone® beyond diabetes](https://www.adocia.com/medias-publications/adocia-announces-expanded-use-of-biochaperone-beyond-diabetes/)
- [Adocia annonce l’extension au-delà du diabète des applications de BioChaperone®](https://www.adocia.com/fr/medias-publications/adocia-annonce-lextension-au-dela-du-diabete-des-applications-de-biochaperone/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 novembre 2017](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-novembre-2017/)
- [Number of shares and voting rights of ADOCIA as of November 30, 2017](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-november-30-2017/)
- [Adocia annonce les résultats principaux positifs d’une étude comparant l’insuline ultra-rapide BioChaperone® Lispro à Novolog® et Fiasp® chez des personnes avec un diabète de type 1](https://www.adocia.com/fr/medias-publications/adocia-annonce-les-resultats-principaux-positifs-dune-etude-comparant-linsuline-ultra-rapide-biochaperone-lispro-a-novolog-et-fiasp-chez-des-personnes-avec-un-diabe/)
- [Adocia announces positive topline study results comparing ultra-rapid insulin BioChaperone® Lispro with Novolog® and Fiasp® in people with type 1 diabetes](https://www.adocia.com/medias-publications/adocia-announces-positive-topline-study-results-comparing-ultra-rapid-insulin-biochaperone-lispro-with-novolog-and-fiasp-in-people-with-type-1-diabetes/)
- [Adocia annonce les résultats principaux  d’une étude de Phase 1 de BioChaperone® Glucagon](https://www.adocia.com/fr/medias-publications/adocia-annonce-les-resultats-principaux-dune-etude-de-phase-1-de-biochaperone-glucagon/)
- [Adocia Reports Topline Results of BioChaperone® Glucagon Phase 1 Study](https://www.adocia.com/medias-publications/adocia-reports-topline-results-of-biochaperone-glucagon-phase-1-study/)
- [“Ultra-rapid BioChaperone® Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Excursions vs. Insulin Lispro (LIS) in a 14-Day Treatment Study in Subjects with Type 1 Diabetes (T1DM)” (Poster 964) presented by Dr. Tim Heise, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)](https://www.adocia.com/medias-publications/biochaperone-combo-une-co-formulation-liquide-des-insulines-lispro-et-glargine-presente-un-controle-glycemique-ameliore-par-rapport-a-un-premix-dinsuline-abstract/)
- [Number of shares and voting rights of ADOCIA as of October 31, 2017](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-october-31-2017/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 octobre 2017](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-octobre-2017/)
- [“Ultra-rapid BioChaperone® Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Control vs. Insulin Lispro (LIS) in a14-Day Treatment Study in Subjects with Type 2 Diabetes (T2DM)” (Poster 994) presented by Dr. Tim Heise, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)](https://www.adocia.com/medias-publications/linsuline-ultra-rapide-biochaperone-lispro-ameliore-le-controle-glycemique-postprandial-par-rapport-a-humalog-chez-des-sujets-diabetiques-de-type-1-abstract-cad/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 Septembre 2017](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-septembre-2017/)
- [Number of shares and voting rights of ADOCIA as of September 30, 2017](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-september-30-2017/)
- [Adocia annonce ses résultats financiers pour le troisième trimestre 2017](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-pour-le-troisieme-trimestre-2017/)
- [Number of shares and voting rights of ADOCIA as of August 31, 2017](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-august-31-2017/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 Aout 2017](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-aout-2017/)
- [Adocia annonce deux présentations à l’occasion du 53ème congrès annuel de l’Association Européenne pour l’Etude du Diabète (EASD)](https://www.adocia.com/fr/medias-publications/adocia-annonce-deux-presentations-a-loccasion-du-53eme-congres-annuel-de-lassociation-europeenne-pour-letude-du-diabete-easd/)
- [Adocia Announces Two Data Presentations at the 53rd Annual Meeting of the European Association for the Study of Diabetes](https://www.adocia.com/medias-publications/adocia-announces-two-data-presentations-at-the-53rd-annual-meeting-of-the-european-association-for-the-study-of-diabetes/)
- [Adocia announces appointment of Dr. Stanislav Glezer as Chief Medical Officer](https://www.adocia.com/medias-publications/adocia-announces-appointment-of-dr-stanislav-glezer-as-chief-medical-officer/)
- [Adocia annonce le recrutement du Dr Stanislav Glezer en tant que Directeur Médical](https://www.adocia.com/fr/medias-publications/adocia-annonce-le-recrutement-du-dr-stanislav-glezer-en-tant-que-directeur-medical/)
- [Adocia annonce ses résultats financiers  pour le premier semestre 2017](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-pour-le-premier-semestre-2017/)
- [Adocia presents first half 2017 financial results](https://www.adocia.com/medias-publications/adocia-presents-first-half-2017-financial-results/)
- [Number of shares and voting rights of ADOCIA as of June 30, 2017](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-june-30-2017/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 juin 2017](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-juin-2017/)
- [Number of shares and voting rights of ADOCIA as of May 31, 2017](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-may-31-2017/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mai 2017](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mai-2017/)
- [“Preclinical Efficacy of a Stable Aqueous Formulation of Human Glucagon with BioChaperone® Technology (BC GLU)” (Poster 1150), presented by Dr Grégory Meiffren, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)](https://www.adocia.com/medias-publications/preclinical-efficacy-of-a-stable-aqueous-formulation-of-human-glucagon-with-biochaperone-technology-bc-glu-poster-1150-presented-by-dr-gregory-meiffren-77th-scientific-se/)
- [“Profil pharmacodynamique de BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, chez des sujets diabétiques de type 2” (Abstract CAD-19), presented by Dr. Martin Gaudier, 2017, Société Francophone du Diabète (France)](https://www.adocia.com/medias-publications/proportional-dose-exposure-relationship-of-ultra-rapid-biochaperone-lispro-bclis-in-healthy-japanese-subjects-poster-996-presented-by-dr-gregory-meiffren-77th-scientific/)
- [“BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, présente un contrôle glycémique amélioré par rapport à un premix d’insuline.” (Abstract CAD-19), presented by Dr. Claire Megret, 2017, Société Francophone du Diabète (France)](https://www.adocia.com/medias-publications/ultra-rapid-biochaperone-lispro-ameliorates-postprandial-blood-glucose-ppg-control-compared-to-humalog-in-subjects-with-type-1-diabetes-mellitus-poster-pi005-presented-by-2/)
- [Adocia initie une étude clinique de Phase 1b sur la  dose-proportionnalité de BioChaperone® Combo  chez des personnes diabétiques de type 2](https://www.adocia.com/fr/medias-publications/adocia-initie-une-etude-clinique-de-phase-1b-sur-la-dose-proportionnalite-de-biochaperone-combo-chez-des-personnes-diabetiques-de-type-2/)
- [Adocia Initiates a Phase 1b Clinical Study on the  Dose-Proportionality of BioChaperone® Combo in  People with Type 2 Diabetes](https://www.adocia.com/medias-publications/adocia-initiates-a-phase-1b-clinical-study-on-the-dose-proportionality-of-biochaperone-combo-in-people-with-type-2-diabetes/)
- [Adocia Announces Positive Topline Results from a  Meal-Test Clinical Study of BioChaperone® Combo  in People with Type 2 Diabetes](https://www.adocia.com/medias-publications/adocia-announces-positive-topline-results-from-a-meal-test-clinical-study-of-biochaperone-combo-in-people-with-type-2-diabetes/)
- [Adocia annonce les résultats principaux positifs d’une étude clinique mesurant l’effet postprandial  de BioChaperone® Combo  chez des personnes diabétiques de type 2](https://www.adocia.com/fr/medias-publications/adocia-annonce-les-resultats-principaux-positifs-dune-etude-clinique-mesurant-leffet-postprandial-de-biochaperone-combo-chez-des-personnes-diabetiques-de-type-2/)
- [Adocia initiates a study comparing ultra-rapid insulin BioChaperone® Lispro U100 with Fiasp® and Novolog® administered with an insulin pump](https://www.adocia.com/medias-publications/adocia-initiates-a-study-comparing-ultra-rapid-insulin-biochaperone-lispro-u100-with-fiasp-and-novolog-administered-with-an-insulin-pump/)
- [Adocia initie une étude clinique comparant l’insuline ultra-rapide BioChaperone® Lispro U100 à Fiasp® et Novolog®, administrés par une pompe à insuline](https://www.adocia.com/fr/medias-publications/adocia-initie-une-etude-clinique-comparant-linsuline-ultra-rapide-biochaperone-lispro-u100-a-fiasp-et-novolog-administres-par-une-pompe-a-insuline/)
- [Adocia initie une première étude clinique chez l’homme de BioChaperone® Glucagon](https://www.adocia.com/fr/medias-publications/adocia-initie-une-premiere-etude-clinique-chez-lhomme-de-biochaperone-glucagon/)
- [Adocia Launches First-in-Man Clinical Study  of BioChaperone® Glucagon](https://www.adocia.com/medias-publications/adocia-launches-first-in-man-clinical-study-of-biochaperone-glucagon/)
- [Adocia fera une présentation à la conférence 2017 Global Healthcare de Jefferies à New York](https://www.adocia.com/fr/medias-publications/adocia-fera-une-presentation-a-la-conference-2017-global-healthcare-de-jefferies-a-new-york/)
- [Adocia Announces Six Data Presentations at the American Diabetes Association® 77th Scientific Sessions](https://www.adocia.com/medias-publications/adocia-announces-six-data-presentations-at-the-american-diabetes-association-77th-scientific-sessions/)
- [Adocia annonce six présentations à l’occasion des 77èmes Sessions Scientifiques de l’American Diabetes Association®](https://www.adocia.com/fr/medias-publications/adocia-annonce-six-presentations-a-loccasion-des-77emes-sessions-scientifiques-de-lamerican-diabetes-association/)
- [Adocia to Present at the Jefferies 2017 Global Healthcare Conference in New York](https://www.adocia.com/medias-publications/adocia-to-present-at-the-jefferies-2017-global-healthcare-conference-in-new-york/)
- [Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris](https://www.adocia.com/medias-publications/adocia-to-hold-its-annual-shareholders-meeting-on-june-27-2017-in-paris/)
- [Adocia annonce la tenue de son assemblée générale annuelle le 27 juin 2017 à Paris](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-tenue-de-son-assemblee-generale-annuelle-le-27-juin-2017-a-paris/)
- [Number of shares and voting rights of ADOCIA as of April 30, 2017](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-april-30-2017/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 avril 2017](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-30-avril-2017/)
- [Adocia annonce la mise à disposition de  son document de référence pour l’année 2016  contenant le rapport financier annuel et le rapport de gestion](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-mise-a-disposition-de-son-document-de-reference-pour-lannee-2016-contenant-le-rapport-financier-annuel-et-le-rapport-de-gestion/)
- [Adocia announces the release  of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016](https://www.adocia.com/medias-publications/adocia-announces-the-release-of-its-reference-document-containing-the-annual-financial-report-and-the-management-report-for-the-year-2016/)
- [Adocia announces first quarter 2017 financial results](https://www.adocia.com/medias-publications/adocia-announces-first-quarter-2017-financial-results/)
- [Adocia annonce ses résultats financiers  du 1er trimestre 2017](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-du-1er-trimestre-2017/)
- [Adocia : information relative au nombre d'actions et de droits de vote en date du 31 mars 2017](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-31-mars-2017/)
- [Number of shares and voting rights of Adocia as of March 31, 2017](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-march-31-2017/)
- [ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 28 février 2017](https://www.adocia.com/fr/medias-publications/adocia-information-relative-au-nombre-dactions-et-de-droits-de-vote-en-date-du-28-fevrier-2017/)
- [Number of shares and voting rights of ADOCIA as of February 28, 2017](https://www.adocia.com/medias-publications/number-of-shares-and-voting-rights-of-adocia-as-of-february-28-2017/)
- [ADOCIA announced its financial results for 2016  and its perspectives for 2017](https://www.adocia.com/medias-publications/adocia-announced-its-financial-results-for-2016-and-its-perspectives-for-2017/)
- [ADOCIA annonce ses résultats annuels 2016  et ses perspectives pour 2017](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-annuels-2016-et-ses-perspectives-pour-2017/)
- [ADOCIA annonce son chiffre d’affaires et sa position de trésorerie pour l’année 2016](https://www.adocia.com/fr/medias-publications/adocia-annonce-son-chiffre-daffaires-et-sa-position-de-tresorerie-pour-lannee-2016/)
- [Adocia announces its revenue and cash position for 2016](https://www.adocia.com/medias-publications/adocia-announces-its-revenue-and-cash-position-for-2016/)
- [Adocia to Present at the Leerink Partners 6th Annual Global Healthcare Conference](https://www.adocia.com/medias-publications/adocia-to-present-at-the-leerink-partners-6th-annual-global-healthcare-conference/)
- [Adocia to hold conference call on Monday January 30, 2017](https://www.adocia.com/medias-publications/adocia-to-hold-conference-call-on-monday-january-30-2017/)
- [Adocia organise une conférence téléphonique  le lundi 30 Janvier 2017](https://www.adocia.com/fr/medias-publications/adocia-organise-une-conference-telephonique-le-lundi-30-janvier-2017/)
- [Adocia announces the termination by Eli Lilly of the collaboration on BioChaperone Lispro](https://www.adocia.com/medias-publications/adocia-announces-the-termination-by-eli-lilly-of-the-collaboration-on-biochaperone-lispro/)
- [Adocia annonce la décision d’Eli Lilly de mettre fin à la collaboration sur BioChaperone Lispro](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-decision-deli-lilly-de-mettre-fin-a-la-collaboration-sur-biochaperone-lispro/)
- [Adocia to hold conference call providing  an update on its programs](https://www.adocia.com/medias-publications/adocia-to-hold-conference-call-providing-an-update-on-its-programs/)
- [Adocia organise une conférence téléphonique pour faire une mise à jour de ses programmes](https://www.adocia.com/fr/medias-publications/adocia-organise-une-conference-telephonique-pour-faire-une-mise-a-jour-de-ses-programmes/)
- [Adocia announces the transformation of its business model to increase the value of its projects](https://www.adocia.com/medias-publications/adocia-announces-the-transformation-of-its-business-model-to-increase-the-value-of-its-projects/)
- [Adocia annonce l’évolution de son modèle économique afin d’augmenter la valeur de ses projets](https://www.adocia.com/fr/medias-publications/adocia-annonce-levolution-de-son-modele-economique-afin-daugmenter-la-valeur-de-ses-projets/)
- [Bilan semestriel du contrat de liquidité Adocia conclu avec la société Kepler Chevreux](https://www.adocia.com/fr/medias-publications/bilan-semestriel-du-contrat-de-liquidite-adocia-conclu-avec-la-societe-kepler-chevreux/)
- [Half year report on Adocia’s liquidity agreement  with Kepler Chevreux](https://www.adocia.com/medias-publications/half-year-report-on-adocias-liquidity-agreement-with-kepler-chevreux/)
- [Adocia announces two new multi-hormonal combination projects for the treatment of type 1 diabetes](https://www.adocia.com/medias-publications/adocia-announces-two-new-multi-hormonal-combination-projects-for-the-treatment-of-type-1-diabetes/)
- [Adocia annonce deux nouveaux projets de combinaisons multi-hormonales pour le traitement du diabète de type 1](https://www.adocia.com/fr/medias-publications/adocia-annonce-deux-nouveaux-projets-de-combinaisons-multi-hormonales-pour-le-traitement-du-diabete-de-type-1/)
- [Adocia annonce son calendrier financier pour l’année 2017](https://www.adocia.com/fr/medias-publications/adocia-annonce-son-calendrier-financier-pour-lannee-2017/)
- [Adocia announces its financial calendar for 2017](https://www.adocia.com/medias-publications/adocia-announces-its-financial-calendar-for-2017/)
- [Adocia et Eli Lilly annoncent conjointement le succès d’une étude évaluant BioChaperone Lispro](https://www.adocia.com/fr/medias-publications/adocia-et-eli-lilly-annoncent-conjointement-le-succes-dune-etude-evaluant-biochaperone-lispro/)
- [Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro](https://www.adocia.com/medias-publications/adocia-and-lilly-announce-successful-completion-of-an-insulin-pump-study-with-biochaperone-lispro/)
- [Adocia to Participate in Upcoming Investor Conferences](https://www.adocia.com/medias-publications/adocia-to-participate-in-upcoming-investor-conferences/)
- [Adocia participera prochainement à deux conférences dédiées aux investisseurs](https://www.adocia.com/fr/medias-publications/adocia-participera-prochainement-a-deux-conferences-dediees-aux-investisseurs/)
- [Adocia receives the 1st prize for ‘Profitable Growth’ and the 3rd ‘Technology Fast 50’ prize as part of the 2016 Deloitte In Extenso Technology Fast 50 Grand Rhône Alpes](https://www.adocia.com/medias-publications/adocia-receives-the-1st-prize-for-profitable-growth-and-the-3rd-technology-fast-50-prize-as-part-of-the-2016-deloitte-in-extenso-technology-fast-50-grand-rhone-alpe/)
- [Adocia lauréat du 1er prix ‘Croissance Rentable’ et du 3ème prix ‘Technology Fast 50’ au palmarès Grand Rhône Alpes 2016 du Deloitte In Extenso Technology Fast 50](https://www.adocia.com/fr/medias-publications/adocia-laureat-du-1er-prix-croissance-rentable-et-du-3eme-prix-technology-fast-50-au-palmares-grand-rhone-alpes-2016-du-deloitte-in-extenso-technology-fast-50/)
- [Adocia Announces Positive Topline Results from a Phase 1b Clinical Trial Measuring the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100](https://www.adocia.com/medias-publications/adocia-announces-positive-topline-results-from-a-phase-1b-clinical-trial-measuring-the-post-meal-effect-of-rapid-acting-human-insulin-hinsbet-u100/)
- [Adocia annonce les résultats principaux positifs d’une étude clinique de Phase 1b mesurant l’effet postprandial de son insuline humaine à action rapide, HinsBet® U100](https://www.adocia.com/fr/medias-publications/adocia-annonce-les-resultats-principaux-positifs-dune-etude-clinique-de-phase-1b-mesurant-leffet-postprandial-de-son-insuline-humaine-a-action-rapide-hinsbet-u100/)
- [Adocia announces third quarter 2016 financial results](https://www.adocia.com/medias-publications/adocia-announces-third-quarter-2016-financial-results/)
- [ADOCIA annonce ses résultats financiers pour le 3ème trimestre 2016](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-pour-le-3eme-trimestre-2016/)
- [Adocia received the EY Global Company Award for the Auvergne Rhône-Alpes region](https://www.adocia.com/medias-publications/adocia-received-the-ey-global-company-award-for-the-auvergne-rhone-alpes-region/)
- [Adocia reçoit le prix EY de l’Entreprise Globale pour la région Auvergne Rhône-Alpes](https://www.adocia.com/fr/medias-publications/adocia-recoit-le-prix-ey-de-lentreprise-globale-pour-la-region-auvergne-rhone-alpes/)
- [Adocia initie une nouvelle étude clinique sur BioChaperone® Combo, sa combinaison d’insuline basale glargine et d’insuline prandiale lispro, chez des sujets diabétiques de type 2](https://www.adocia.com/fr/medias-publications/adocia-initie-une-nouvelle-etude-clinique-sur-biochaperone-combo-sa-combinaison-dinsuline-basale-glargine-et-dinsuline-prandiale-lispro-chez-des-sujets-diabetiques-de-type-2/)
- [Adocia launches a new clinical study of BioChaperone® Combo, its combination of long-acting insulin glargine and fast-acting insulin lispro, in people with type 2 diabetes](https://www.adocia.com/medias-publications/adocia-launches-a-new-clinical-study-of-biochaperone-combo-its-combination-of-long-acting-insulin-glargine-and-fast-acting-insulin-lispro-in-people-with-type-2-diabetes/)
- [Adocia organise une conférence téléphonique pour présenter un bilan de ses activités et ses perspectives de croissance Mercredi 21 septembre 2016 à 18h (CET)](https://www.adocia.com/fr/medias-publications/adocia-organise-une-conference-telephonique-pour-presenter-un-bilan-de-ses-activites-et-ses-perspectives-de-croissance-mercredi-21-septembre-2016-a-18h-cet/)
- [Adocia to hold conference call for investors to provide business update and growth perspectives Wednesday September 21st, 2016 at 6 PM (CET)](https://www.adocia.com/medias-publications/adocia-to-hold-conference-call-for-investors-to-provide-business-update-and-growth-perspectives-wednesday-september-21st-2016-at-6-pm-cet/)
- [BioChaperone® Combo, a co-formulation of lispro and glargine, demonstrates both prandial and basal insulin time-action profiles in a single injection in type 2 diabetes, Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)](https://www.adocia.com/medias-publications/biochaperone-combo-a-co-formulation-of-lispro-and-glargine-demonstrates-both-prandial-and-basal-insulin-time-action-profiles-in-a-single-injection-in-type-2-diabetes-dr-s-bruce-52nd-europe/)
- [Adocia présentera des données cliniques validant le potentiel de la technologie BioChaperone® au congrès annuel de l’EASD](https://www.adocia.com/fr/medias-publications/adocia-presentera-des-donnees-cliniques-validant-le-potentiel-de-la-technologie-biochaperone-au-congres-annuel-de-leasd/)
- [Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting](https://www.adocia.com/medias-publications/adocia-to-present-clinical-data-validating-biochaperone-technology-at-the-2016-easd-annual-meeting/)
- [Adocia announces new BioChaperone program combining a basal insulin and GLP-1s](https://www.adocia.com/medias-publications/adocia-announces-new-biochaperone-program-combining-a-basal-insulin-and-glp-1s/)
- [Adocia annonce un nouveau programme BioChaperone combinant une insuline basale avec des GLP-1s](https://www.adocia.com/fr/medias-publications/adocia-annonce-un-nouveau-programme-biochaperone-combinant-une-insuline-basale-avec-des-glp-1s/)
- [Adocia announces topline results of Indian Phase 3 trial of BioChaperone PDGF for diabetic foot ulcer](https://www.adocia.com/medias-publications/adocia-announces-topline-results-of-indian-phase-3-trial-of-biochaperone-pdgf-for-diabetic-foot-ulcer/)
- [Adocia annonce les résultats principaux d’une étude clinique de Phase 3 en Inde de BioChaperone PDGF pour l’ulcère du pied diabétique](https://www.adocia.com/fr/medias-publications/adocia-annonce-les-resultats-principaux-dune-etude-clinique-de-phase-3-en-inde-de-biochaperone-pdgf-pour-lulcere-du-pied-diabetique/)
- [Adocia presents first half 2016 financial results](https://www.adocia.com/medias-publications/adocia-presents-first-half-2016-financial-results/)
- [Adocia annonce ses résultats financiers pour le premier semestre 2016](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-pour-le-premier-semestre-2016/)
- [Half year report on Adocia’s liquidity agreement with Kepler Capital Markets](https://www.adocia.com/medias-publications/half-year-report-on-adocias-liquidity-agreement-with-kepler-capital-markets-3/)
- [“A Pilot Bioequivalence (BE) Study of Ultra-Rapid Concentrated BioChaperone® Lispro (BCLIS) U200 to BCLIS U100”, (Abstract 2242-PUB), presented by Dr. Grit Anderson, 76th Scientific Sessions of the American Diabetes Association, 10-14 June 2016, New Orleans, LO (USA)](https://www.adocia.com/medias-publications/pharmacodynamic-pd-profile-of-biochaperone-combo-bc-combo-a-new-combination-of-rapid-acting-and-long-acting-insulin-in-subjects-with-type-2-diabetes-mellitus-t2dm-post/)
- [“Pharmacodynamic (PD) Profile of BioChaperone® Combo (BC Combo), a New Combination of Rapid-Acting and Long-Acting Insulin, in Subjects with Type 2 Diabetes Mellitus (T2DM)” (Poster 942), presented by Dr. Simon Bruce, 76th Scientific Sessions American Diabetes Association 11-13 June 2016, New Orleans, LO (USA)](https://www.adocia.com/medias-publications/a-pilot-bioequivalence-be-study-of-ultra-rapid-concentrated-biochaperone-lispro-bclis-u200-to-bclis-u100-abstract-2242-pub-presented-by-dr-grit-anderson-76th-scientif/)
- [Adocia renforce son engagement dans le diabète avec le lancement d'un nouveau projet : BioChaperone Glucagon](https://www.adocia.com/fr/medias-publications/adocia-renforce-son-engagement-dans-le-diabete-avec-le-lancement-dun-nouveau-projet-biochaperone-glucagon/)
- [Adocia présentera les données validant le potentiel de la technologie BioChaperone® à l’occasion des 76e sessions scientifiques de l’American Diabetes Association®.](https://www.adocia.com/fr/medias-publications/adocia-presentera-les-donnees-validant-le-potentiel-de-la-technologie-biochaperone-a-loccasion-des-76e-sessions-scientifiques-de-lamerican-diabetes-association/)
- [Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76th Scientific Sessions](https://www.adocia.com/medias-publications/adocia-to-present-data-validating-the-potential-of-biochaperone-technology-at-the-american-diabetes-association-76th-scientific-sessions/)
- [Adocia donnera une présentation à l’occasion de la Jefferies Global Healthcare Conference 2016](https://www.adocia.com/fr/medias-publications/adocia-donnera-une-presentation-a-loccasion-de-la-jefferies-global-healthcare-conference-2016/)
- [Adocia to Present at the Jefferies 2016 Global Healthcare Conference](https://www.adocia.com/medias-publications/adocia-to-present-at-the-jefferies-2016-global-healthcare-conference/)
- [Adocia et Lilly annoncent les résultats principaux positifs d’une étude de phase 1 évaluant l’insuline ultrarapide BioChaperone Lispro U100 chez des sujets japonais](https://www.adocia.com/fr/medias-publications/adocia-et-lilly-annoncent-les-resultats-principaux-positifs-dune-etude-de-phase-1-evaluant-linsuline-ultrarapide-biochaperone-lispro-u100-chez-des-sujets-japonais/)
- [Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects](https://www.adocia.com/medias-publications/adocia-and-lilly-announce-positive-topline-results-from-a-phase-1-study-evaluating-ultra-rapid-insulin-biochaperone-lispro-u100-in-healthy-japanese-subjects/)
- [Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris](https://www.adocia.com/medias-publications/adocia-to-hold-its-annual-shareholders-meeting-on-june-21-2016-in-paris/)
- [Adocia annonce la tenue de son assemblée générale annuelle le 21 juin 2016 à Paris](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-tenue-de-son-assemblee-generale-annuelle-le-21-juin-2016-a-paris/)
- [Adocia strengthens its BioChaperone Combo patent portfolio](https://www.adocia.com/medias-publications/adocia-strengthens-its-biochaperone-combo-patent-portfolio/)
- [Adocia renforce son portefeuille de brevets portant sur BioChaperone Combo](https://www.adocia.com/fr/medias-publications/adocia-renforce-son-portefeuille-de-brevets-portant-sur-biochaperone-combo/)
- [Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes](https://www.adocia.com/medias-publications/adocia-and-lilly-announce-positive-topline-results-from-a-phase-1b-study-of-repeated-administration-of-ultra-rapid-biochaperone-lispro-u100-in-people-with-type-2-diabetes/)
- [Adocia et Lilly annoncent les principaux résultats positifs d’une étude de Phase 1b sur l’administration répétée de l’insuline ultra-rapide BioChaperone Lispro U100 chez des personnes diabétiques de type 2](https://www.adocia.com/fr/medias-publications/adocia-et-lilly-annoncent-les-principaux-resultats-positifs-dune-etude-de-phase-1b-sur-ladministration-repetee-de-linsuline-ultra-rapide-biochaperone-lispro-u100-chez-des-pe/)
- [Adocia annonce ses résultats financiers du 1er trimestre 2016](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-du-1er-trimestre-2016/)
- [Adocia announces first quarter 2016 results](https://www.adocia.com/medias-publications/adocia-announces-first-quarter-2016-results/)
- [Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100](https://www.adocia.com/medias-publications/adocia-initiates-a-phase-1-2-clinical-trial-on-the-post-meal-effect-of-rapid-acting-human-insulin-hinsbet-u100/)
- [Adocia lance une étude clinique de phase 1/2 évaluant l’effet postprandial de l’insuline humaine à action rapide HinsBet® U100](https://www.adocia.com/fr/medias-publications/adocia-lance-une-etude-clinique-de-phase-1-2-evaluant-leffet-postprandial-de-linsuline-humaine-a-action-rapide-hinsbet-u100/)
- [Adocia announces the release of its Reference Document,  for the year 2015](https://www.adocia.com/medias-publications/adocia-announces-the-release-of-its-reference-document-for-the-year-2015/)
- [Adocia annonce la mise à disposition de son document de référence pour l'année 2015](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-mise-a-disposition-de-son-document-de-reference-pour-lannee-2015/)
- [ADOCIA confirms its eligibility for the PEA – PME](https://www.adocia.com/medias-publications/adocia-confirms-its-eligibility-for-the-pea-pme/)
- [Adocia accueille des experts du diabète de renommée internationale au sein de son nouveau Conseil Médical](https://www.adocia.com/fr/medias-publications/adocia-accueille-des-experts-du-diabete-de-renommee-internationale-au-sein-de-son-nouveau-conseil-medical/)
- [Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board](https://www.adocia.com/medias-publications/adocia-welcomes-internationally-renowned-diabetes-experts-to-inaugural-medical-advisory-board/)
- [Résultats Annuels 2015](https://www.adocia.com/fr/medias-publications/resultats-annuels-2015/)
- [Annual Financial Results 2015](https://www.adocia.com/medias-publications/annual-financial-results-2015/)
- [Adocia et Lilly annoncent les résultats principaux positifs d’une étude de Phase 1b sur l’administration répétée d’insuline ultra-rapide BioChaperone Lispro chez des patients diabétiques de type 1](https://www.adocia.com/fr/medias-publications/adocia-et-lilly-annoncent-les-resultats-principaux-positifs-dune-etude-de-phase-1b-sur-ladministration-repetee-dinsuline-ultra-rapide-biochaperone-lispro-chez-des-patients-d/)
- [Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes](https://www.adocia.com/medias-publications/adocia-and-lilly-announce-positive-topline-results-from-a-phase-1b-study-of-repeated-administration-of-ultra-rapid-biochaperone-lispro-in-patients-with-type-1-diabetes/)
- [ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015](https://www.adocia.com/medias-publications/adocia-announced-significant-revenue-growth-with-eur-36-9-million-eur-0-7-million-in-2014-in-revenue-and-a-solid-cash-position-of-eur-72-million-as-of-december-31-2015/)
- [ADOCIA annonce un chiffre d’affaires en très forte progression à 36,9 millions d’euros (0,7 million d’euros en 2014) et une solide](https://www.adocia.com/fr/medias-publications/adocia-annonce-un-chiffre-daffaires-en-tres-forte-progression-a-369-millions-deuros-07-million-deuros-en-2014-et-une-solide/)
- [Adocia donnera une présentation lors de la Conférence Leerink Global Healthcare 2016](https://www.adocia.com/fr/medias-publications/adocia-donnera-une-presentation-lors-de-la-conference-leerink-global-healthcare-2016/)
- [Adocia to Present at the 2016 Leerink Global Healthcare Conference](https://www.adocia.com/medias-publications/adocia-to-present-at-the-2016-leerink-global-healthcare-conference/)
- [Adocia and Lilly initiate Phase 1b study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects](https://www.adocia.com/medias-publications/adocia-and-lilly-initiate-phase-1b-study-evaluating-ultra-rapid-insulin-biochaperone-lispro-u100-in-healthy-japanese-subjects/)
- [Adocia et Lilly initient une étude de phase 1b évaluant l’insuline ultra rapide BioChaperone Lispro chez des sujets sains japonais](https://www.adocia.com/fr/medias-publications/adocia-et-lilly-initient-une-etude-de-phase-1b-evaluant-linsuline-ultra-rapide-biochaperone-lispro-chez-des-sujets-sains-japonais/)
- [Half year report on Adocia' s liquidity agreement with Kepler Capital Markets](https://www.adocia.com/medias-publications/half-year-report-on-adocia-s-liquidity-agreement-with-kepler-capital-markets/)
- [Bilan semestriel du contrat de liquidité conclu avec la société Kepler Capital Markets](https://www.adocia.com/fr/medias-publications/bilan-semestriel-du-contrat-de-liquidite-conclu-avec-la-societe-kepler-capital-markets/)
- [Adocia announces its financial calendar for 2016](https://www.adocia.com/medias-publications/adocia-announces-its-financial-calendar-for-2016/)
- [Adocia annonce son calendrier financier pour l’année 2016](https://www.adocia.com/fr/medias-publications/adocia-annonce-son-calendrier-financier-pour-lannee-2016/)
- [Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016](https://www.adocia.com/medias-publications/adocia-to-hold-conference-call-for-investors-to-provide-2015-annual-business-update-and-perspectives-for-2016/)
- [Adocia vous convie à une conférence téléphonique Jeudi 17 décembre 2015 à 17h45 (CET) Bilan 2015 et Perspectives 2016](https://www.adocia.com/fr/medias-publications/adocia-vous-convie-a-une-conference-telephonique-jeudi-17-decembre-2015-a-17h45-cet-bilan-2015-et-perspectives-2016/)
- [Adocia and Lilly report positive results of a pilot bioequivalence study comparing BioChaperone Lispro U200 to BioChaperone Lispro U100](https://www.adocia.com/medias-publications/adocia-and-lilly-report-positive-results-of-a-pilot-bioequivalence-study-comparing-biochaperone-lispro-u200-to-biochaperone-lispro-u100/)
- [Adocia et Lilly annoncent les résultats positifs d’une étude pilote de bioéquivalence comparant BioChaperone Lispro U200 à BioChaperone Lispro U100](https://www.adocia.com/fr/medias-publications/adocia-et-lilly-annoncent-les-resultats-positifs-dune-etude-pilote-de-bioequivalence-comparant-biochaperone-lispro-u200-a-biochaperone-lispro-u100/)
- [Adocia annonce des résultats positifs de phase 1b sur BioChaperone® Combo chez les patients diabétiques de type 2](https://www.adocia.com/fr/medias-publications/adocia-annonce-des-resultats-positifs-de-phase-1b-sur-biochaperone-combo-chez-les-patients-diabetiques-de-type-2/)
- [Adocia announces positive Phase 1b results of BioChaperone® Combo in patients with type 2 diabetes](https://www.adocia.com/medias-publications/adocia-announces-positive-phase-1b-results-of-biochaperone-combo-in-patients-with-type-2-diabetes/)
- [Adocia receives the Deloitte In Extenso Technology Fast 50 Prize in the "Listed Company" category for the Grand Rhône-Alpes region](https://www.adocia.com/medias-publications/adocia-receives-the-deloitte-in-extenso-technology-fast-50-prize-in-the-listed-company-category-for-the-grand-rhone-alpes-region/)
- [Adocia reçoit le prix Deloitte In Extenso Technology Fast 50 « Entreprise Cotée » pour la région Grand Rhône-Alpes](https://www.adocia.com/fr/medias-publications/adocia-recoit-le-prix-deloitte-in-extenso-technology-fast-50-entreprise-cotee-pour-la-region-grand-rhone-alpes/)
- [Adocia announces positive Phase 1b results on the post-meal effect of BioChaperone® Combo in patients with type 1 diabetes](https://www.adocia.com/medias-publications/adocia-announces-positive-phase-1b-results-on-the-post-meal-effect-of-biochaperone-combo-in-patients-with-type-1-diabetes/)
- [Adocia annonce les résultats positifs d’une étude clinique de Phase 1b évaluant l’effet après un repas de BioChaperone® Combo chez les patients diabétiques de type 1](https://www.adocia.com/fr/medias-publications/adocia-annonce-les-resultats-positifs-dune-etude-clinique-de-phase-1b-evaluant-leffet-apres-un-repas-de-biochaperone-combo-chez-les-patients-diabetiques-de-type-1/)
- [ADOCIA Reports Third Quarter 2015 Financial Results](https://www.adocia.com/medias-publications/adocia-reports-third-quarter-2015-financial-results/)
- [ADOCIA annonce ses résultats financiers  pour le 3ème trimestre 2015](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-financiers-pour-le-3eme-trimestre-2015/)
- [Adocia et Lilly initient une étude de phase 1b évaluant l’insuline ultra rapide BioChaperone Lispro chez des patients diabétiques de type 1 utilisant une pompe à insuline](https://www.adocia.com/fr/medias-publications/adocia-et-lilly-initient-une-etude-de-phase-1b-evaluant-linsuline-ultra-rapide-biochaperone-lispro-chez-des-patients-diabetiques-de-type-1-utilisant-une-pompe-a-insuline/)
- [Adocia and Lilly initiate a Phase 1b study evaluating  ultra-rapid BioChaperone Lispro in patients with type 1 diabetes using insulin pump therapy](https://www.adocia.com/medias-publications/adocia-and-lilly-initiate-a-phase-1b-study-evaluating-ultra-rapid-biochaperone-lispro-in-patients-with-type-1-diabetes-using-insulin-pump-therapy/)
- [Adocia annonce la tenue d’une assemblée générale extraordinaire le 12 novembre 2015 à Lyon](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-tenue-dune-assemblee-generale-extraordinaire-le-12-novembre-2015-a-lyon/)
- [Adocia to hold an extraordinary shareholders’ meeting on November 12, 2015 in Lyon](https://www.adocia.com/medias-publications/adocia-to-hold-an-extraordinary-shareholders-meeting-on-november-12-2015-in-lyon/)
- [Adocia et Lilly initient une nouvelle étude de phase 1b sur l’administration répétée d’insuline ultra-rapide BioChaperone Lispro chez des patients diabétiques  de type 2](https://www.adocia.com/fr/medias-publications/adocia-et-lilly-initient-une-nouvelle-etude-de-phase-1b-sur-ladministration-repetee-dinsuline-ultra-rapide-biochaperone-lispro-chez-des-patients-diabetiques-de-type-2/)
- [Adocia and Lilly initiate a new Phase 1b study of repeat administration of ultra-rapid BioChaperone Lispro in patients with type 2 diabetes](https://www.adocia.com/medias-publications/adocia-and-lilly-initiate-a-new-phase-1b-study-of-repeat-administration-of-ultra-rapid-biochaperone-lispro-in-patients-with-type-2-diabetes/)
- [ADOCIA : apport complémentaire au contrat de liquidité](https://www.adocia.com/fr/medias-publications/adocia-apport-complementaire-au-contrat-de-liquidite/)
- [ADOCIA:  additional contribution to the liquidity agreement](https://www.adocia.com/medias-publications/adocia-additional-contribution-to-the-liquidity-agreement/)
- [Adocia et Lilly lancent une nouvelle étude de phase 1b sur l’administration répétée d’insuline ultra-rapide  BioChaperone Lispro chez des diabétiques de type 1](https://www.adocia.com/fr/medias-publications/adocia-et-lilly-lancent-une-nouvelle-etude-de-phase-1b-sur-ladministration-repetee-dinsuline-ultra-rapide-biochaperone-lispro-chez-des-diabetiques-de-type-1/)
- [Adocia and Lilly initiate new Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes](https://www.adocia.com/medias-publications/adocia-and-lilly-initiate-new-phase-1b-study-of-repeated-administration-of-ultra-rapid-biochaperone-lispro-in-patients-with-type-1-diabetes/)
- [Adocia présente des résultats financiers au premier semestre 2015 en forte progression](https://www.adocia.com/fr/medias-publications/adocia-presente-des-resultats-financiers-au-premier-semestre-2015-en-forte-progression/)
- [Adocia lance deux études cliniques sur sa combinaison de l’insuline lente glargine et de l’insuline rapide lispro, BioChaperone® Combo](https://www.adocia.com/fr/medias-publications/adocia-lance-deux-etudes-cliniques-sur-sa-combinaison-de-linsuline-lente-glargine-et-de-linsuline-rapide-lispro-biochaperone-combo/)
- [Adocia initiates two clinical studies on its combination of  long-acting insulin glargine and fast-acting insulin lispro, BioChaperone® Combo](https://www.adocia.com/medias-publications/adocia-initiates-two-clinical-studies-on-its-combination-of-long-acting-insulin-glargine-and-fast-acting-insulin-lispro-biochaperone-combo/)
- [Adocia and Lilly report positive Phase 1b topline results  on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes](https://www.adocia.com/medias-publications/adocia-and-lilly-report-positive-phase-1b-topline-results-on-the-post-meal-effect-of-ultra-rapid-biochaperone-lispro-in-patients-with-type-1-diabetes/)
- [ADOCIA et Lilly annoncent des résultats positifs de phase 1b sur l’effet postprandial de l'insuline ultra-rapide BioChaperone Lispro chez des diabétiques de type 1](https://www.adocia.com/fr/medias-publications/adocia-et-lilly-annoncent-des-resultats-positifs-de-phase-1b-sur-leffet-postprandial-de-linsuline-ultra-rapide-biochaperone-lispro-chez-des-diabetiques-de-type-1/)
- [Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices](https://www.adocia.com/medias-publications/adocia-is-now-integrated-into-the-cac-mid-60-and-sbf-120-indices/)
- [Adocia intègre les indices CAC Mid 60 et SBF 120](https://www.adocia.com/fr/medias-publications/adocia-integre-les-indices-cac-mid-60-et-sbf-120/)
- [“Ultra-Rapid BioChaperone® Insulin Lispro (BC LIS): Linear Dose-Response and Faster Absorption than Insulin Lispro (LIS)” (Poster 979), presented by Dr. Grit Anderson, 75th Scientific Sessions of the American Diabetes Association, 5-9 June 2015, Boston, MA (USA)](https://www.adocia.com/medias-publications/ultra-rapid-biochaperone-insulin-lispro-bc-lis-linear-dose-response-and-faster-absorption-than-insulin-lispro-lis-poster-979-presented-by-dr-grit-anderson-75th-scient/)
- [Adocia présentera des résultats cliniques positifs pour BioChaperone® Lispro lors des 75ème Sessions Scientifiques de l’American Diabetes Association le 6 juin 2015](https://www.adocia.com/fr/medias-publications/adocia-presentera-des-resultats-cliniques-positifs-pour-biochaperone-lispro-lors-des-75eme-sessions-scientifiques-de-lamerican-diabetes-association-le-6-juin-2015/)
- [Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015](https://www.adocia.com/medias-publications/adocia-to-present-positive-clinical-results-for-biochaperone-lispro-at-the-american-diabetes-association-75th-scientific-sessions-on-june-6th-2015/)
- [Adocia présentera à la conférence Global Healthcare de Jefferies en 2015 à New-York City (USA)](https://www.adocia.com/fr/medias-publications/adocia-presentera-a-la-conference-global-healthcare-de-jefferies-en-2015-a-new-york-city-usa/)
- [Adocia to Present at the Jefferies 2015 Global Healthcare Conference in New-York City (USA)](https://www.adocia.com/medias-publications/adocia-to-present-at-the-jefferies-2015-global-healthcare-conference-in-new-york-city-usa/)
- [Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014](https://www.adocia.com/medias-publications/adocia-announces-the-release-of-its-reference-document-containing-the-annual-financial-report-for-the-year-2014/)
- [Adocia annonce la mise à disposition de  son document de référence pour l’année 2014  contenant le rapport financier annuel](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-mise-a-disposition-de-son-document-de-reference-pour-lannee-2014-contenant-le-rapport-financier-annuel/)
- [Adocia is now integrated into the EnterNext Tech 40 Index](https://www.adocia.com/medias-publications/adocia-is-now-integrated-into-the-enternext-tech-40-index/)
- [Adocia intègre l’indice Tech 40 d’EnterNext](https://www.adocia.com/fr/medias-publications/adocia-integre-lindice-tech-40-denternext/)
- [Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon](https://www.adocia.com/medias-publications/adocia-to-hold-its-annual-shareholders-meeting-on-may-27-2015-in-lyon/)
- [Adocia annonce la tenue de son assemblée générale annuelle le 27 mai 2015 à Lyon](https://www.adocia.com/fr/medias-publications/adocia-annonce-la-tenue-de-son-assemblee-generale-annuelle-le-27-mai-2015-a-lyon/)
- [Adocia announces first quarter 2015 results](https://www.adocia.com/medias-publications/adocia-announces-first-quarter-2015-results/)
- [Adocia annonce ses résultats du 1er trimestre 2015](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-du-1er-trimestre-2015/)
- [Adocia confirme son éligibilité au PEA - PME](https://www.adocia.com/fr/medias-publications/adocia-confirme-son-eligibilite-au-pea-pme/)
- [Adocia will present its 2014 annual results and its perspectives of growth during a conference call](https://www.adocia.com/medias-publications/adocia-will-present-its-2014-annual-results-and-its-perspectives-of-growth-during-a-conference-call/)
- [ADOCIA présentera ses résultats annuels 2014 et ses perspectives de croissance  lors de la conférence téléphonique du 17 mars 2015](https://www.adocia.com/fr/medias-publications/adocia-presentera-ses-resultats-annuels-2014-et-ses-perspectives-de-croissance-lors-de-la-conference-telephonique-du-17-mars-2015/)
- [Adocia affiche une position de trésorerie consolidée et intensifie son développement clinique](https://www.adocia.com/fr/medias-publications/adocia-affiche-une-position-de-tresorerie-consolidee-et-intensifie-son-developpement-clinique/)
- [Adocia reports a strengthened cash position and intensifies clinical development](https://www.adocia.com/medias-publications/adocia-reports-a-strengthened-cash-position-and-intensifies-clinical-development/)
- [Adocia crée une filiale aux Etats-Unis et a le plaisir d’accueillir Dr Simon Bruce et Stephen Daly](https://www.adocia.com/fr/medias-publications/adocia-cree-une-filiale-aux-etats-unis-et-a-le-plaisir-daccueillir-dr-simon-bruce-et-stephen-daly/)
- [Adocia opens a subsidiary in the USA and is pleased to appoint Simon Bruce, MD and Stephen Daly](https://www.adocia.com/medias-publications/adocia-opens-a-subsidiary-in-the-usa-and-is-pleased-to-appoint-simon-bruce-md-and-stephen-daly/)
- [ADOCIA: annual revenue and net cash position for 2014](https://www.adocia.com/medias-publications/adocia-annual-revenue-and-net-cash-position-for-2014/)
- [ADOCIA : chiffre d’affaires et situation nette de trésorerie pour l’année 2014](https://www.adocia.com/fr/medias-publications/adocia-chiffre-daffaires-et-situation-nette-de-tresorerie-pour-lannee-2014/)
- [ADOCIA : modification des moyens alloués  au contrat de liquidité](https://www.adocia.com/fr/medias-publications/adocia-modification-des-moyens-alloues-au-contrat-de-liquidite/)
- [Adocia:  modification of the means allocated to the liquidity agreement](https://www.adocia.com/medias-publications/adocia-modification-of-the-means-allocated-to-the-liquidity-agreement/)
- [Adocia reports positive results from phase IIa clinical study of fast-acting human insulin, HinsBet](https://www.adocia.com/medias-publications/adocia-reports-positive-results-from-phase-iia-clinical-study-of-fast-acting-human-insulin-hinsbet/)
- [Adocia annonce des résultats de phase IIa positifs pour l’insuline humaine rapide HinsBet](https://www.adocia.com/fr/medias-publications/adocia-annonce-des-resultats-de-phase-iia-positifs-pour-linsuline-humaine-rapide-hinsbet/)
- [Adocia initiates a clinical study on the post-meal effect of ultra-rapid BioChaperone Lispro insulin formulation](https://www.adocia.com/medias-publications/adocia-initiates-a-clinical-study-on-the-post-meal-effect-of-ultra-rapid-biochaperone-lispro-insulin-formulation/)
- [Adocia lance une étude clinique sur l’effet de l’insuline ultra-rapide BioChaperone® Lispro après le repas](https://www.adocia.com/fr/medias-publications/adocia-lance-une-etude-clinique-sur-leffet-de-linsuline-ultra-rapide-biochaperone-lispro-apres-le-repas/)
- [Half year report on Adocia's liquidity agreement with Kepler Capital Markets](https://www.adocia.com/medias-publications/half-year-report-on-adocias-liquidity-agreement-with-kepler-capital-markets-2/)
- [ADOCIA annonce son calendrier financier pour l'année 2015](https://www.adocia.com/fr/medias-publications/adocia-annonce-son-calendrier-financier-pour-lannee-2015/)
- [ADOCIA announces its financial calendar for 2015](https://www.adocia.com/medias-publications/adocia-announces-its-financial-calendar-for-2015/)
- [ADOCIA adresse une lettre aux actionnaires et une invitation à rejoindre deux conférences téléphoniques ce jour et demain](https://www.adocia.com/fr/medias-publications/adocia-adresse-une-lettre-aux-actionnaires-et-une-invitation-a-rejoindre-deux-conferences-telephoniques-ce-jour-et-demain/)
- [ADOCIA: shareholder newsletter and invitation to two conference calls today and tomorrow](https://www.adocia.com/medias-publications/adocia-shareholder-newsletter-and-invitation-to-two-conference-calls-today-and-tomorrow/)
- [Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology](https://www.adocia.com/medias-publications/lilly-and-adocia-announce-alliance-to-co-develop-ultra-rapid-insulin-based-on-biochaperone-technology/)
- [Lilly et Adocia annoncent leur alliance pour co-développer une insuline ultra-rapide grâce à la technologie BioChaperone](https://www.adocia.com/fr/medias-publications/lilly-et-adocia-annoncent-leur-alliance-pour-co-developper-une-insuline-ultra-rapide-grace-a-la-technologie-biochaperone/)
- [ADOCIA annonce ses résultats du 3ème trimestre 2014](https://www.adocia.com/fr/medias-publications/adocia-annonce-ses-resultats-du-3eme-trimestre-2014/)
- [ADOCIA Announces Third-quarter Financial 2014 Results](https://www.adocia.com/medias-publications/adocia-announces-third-quarter-financial-2014-results/)
- [ADOCIA Wins Frost & Sullivan 2014 Technology Innovation Leadership Award in the Therapeutic Proteins Industry](https://www.adocia.com/medias-publications/adocia-wins-frost-sullivan-2014-technology-innovation-leadership-award-in-the-therapeutic-proteins-industry/)
- [ADOCIA reçoit le prix Frost & Sullivan 2014 du Leadership en Innovation Technologique pour l’Industrie des Protéines Thérapeutiques](https://www.adocia.com/fr/medias-publications/adocia-recoit-le-prix-frost-sullivan-2014-du-leadership-en-innovation-technologique-pour-lindustrie-des-proteines-therapeutiques/)
- [Adocia Reports Positive Preliminary Results from Dose Response Clinical Study of Ultra-fast acting BioChaperone® Lispro U100 in Patients with Type 1 Diabetes](https://www.adocia.com/medias-publications/adocia-reports-positive-preliminary-results-from-dose-response-clinical-study-of-ultra-fast-acting-biochaperone-lispro-u100-in-patients-with-type-1-diabetes/)
- [Adocia annonce des résultats préliminaires positifs de l’étude clinique de dose-réponse de BioChaperone® Lispro U100, insuline ultra-rapide, chez des patients diabétiques de Type 1](https://www.adocia.com/fr/medias-publications/adocia-annonce-des-resultats-preliminaires-positifs-de-letude-clinique-de-dose-reponse-de-biochaperone-lispro-u100-insuline-ultra-rapide-chez-des-patients-diabetiques-de-type-1/)
- [Adocia Launches Phase III Clinical Study in India Of Treatment for Diabetic Foot Ulcer](https://www.adocia.com/medias-publications/adocia-launches-phase-iii-clinical-study-in-india-of-treatment-for-diabetic-foot-ulcer/)
- [Adocia démarre une étude clinique de phase III en Inde sur son traitement de l’ulcère du pied diabétique](https://www.adocia.com/fr/medias-publications/adocia-demarre-une-etude-clinique-de-phase-iii-en-inde-sur-son-traitement-de-lulcere-du-pied-diabetique/)
- [Adocia : activité et résultats du premier semestre 2014](https://www.adocia.com/fr/medias-publications/adocia-activite-et-resultats-du-premier-semestre-2014/)
- [Adocia Reports Operational and Financial Results for the First Half of 2014](https://www.adocia.com/medias-publications/adocia-reports-operational-and-financial-results-for-the-first-half-of-2014/)
- [Bilan semestriel du contrat de liquidité Adocia conclu avec la société Kepler Capital Markets](https://www.adocia.com/fr/medias-publications/bilan-semestriel-du-contrat-de-liquidite-adocia-conclu-avec-la-societe-kepler-capital-markets/)
- [Half year report on Adocia’s liquidity agreement  with Kepler Capital Markets](https://www.adocia.com/medias-publications/half-year-report-on-adocias-liquidity-agreement-with-kepler-capital-markets/)
- [Adocia Announces Approval to Start a Phase IIa Clinical Study of HinsBet®, its Fast-acting Human Insulin, in Type 1 Diabetes](https://www.adocia.com/medias-publications/adocia-announces-approval-to-start-a-phase-iia-clinical-study-of-hinsbet-its-fast-acting-human-insulin-in-type-1-diabetes/)
- [Adocia annonce l’autorisation de lancer une étude clinique de Phase IIa sur HinsBet®, son insuline humaine à action rapide, dans le diabète de type 1](https://www.adocia.com/fr/medias-publications/adocia-annonce-lautorisation-de-lancer-une-etude-clinique-de-phase-iia-sur-hinsbet-son-insuline-humaine-a-action-rapide-dans-le-diabete-de-type-1/)
- [ADA 74th Edition: Poster of positive results of Bio Chaperone® Lispro (english only)](https://www.adocia.com/medias-publications/ada-74th-edition-poster-of-positive-results-of-bio-chaperone-lispro-english-only/)
- [74ème édition de ADA : Poster sur les résultats positifs de BioChaperone® Lispro (en anglais)](https://www.adocia.com/fr/medias-publications/74eme-edition-de-ada-poster-sur-les-resultats-positifs-de-biochaperone-lispro-en-anglais/)
- [ADA 74th Edition: Poster of positive results of BioChaperone® Combo (english only)](https://www.adocia.com/medias-publications/ada-74th-edition-poster-of-positive-results-of-biochaperone-combo-english-only/)
- [74ème édition de ADA : Poster sur les résultats positifs de BioChaperone Combo (en anglais)](https://www.adocia.com/fr/medias-publications/74eme-edition-de-ada-poster-sur-les-resultats-positifs-de-biochaperone-combo-en-anglais/)
- [“Pharmacokinetic (PK) and Pharmacodynamic (PD) Characteristics of BioChaperone Combo (BC Combo), the First Fixed Combination of Glargine and Lispro, in Type 1 Diabetes”, (Poster 83-LB), presented by Dr. Ulrike Hövelmann, 74th Scientific Sessions American Diabetes Association 13-17 June 2014, San Francisco, CA, (USA)](https://www.adocia.com/medias-publications/pharmacokinetic-pk-and-pharmacodynamic-pd-characteristics-of-biochaperone-combo-bc-combo-the-first-fixed-combination-of-glargine-and-lispro-in-type-1-diabetes-poster-83-lb/)
- [“The Ultra-Rapid BioChaperone® Insulin Lispro shows a Faster Onset of Action and Stronger Early Metabolic Effect than Native Insulin Lispro” (Poster 78-LB), presented by Dr. Grit Anderson, 74th Scientific Sessions of the American Diabetes Association, 13-17 June 2014, San Francisco, CA (USA)](https://www.adocia.com/medias-publications/the-ultra-rapid-biochaperone-insulin-lispro-shows-a-faster-onset-of-action-and-stronger-early-metabolic-effect-than-native-insulin-lispro-poster-78-lb-presented-by-dr-grit/)
- [Adocia annonce des résultats précliniques positifs pour une insuline ultra rapide concentrée, BioChaperone® Lispro U300](https://www.adocia.com/fr/medias-publications/adocia-annonce-des-resultats-precliniques-positifs-pour-une-insuline-ultra-rapide-concentree-biochaperone-lispro-u300/)
- [Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300](https://www.adocia.com/medias-publications/adocia-announces-positive-preclinical-results-for-a-concentrated-ultra-fast-insulin-biochaperone-lispro-u300/)
- [Adocia to Present Successful Clinical Results for BioChaperone® Lispro and BioChaperone® Combo at the American Diabetes Association 74th Scientific Sessions on June 15th 2014](https://www.adocia.com/medias-publications/adocia-to-present-successful-clinical-results-for-biochaperone-lispro-and-biochaperone-combo-at-the-american-diabetes-association-74th-scientific-sessions-on-june-15th-2014/)
- [Adocia présentera des résultats cliniques positifs pour BioChaperone® Lispro et BioChaperone Combo lors des 74ème Sessions Scientifiques de l’American Diabetes Association le 15 juin 2014](https://www.adocia.com/fr/medias-publications/adocia-presentera-des-resultats-cliniques-positifs-pour-biochaperone-lispro-et-biochaperone-combo-lors-des-74eme-sessions-scientifiques-de-lamerican-diabetes-association-le-15-juin-2014/)
- [Adocia initiates ADR program in the United States](https://www.adocia.com/medias-publications/adocia-initiates-adr-program-in-the-united-states/)
- [Adocia lance un programme d’ADR aux Etats-Unis](https://www.adocia.com/fr/medias-publications/adocia-lance-un-programme-dadr-aux-etats-unis/)
- [Adocia: PR BC Lispro Initiation of phase 2a](https://www.adocia.com/medias-publications/adocia-pr-bc-lispro-initiation-of-phase-2a/)
- [Adocia : Initiation Deuxième Phase 2a dose-réponse](https://www.adocia.com/fr/medias-publications/adocia-initiation-deuxieme-phase-2a-dose-reponse/)
- [Adocia : Contrat de liquidité avec Kepler](https://www.adocia.com/fr/medias-publications/adocia-contrat-de-liquidite-avec-kepler/)
- [Adocia Press Release Liquidity Agreement with Kepler](https://www.adocia.com/medias-publications/adocia-press-release-liquidity-agreement-with-kepler/)
- [Termination of Liquidity Agreement with DSF Markets](https://www.adocia.com/medias-publications/termination-of-liquidity-agreement-with-dsf-markets/)
- [Mise à disposition du document de référence 2013](https://www.adocia.com/fr/medias-publications/mise-a-disposition-du-document-de-reference-2013/)
- [Résultats Phase 2a sur l'Ultra fast Lispro](https://www.adocia.com/fr/medias-publications/resultats-phase-2a-sur-lultra-fast-lispro/)
- [Chiffre d'affaires Q1 2014](https://www.adocia.com/fr/medias-publications/chiffre-daffaires-q1-2014/)
- [Adocia: Ultra Fast Lispro Clinical Results](https://www.adocia.com/medias-publications/adocia-ultra-fast-lispro-clinical-results/)
- [Adocia: Revenue Q1 2014](https://www.adocia.com/medias-publications/adocia-revenue-q1-2014/)
- [Eligibilité PEA PME 2014](https://www.adocia.com/fr/medias-publications/eligibilite-pea-pme-2014/)
- [Interview de Gérard Soula : La bourse et la vie - 26 mars 2014](https://www.adocia.com/fr/medias-publications/interview-de-gerard-soula-la-bourse-et-la-vie-26-mars-2014/)
- [Gerard Soula Interview - La bourse et la vie (Transcript)](https://www.adocia.com/medias-publications/gerard-soula-interview-la-bourse-et-la-vie-transcript/)
- [Résultats financiers 2013](https://www.adocia.com/fr/medias-publications/resultats-financiers-2013/)
- [Adocia: Annual results 2013](https://www.adocia.com/medias-publications/adocia-annual-results-2013/)
- [Confirmation des résultats cliniques Combo](https://www.adocia.com/fr/medias-publications/confirmation-des-resultats-cliniques-combo/)
- [Adocia: confirmation of positive clinical results Combo](https://www.adocia.com/medias-publications/adocia-confirmation-of-positive-clinical-results-combo/)
- [Positive Clinical Results for Combo](https://www.adocia.com/medias-publications/positive-clinical-results-for-combo/)
- [Résultats cliniques Combo positifs](https://www.adocia.com/fr/medias-publications/resultats-cliniques-combo-positifs/)
- [Chiffre d'affaires de 5.6 millions d'euros en 2013](https://www.adocia.com/fr/medias-publications/chiffre-daffaires-de-5-6-millions-deuros-en-2013/)
- [2014 Financial Calendar](https://www.adocia.com/medias-publications/2014-financial-calendar/)
- [Contrat de liquidité - Bilan semestriel](https://www.adocia.com/fr/medias-publications/contrat-de-liquidite-bilan-semestriel/)

## Regulated information

- [2026](https://www.adocia.com/regulated-information/2026/)
- [2026](https://www.adocia.com/regulated-information/2026/)
- [2025](https://www.adocia.com/regulated-information/2025/)
- [2025](https://www.adocia.com/regulated-information/2025/)
- [2024](https://www.adocia.com/fr/regulated-information/2024/)
- [2024](https://www.adocia.com/regulated-information/2024/)
- [2022](https://www.adocia.com/regulated-information/2022/)
- [2019](https://www.adocia.com/regulated-information/2019/)
- [2019](https://www.adocia.com/regulated-information/2019/)
- [2020](https://www.adocia.com/regulated-information/2020/)
- [2020](https://www.adocia.com/regulated-information/2020/)
- [2023](https://www.adocia.com/regulated-information/2023/)
- [2023](https://www.adocia.com/regulated-information/2023/)
- [2022](https://www.adocia.com/regulated-information/2022/)
- [2015](https://www.adocia.com/regulated-information/2015/)
- [2016](https://www.adocia.com/regulated-information/2016/)
- [2018](https://www.adocia.com/regulated-information/2018/)
- [2014](https://www.adocia.com/regulated-information/2014/)
- [2015](https://www.adocia.com/regulated-information/2015/)
- [2016](https://www.adocia.com/regulated-information/2016/)
- [2017](https://www.adocia.com/regulated-information/2017/)
- [2018](https://www.adocia.com/regulated-information/2018/)
- [2017](https://www.adocia.com/regulated-information/2017/)
- [2021](https://www.adocia.com/regulated-information/2021/)
- [2021](https://www.adocia.com/regulated-information/2021/)
- [2014](https://www.adocia.com/regulated-information/2014/)
- [2013](https://www.adocia.com/regulated-information/2013/)
- [2013](https://www.adocia.com/regulated-information/2013/)
- [2012](https://www.adocia.com/regulated-information/2012/)
- [2012](https://www.adocia.com/regulated-information/2012/)

## General meeting

- [2026](https://www.adocia.com/general-meeting/2026/)
- [2026](https://www.adocia.com/fr/general-meeting/2026/)
- [2025](https://www.adocia.com/general-meeting/2025/)
- [2025](https://www.adocia.com/general-meeting/2025/)
- [2018](https://www.adocia.com/general-meeting/2018/)
- [2023](https://www.adocia.com/general-meeting/2023/)
- [2023](https://www.adocia.com/general-meeting/2023/)
- [2020](https://www.adocia.com/general-meeting/5311/)
- [2021](https://www.adocia.com/general-meeting/2021/)
- [2022](https://www.adocia.com/general-meeting/2022/)
- [2024](https://www.adocia.com/fr/general-meeting/2024/)
- [2020](https://www.adocia.com/general-meeting/5311/)
- [2021](https://www.adocia.com/general-meeting/2021/)
- [2022](https://www.adocia.com/general-meeting/2022/)
- [2024](https://www.adocia.com/general-meeting/2024/)
- [2019](https://www.adocia.com/general-meeting/2019/)
- [2019](https://www.adocia.com/general-meeting/2019/)
- [2012](https://www.adocia.com/general-meeting/2012/)
- [2013](https://www.adocia.com/general-meeting/2013/)
- [2014](https://www.adocia.com/general-meeting/2014/)
- [2015](https://www.adocia.com/general-meeting/2015/)
- [2016](https://www.adocia.com/general-meeting/2016/)
- [2017](https://www.adocia.com/general-meeting/2017/)
- [2018](https://www.adocia.com/general-meeting/2018/)
- [2017](https://www.adocia.com/general-meeting/2017/)
- [2016](https://www.adocia.com/general-meeting/2016/)
- [2015](https://www.adocia.com/general-meeting/2015/)
- [2014](https://www.adocia.com/general-meeting/2014/)
- [2013](https://www.adocia.com/general-meeting/2013/)
- [2012](https://www.adocia.com/general-meeting/2012/)